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A B S T R A C T
Background
Although delirium is typically an acute reversible cognitive impairment, its presence is associated with devastating impact on both short-
term and long-term outcomes for critically ill patients. Advances in our understanding of the negative impact of delirium on patient
outcomes have prompted trials evaluating multiple pharmacological interventions. However, considerable uncertainty surrounds the
relative benefits and safety of available pharmacological interventions for this population.
Objectives
Primary objective
1. To assess the effects of pharmacological interventions for treatment of delirium on duration of delirium in critically ill adults with
confirmed or documented high risk of delirium
Secondary objectives
To assess the following:
1. effects of pharmacological interventions on delirium-free and coma-free days; days with coma; delirium relapse; duration of me-
chanical ventilation; intensive care unit (ICU) and hospital length of stay; mortality; and long-term outcomes (e.g. cognitive; discharge
disposition; health-related quality of life); and
2. the safety of such treatments for critically ill adult patients.
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Search methods
We searched the following databases from their inception date to 21 March 2019: Ovid MEDLINE®, Ovid MEDLINE® In-
Process & Other Non-Indexed Citations, Embase Classic+Embase, and PsycINFO using the Ovid platform. We also searched the
Cochrane Library on Wiley, the International Prospective Register of Systematic Reviews (PROSPERO) ( http://www.crd.york.ac.uk/
PROSPERO/), the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science. We performed a grey
literature search of relevant databases and websites using the resources listed in Grey Matters developed by the Canadian Agency for
Drugs and Technologies in Health (CADTH). We also searched trial registries and abstracts from annual scientific critical care and
delirium society meetings.
Selection criteria
We sought randomized controlled trials (RCTs), including quasi-RCTs, of any pharmacological (drug) for treatment of delirium in
critically ill adults. The drug intervention was to be compared to another active drug treatment, placebo, or a non-pharmacological
intervention (e.g. mobilization). We did not apply any restrictions in terms of drug class, dose, route of administration, or duration
of delirium or drug exposure. We defined critically ill patients as those treated in an ICU of any specialty (e.g. burn, cardiac, medical,
surgical, trauma) or high-dependency unit.
Data collection and analysis
Two review authors independently identified studies from the search results; four review authors (in pairs) performed data extraction
and assessed risk of bias independently. We performed data synthesis through pairwise meta-analysis and network meta-analysis (NMA).
Our hypothetical network structure was designed to be analysed at the drug class level and illustrated a network diagram of ’nodes’ (i.e.
drug classes) and ’edges’ (i.e. comparisons between different drug classes from existing trials), thus describing a treatment network of
all possible comparisons between drug classes. We assessed the quality of the body of evidence according to GRADE, as very low, low,
moderate, or high.
Main results
We screened 7674 citations, from which 14 trials with 1844 participants met our inclusion criteria. Ten RCTs were placebo-controlled,
and four reported comparisons of different drugs. Drugs examined in these trials were the following: antipsychotics (n = 10), alpha2
agonists (n = 3; all dexmedetomidine), statins (n = 2), opioids (n = 1; morphine), serotonin antagonists (n = 1; ondansetron), and
cholinesterase (CHE) inhibitors (n = 1; rivastigmine). Only one of these trials consistently used non-pharmacological interventions
that are known to improve patient outcomes in both intervention and control groups.
Eleven studies (n = 1153 participants) contributed to analysis of the primary outcome. Results of the NMA showed that the intervention
with the smallest ratio of means (RoM) (i.e. most preferred) compared with placebo was the alpha2 agonist dexmedetomidine (0.58;
95% credible interval (CrI) 0.26 to 1.27; surface under the cumulative ranking curve (SUCRA) 0.895; moderate-quality evidence).
In order of descending SUCRA values (best to worst), the next best interventions were atypical antipsychotics (RoM 0.80, 95% CrI
0.50 to 1.11; SUCRA 0.738; moderate-quality evidence), opioids (RoM 0.88, 95% CrI 0.37 to 2.01; SUCRA 0.578; very-low quality
evidence), and typical antipsychotics (RoM 0.96, 95% CrI 0.64 to1.36; SUCRA 0.468; high-quality evidence).
The NMAs of multiple secondary outcomes revealed that only the alpha2 agonist dexmedetomidine was associated with a shorter
duration of mechanical ventilation (RoM 0.55, 95% CrI 0.34 to 0.89; moderate-quality evidence), and the CHE inhibitor rivastigmine
was associated with a longer ICU stay (RoM 2.19, 95% CrI 1.47 to 3.27; moderate-quality evidence). Adverse events often were not
reported in these trials or, when reported, were rare; pair-wise analysis of QTc prolongation in seven studies did not show significant
differences between antipsychotics, ondansetron, dexmedetomidine, and placebo.
Authors’ conclusions
We identified trials of varying quality that examined six different drug classes for treatment of delirium in critically ill adults. We found
evidence that the alpha2 agonist dexmedetomidine may shorten delirium duration, although this small effect (compared with placebo)
was seen in pairwise analyses based on a single study and was not seen in the NMA results. Alpha2 agonists also ranked best for duration
of mechanical ventilation and length of ICU stay, whereas the CHE inhibitor rivastigmine was associated with longer ICU stay. We
found no evidence of a difference between placebo and any drug in terms of delirium-free and coma-free days, days with coma, physical
restraint use, length of stay, long-term cognitive outcomes, or mortality. No studies reported delirium relapse, resolution of symptoms,
or quality of life. The ten ongoing studies and the six studies awaiting classification that we identified, once published and assessed,
may alter the conclusions of the review.
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P L A I N L A N G U A G E S U M M A R Y
Medicines to treat delirium in critically ill adult patients
Review question
We reviewed the evidence from randomized controlled trials for the benefits and safety of all prescription medicines used to treat
critically ill adult patients with delirium in the intensive care units (ICUs) of hospitals.
Background
Delirium is commonly associated with surgery, infection, or critical illness. It is experienced as new-onset, generally short-term inability
to think clearly. Patients with delirium shift between periods of clear thinking and periods of agitation and/or great sleepiness and
confusion. Lack of sleep, pain, a noisy environment, physical restraint, and the use of sedatives and strong analgesics are some of the
contributing factors. Delirium affects both immediate and longer-term health outcomes of critically ill patients as it can increase the
length of time a breathing machine is required, time spent in the ICU and in hospital, and the chance of functional weakening and
death. The odds of a poor outcome with delirium are increased with frail patients and those of advanced age and already present
cognitive difficulties. Frequently, delirious ICU patients are given medicines to help treat symptoms such as agitation.
Study characteristics
This review is current to 21 March 2019. We found 14 randomized controlled studies that enrolled a total of 1844 adult participants.
Six different classes of medicines were tested. These were antipsychotic drugs used as tranquillizers in ten studies; the sedative alpha2
agonist dexmedetomidine in three studies; statins that reduce cholesterol in two studies; opioids as part of pain management in one
study; serotonin antagonists for nausea and vomiting in one study; and cholinesterase inhibitors, which are medicines for Alzheimer’s
disease, in one study. Ten studies compared medicine to placebo - an inactive medicine also known as a sugar pill; four studies compared
different drugs. Eleven studies with 1153 participants reported on the main outcome of this review - duration of delirium.
Key findings
When drug classes were directly compared with placebo, only the alpha2 agonist dexmedetomidine was found to reduce the duration
of delirium, and the cholinesterase inhibitor rivastigmine was found to prolong the duration of delirium. Each of these results is based
on findings from a single small study. The other drugs when compared to placebo did not change delirium duration. The Review
authors used the statistical method of network meta-analysis to compare the six different drug classes. Dexmedetomidine was ranked
most effective in reducing delirium duration, followed by atypical antipsychotics. However, network meta-analysis of delirium duration
failed to rule out the possibility of no difference for all six drug classes compared to placebo. Using this method, we did not find that
any drug improved the duration of coma, length of stay, long-term cognitive outcomes, or death. The alpha2 agonist dexmedetomidine
shortened time spent on a breathing machine. Adverse events often were not reported in these trials or were rare when reported. An
analysis of reported events showed that events were similar to those reported with placebo. We found 10 ongoing studies and six studies
awaiting classification that, once published and assessed, may change the conclusions of this review.
Quality of the evidence
Most of the included studies were small but of good design. Nine of the 14 studies were considered to have low risk of bias.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Outcome: duration of delirium
Patient or population: crit ically ill adults with conf irmed or at high risk of delirium
Settings: intensive care units in Australia and New Zealand, Canada, Egypt, Netherlands, Turkey, USA, UK
Intervention: any pharmacological intervent ion
Control: placebo or act ive comparator
Comparisons Illustrative comparative risks* (95% CrI) Ratio of means (RoM)
based on log RoM esti-
mates from meta-anal-
ysis
(IV, random, 95% CI)
Number of participants
(studies)












Median durat ion of
delirium: 3 to 5 days for
placebo
3.86 days of delirium
(95% CrI 2.57 to
5.46) corresponding to
4 days in the placebo
group
RoM: exp(0.02) = 1.02
(95% CI 0.91 to 1.14);
log RoM: 0.02 (-0.09 to







SUCRA = 0.468, mean




Median durat ion of
delirium: 3 to 5 days for
placebo
3.22 days of delirium
(95% CrI 2.01 to
4.43) corresponding to
4 days in the placebo
group
RoM: exp(-0.31) = 0.73
(95% CI 0.49 to 1.11);
log RoM: -0.31 (-0.71 to







SUCRA = 0.738, mean




Mean durat ion of delir-
ium: 6.8 to 8.68 days
for placebo
4.20 days of delirium
(95% CrI 2.44 to
7.09) corresponding to
4 days in the placebo
group
RoM: exp(0.07) = 1.07
(95% CI 0.91 to 1.25);
log RoM: 0.07 (-0.09 to







SUCRA = 0.365, mean















































































































Median durat ion of
delirium: 2.583 days for
placebo
2.31 days of delirium
(95% CrI 1.06 to
5.06) corresponding to
4 days in the placebo
group
RoM: exp(-0.55) = 0.58
(95% CI 0.43 to 0.79);
log RoM: -0.55 (-0.85 to







SUCRA = 0.895, mean





Median durat ion of
delirium: 3 days for
placebo
7.37 days of delirium
(95% CrI 3.26 to
16.38) corresponding
to 4 days in the placebo
group
RoM: exp(0.61) = 1.84
(95% CI 1.25 to 2.69);
log RoM: 0.61 (0.22 to







SUCRA = 0.054, mean




No study reported this
comparison
3.53 days of delirium
(95% CrI 1.46 to
8.05) corresponding to










SUCRA = 0.578, mean
Pr(best) = 0.129, mean
rank = 3.53
* The basis for the assumed risk (e.g. the median control group risk across studies). The corresponding risk (and its 95% CrI) is calculated as the assumed risk mult iplied by
the ratio of means (and its 95% CrI) based on NMA.
Abbreviat ions: CI: conf idence interval; CrI: credible interval; HMG-CoA: 5-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor; NMA: network meta-analysis; Pr(best):
probability(best); RoM: rat io of means; SUCRA: surface under the cumulat ive ranking curve
GRADE Working Group grades of evidence.
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aDowngraded one level for heterogeneity (I² > 75% considered as large heterogeneity).
bDowngraded one level for imprecision (wide credible interval).













































































































B A C K G R O U N D
Description of the condition
Delirium is a reversible, non-specific syndrome of cognitive im-
pairment commonly associated with surgery, infection, or critical
illness (APA 2013). In the intensive care unit (ICU), this acute
brain dysfunction is reported in 40% to 60% of non-ventilated pa-
tients, and in 50% to 80% of mechanically ventilated patients (Ely
2001a; Ely 2001b; Ely 2007; Hipp 2012; Inouye 2014). Delir-
ium is challenging to detect, as symptoms are highly variable, with
either hyperactivity or hypoactivity, or even a mixed picture, and
symptoms fluctuate with periods of lucidity (Inouye 2014). Delir-
ium may be detected by psychiatric assessment based on the Diag-
nostic and Statistical Manual (DSM) criteria (APA 2013), or by use
of a validated screening tool (Bergeron 2001; Ely 2001a; Neelon
1996); however, assessment in the ICU is predicated on the pa-
tient being awake and able to communicate, and delirium is said
to be “unable to be assessed” when the patient does not respond
to verbal communication. In the ICU, commonly used sedatives
and opioids impair consciousness, thereby making identification
of delirium challenging (Patel 2014). Drug exposure should be
considered when ICU delirium is assessed, and if possible, as-
sessments should be co-ordinated with periods of wakefulness or
should be conducted during a sedation interruption (Patel 2014).
Over the past decade, we have acquired a greater understanding of
the effects of delirium on patients, their families, and the health-
care system. Clinically important outcomes of delirious critically
ill patients include prolonged duration of mechanical ventilation
and ICU and hospital stay, as well as long-term cognitive impair-
ment, increased likelihood of transfer to long-term care facilities,
and mortality (Black 2011; Ely 2001b; Ely 2004; Girard 2010b;
Jackson 2004; Lin 2004; Milbrant 2004; Pisani 2009; Van den
Boogaard 2012). The odds of a poor outcome with delirium are
increased by patient frailty, advanced age (> 75 years), pre-existing
cognitive impairment, and visual or hearing impairment (Andrew
2006; Inouye 2006a). Precipitating factors are numerous and in-
clude sleep deprivation, pain, environmental insults (e.g. noise,
physical restraint use, catheters), and psychoactive drug exposure
(e.g. sedatives) (Burry 2017; Fraser 2013; Inouye 2006a; Rose
2016; Zaal 2015).
Description of the intervention
Pharmacological interventions for delirium treatment have fo-
cused on alterations in neurotransmitter pathways, in particular
dopaminergic and cholinergic pathways. At present, the patho-
physiology of delirium is not fully understood (Gunther 2008;
Reade 2014). Hypotheses currently include abnormalities in cere-
bral oxidative metabolism, direct neurotoxic effects of inflamma-
tory cytokines, such as those released during sepsis and septic
shock, and alterations in neurotransmitters that modulate cogni-
tion, behaviour, and mood (e.g. cholinergic, dopaminergic, sero-
tonergic, gamma-aminobutyric acid (GABA) pathways) (Cerejeira
2011; de Rooji 2007; Ebersoldt 2007; Flacker 1999; Gunther
2008; Inouye 2006b; Rudolph 2008; White 2002). These patho-
physiological mechanisms are not thought to be mutually exclu-
sive and are likely to act together.
In the light of these different proposed mechanisms, it is not
surprising that numerous pharmacological strategies for delirium
have been investigated, including alpha2 agonists, antidepressants,
antipsychotic drugs (either typical or atypical agents), benzodi-
azepines, cholinesterase inhibitors, melatonin and melatonin ago-
nists, and opioids (Devlin 2010; Girard 2010a; Maldonado 2009;
Ohta 2013; Reade 2009; Rubino 2010; van Eijk 2010). In consid-
ering these agents, it is important to note that critical care guide-
lines first recommend the use of non-pharmacological strategies
in both prevention and management of delirium (Barr 2013).
These non-pharmacological strategies include early mobilization
and re-orientation, risk factor assessment and modification (e.g.
drugs, medical devices), and normalization of the sleep-wake cycle
(e.g. noise reduction, use of ear plugs) (Inouye 2006a; Schweickert
2009). Guidelines suggest that when delirium is suspected or iden-
tified, patients should be closely evaluated for identification of un-
derlying cause(s), allowing for exposure to be removed or corrected
whenever possible; pharmacological interventions are to be used
only when non-pharmacological methods have failed to control
symptoms (Barr 2013).
How the intervention might work
Given the multiple neurotransmitters linked to development of
delirium, pharmacological strategies have investigated target sus-
pected neurotransmitter imbalances or attempts to control dis-
tressing cognitive (e.g. hallucinations) or dangerous behaviours
(e.g. agitation, interference with medical devices). Pharmaco-
logical strategies may target pain control (e.g. opioids) or the
dopaminergic (e.g. antipsychotics), cholinergic (e.g. cholinesterase
inhibitors), GABA (e.g. benzodiazepines), N-methyl-D-aspar-
tate (NMDA) (e.g. ketamine), serotonergic (e.g. antidepressants,
antinauseants, melatonin), and alpha2 (e.g. clonidine, dexmedeto-
midine) pathways (Devlin 2010; Girard 2010a; Maldonado 2009;
Ohta 2013; Reade 2009; Rubino 2010; van Eijk 2010). The spe-
cific therapeutic effects of such agents are unknown, but effects
may be mediated through their ability to affect sedation and be-
havioural symptoms.
Despite conflicting evidence for the benefits of various pharma-
cological interventions, many of these agents are routinely used
to treat ICU delirium, or to at least manage symptoms (e.g. ag-
itation), and they are often continued after hospital discharge
(Bell 2007; MacSweeney 2009). Of the available pharmacological
strategies, antipsychotics represent the most common treatment
for ICU delirium, despite limited evidence regarding their benefit
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and studies in non-critically ill patients identifying significant ad-
verse effects, including sudden death (Barr 2013; Briskman 2010;
Burry 2014; Gill 2007; MacSweeney 2009; Tropea 2009; Wang
2005).
Why it is important to do this review
ICU delirium is associated with prolonged duration of mechan-
ical ventilation and ICU and hospital stay, as well as increased
mortality (Ely 2001b; Ely 2004; Girard 2010b; Jackson 2004; Lin
2004; Milbrant 2004; Pisani 2009; Van den Boogaard 2012). ICU
delirium initiates a cascade of events that can include functional
decline and long-term cognitive impairment, with resultant care-
giver burden (Girard 2010b; Jackson 2004; Van den Boogaard
2012). The geriatric and oncological literature shows that delirium
is traumatic for both patients and family members, and it can lead
to long-term psychological sequelae (Bruera 2009; Morita 2004;
Partridge 2013; Rosenbloom-Brunton 2010). The economic bur-
den of delirium is also significant; each additional day spent in a
delirious state is associated with a 20% increased risk of prolonged
hospitalization, translating to an average of more than 10 addi-
tional hospital days per patient. The annual cost of delirium is esti-
mated to be greater than USD 164 billion in the USA, and greater
than EUR 182 billion as estimated across 18 European countries
(Leslie 2008; OECD 2012; WHO Regional Office 2012). Fur-
thermore, delirium is considered a substantial public health con-
cern that has garnered the attention of patient safety institutes; it
is now included as an indicator of quality care for the elderly (IHI
2015).
Advances in detection of ICU delirium and improved under-
standing of its impact on patient outcomes have prompted tri-
als comparing different treatment options (both pharmacologi-
cal and non-pharmacological), either against each other or ver-
sus placebo. However, there remains considerable uncertainty re-
garding the relative benefits and safety of pharmacological inter-
ventions for the ICU population, and trials have shown benefit
(Devlin 2010; Pandharipande 2007; Reade 2009), indeterminate
outcomes (Girard 2010a; Page 2013), or harm (van Eijk 2010). A
previous Cochrane Review on antipsychotics for delirium did not
specifically address the ICU population (Lonergan 2007); numer-
ous ICU-specific trials have been published since this review was
completed. A recent systematic review of ICU delirium included
both prevention and treatment studies (Al-Qadheeb 2014), as well
as randomized controlled trials (RCTs) evaluating sedation strate-
gies, in which delirium was evaluated as a secondary endpoint
when the study population considered was not restricted to pa-
tients with confirmed delirium. As a Cochrane Review protocol
by Herling and colleagues will provide data on delirium preven-
tion trials in critically ill adult patients (Herling 2018), our review
focuses on delirium treatment trials in critically ill adult patients.
Given the availability of numerous strategies to treat ICU delir-
ium in clinical practice, and the existence of many trials yielding
conflicting results, we planned this systematic review to include a
network meta-analysis (NMA) to determine the comparative ben-
efits and harms of all published pharmacological interventions for
treatment of delirium based on available direct and indirect evi-
dence of relevance. An NMA, also known as a multiple treatment
comparison meta-analysis, is a statistical method used to assess
the comparative effectiveness of multiple different interventions
among similar patient populations that have not been compared
directly in an RCT. In contrast to conventional pairwise meta-
analysis (e.g. RCTs comparing treatment A vs treatment B), NMAs
can provide estimates of relative efficacy between all interventions,
even though some have never been compared head-to-head via
indirect evidence (i.e. comparing results from two or more studies
that have one treatment in common).
O B J E C T I V E S
Primary objective
1. To assess the effects of pharmacological interventions for
treatment of delirium on duration of delirium in critically ill
adults with confirmed or documented high risk of delirium
Secondary objectives
To assess the following:
1. effects of pharmacological interventions on delirium-free
and coma-free days; days with coma; delirium relapse; duration
of mechanical ventilation; ICU and hospital length of stay;
mortality; and long-term outcomes (e.g. cognitive; discharge
disposition; health-related quality of life); and
2. the safety of such treatments for critically ill adult patients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We sought randomized controlled trials (RCTs), including quasi-
RCTs (i.e. when the method of allocation was not strictly random,
such as by alternation, date of birth, or case record number), and
RCTs with an open-label study design. We excluded non-RCT
study designs due to their potential for bias and the anticipated
availability of RCTs.
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Types of participants
We sought RCTs designed to examine pharmacological interven-
tions for treatment of delirium in critically ill adults. We defined
critically ill patients as those treated in an ICU of any specialty
(e.g. burn, cardiac, medical, surgical, trauma) or high-dependency
unit. We included trials in which a trained individual (e.g. psy-
chiatrist) evaluated participants for delirium using the Diagnostic
and Statistical Manual of Mental Disorders (DSM) criteria (APA
2013), or using a validated delirium assessment tool (e.g. Confu-
sion Assessment Method for the ICU (CAM-ICU), Intensive Care
Delirium Screening Checklist (ICDSC), Neelon and Champagne
(NEECHAM) Confusion Scale, Delirium Rating Scale, or Delir-
ium Rating Scale-revised-98) (Bergeron 2001; Ely 2001b; Neelon
1996; Trzepacz 2001). We also included RCTs that treated sub-
syndromal delirium (i.e. some features of delirium), as these pa-
tients are considered to be at high risk of transitioning to delirium
and are often included in ICU delirium treatment studies.
Types of interventions
We sought delirium treatment RCTs that compared use of any
pharmacological (drug) to treat delirium including alpha2 ago-
nists (e.g. clonidine, dexmedetomidine), antidepressants (e.g. flu-
oxetine), antipsychotics (either typical (e.g. haloperidol) or atyp-
ical agents (e.g. quetiapine)), benzodiazepines (e.g. lorazepam),
cholinesterase (CHE) inhibitors (e.g. rivastigmine), N-methyl-D-
aspartate (NMDA) receptor antagonist (e.g. ketamine), melatonin
and melatonin agonists (e.g. ramelteon), opioids (e.g. morphine),
propofol, serotonin receptor antagonists (e.g. ondansetron), and
statins (e.g. atorvastatin) versus another active drug treatment, a
placebo, or a non-pharmacological intervention (e.g. mobiliza-
tion). We did not apply any restrictions in terms of drug class,
dose, route of administration, or duration of delirium or drug ex-
posure.
Our hypothetical network structure published in the protocol was
designed to be analysed at the drug class level and illustrated a
network diagram of ’nodes’ (i.e. drug classes) and ’edges’ (i.e. com-
parisons between different drug classes from existing trials) (Burry
2015), thus describing a treatment network of all possible com-
parisons between drug classes. The extent to which trial data are
available along the ’edges’ for each outcome will depend upon the
search results.
Types of outcome measures
Primary outcomes
1. Duration of delirium (defined as the time from which
delirium was identified or the patient was randomized until
resolution (i.e. screened negative as defined by study authors)),
measured in days
Secondary outcomes
1. Delirium-free and coma-free days (to 14, 21, 28 days) and
days with coma (reported in days)
2. Relapse of delirium (reported as a proportion)
3. Resolution of delirium symptoms (e.g. hallucinations,
agitation)
4. Duration of mechanical ventilation (days)
5. Length of stay (ICU and hospital) (days)
6. Mortality (e.g. 30-day, 60-day, 90-day, ICU, hospital,
following hospital discharge, and one year as reported by study
authors)
7. Use of physical restraint
8. Hospital discharge disposition (e.g. chronic care facility,
home)
9. Long-term cognitive outcomes (e.g. change in Mini Mental
Status Exam) as reported by study authors
10. Health-related quality of life (as reported by study authors)
11. Adverse drug events (e.g. akathisia, arrhythmias,
extrapyramidal side effects, seizures)
Search methods for identification of studies
We sought to identify all eligible trials regardless of publication
status through systematic and sensitive search strategies as outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We did not impose any language or publication
restrictions.
Electronic searches
Our electronic search strategies were developed and tested through
an iterative process with an experienced medical information spe-
cialist (Appendix 1; Appendix 2; Appendix 3; Appendix 4). The
search strategies utilized a combination of controlled vocabulary
terms (e.g. ICU, delirium) and keywords (e.g. ICU, acute brain
dysfunction). We used a validated RCT filter and a filter that
limited studies to humans. We searched the following electronic
databases from their inception date to 21 March 2019: Ovid
MEDLINE ALL®, Embase Classic+Embase, and PsycINFO us-
ing OVID platform. We also searched the Cochrane Library on
Wiley, the International Prospective Register of Systematic Re-
views (PROSPERO; http://www.crd.york.ac.uk/PROSPERO/),
the Cumulative Index to Nursing and Allied Health Literature
(CINAHL), and Web of Science. We adjusted search vocabulary
and syntax for each database. The core strategy was reviewed prior
to execution by another senior information specialist using the
Peer Review for Electronic Search Strategies (PRESS) template
(Sampson 2009).
We performed a separate search for published systematic re-
views to identify additional published or unpublished trials.
We performed a grey literature search of relevant databases
and websites using resources listed in Grey Matters ( http://
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www.cadth.ca/en/resources/finding-evidence-is/grey-matters) de-
veloped by the Canadian Agency for Drugs and Technologies in
Health (CADTH). Last, we scanned the reference lists of all in-
cluded studies and any relevant reviews on delirium treatment to
identify additional studies.
Searching other resources
We hand searched the citations of all included studies and any sys-
tematic reviews identified. We searched abstracts from annual sci-
entific meetings of the Society of Critical Care Medicine, the Eu-
ropean Society of Intensive Care Medicine, the International Sym-
posium on Intensive Care and Emergency Medicine, the American
Delirium Society, the American Thoracic Society, Chest, and the
Australian and New Zealand Intensive Care Society from 2011 to
2019 to identify studies not yet published in full. We also searched




Data collection and analysis
Selection of studies
Two review authors (LB, LR) independently screened all retrieved
titles and abstracts using the selection criteria described in the pro-
tocol (Burry 2015). Next, these two review authors (LB, LR) inde-
pendently reviewed selected full-text articles to determine inclu-
sion. We resolved disagreements by discussion, without the need
to refer to the assigned independent arbiter (EWE). References
were managed in the software package EndNote (Endnote Version
X6, Thomson Reuters, Carlsbad, CA, USA), and we documented
the reasons for exclusion in the notes field. We documented the
process of study selection using a PRISMA flow diagram (Moher
2009).
Data extraction and management
We extracted data from the included trials using a standardized
electronic form (Microsoft Corporation, Redmond, WA, USA).
Four review authors (DW, SM, NA, IE) worked independently
to extract data; two review authors were assigned to each study.
Data extractors were not blinded to the identity of study authors.
We extracted data related to publication (e.g. journal reference,
study authors, year of publication), study design (e.g. number of
centres, country, methods of enrolment, randomization, alloca-
tion concealment, blinding), patient demographics (e.g. age, sex,
severity of illness score, reasons for admission), interventions (e.g.
drug, mode of administration, dose, how titrated, who adminis-
tered, use of rescue medications for agitation), delirium and se-
dation assessment (e.g. method, who assessed), co-interventions
that might alter duration delirium, stay or mechanical ventilation
(e.g. ventilator weaning strategies, type of sedative or analgesic,
early mobilization), and our selected outcomes. We also extracted
data on management of missing data, reporting of outcomes, type
of analysis performed (e.g. intention to treat), and other potential
sources of bias (e.g. funding source, referral bias). When neces-
sary, we (LB) contacted the study corresponding author to clarify
issues related to data reporting or to obtain further study details.
Data extraction was confirmed and discrepancies between review
author pairs resolved by an arbiter (LB). Checked data were then
entered into Review Manager 5 by one review author (WC) and
were double-checked by two review authors (BH, LB) (Review
Manager 2014).
Assessment of risk of bias in included studies
Each data extractor (DW, SM, NA, IE) independently assessed
risk of bias for his/her assigned studies. A third review author (LB)
verified each assessment. Risk of bias was determined via a domain-
based evaluation that was included in the data extraction form,
and as recommended by Cochrane (Higgins 2011). The domains
were as follows.
1. Random sequence generation (i.e. selection bias).
2. Allocation concealment (i.e. selection bias).
3. Blinding of participants and personnel (i.e. performance
bias).
4. Blinding of outcomes assessment (i.e. detection bias).
5. Incomplete outcome data (i.e. attrition bias).
6. Selective reporting.
7. Other bias (e.g. study source of funding, role of the
sponsor, referral bias).
For each domain, we explicitly judged the risk of bias as high, low,
or unclear. We assigned domains ’unclear’ if detail was insufficient
to determine risk, or if risk of bias was unclear or unknown. We
judged incomplete outcome data as low risk of bias when causes of
dropout were similar and numbers were balanced between study
groups and less than 15%. We generated a risk of bias graph and
summary upon completion of assessment.
Measures of treatment effect
For all continuous outcomes (duration of delirium, duration of
ventilation, hospital length of stay, ICU length of stay, delirium-
free and coma-free days, coma days), more than half of the in-
cluded studies reported medians and interquartile ranges (IQRs)
as opposed to means and standard deviations (SDs), standard er-
rors (SEs) or confidence intervals (CIs). We converted medians
and IQRs to means and SDs according to methods described else-
where (Wan 2014). Due to the skewed nature of these outcomes,
we transformed means and SDs to the log scale using methods
outlined previously (Higgins 2008). For continuous outcomes,
the mean difference (MD) between two interventions on the log
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scale equals the log ratio of means (log RoM); after exponenti-
ation, estimates can be interpreted as the RoM of two interven-
tions. Evidence synthesis on the log RoM scale allows continuous
outcomes measured within various lengths of time windows across
studies. Findings for binary outcomes were expressed in terms of
odds ratios (ORs).
Based on mean and SD values following transformation, fixed-
effect and random-effects NMA models with Normal Likeli-
hood and the identify link were fit to the data (Dias 2011b).
We present comparisons between interventions in terms of RoM
(RoM: mean[expt]/mean[ctrl]) with 95% credible intervals (CrI).
Values of RoM < 1 favour the active intervention, whereas val-
ues of RoM > 1 favour the placebo or comparator for all con-
tinuous outcomes except for delirium-free and coma-free days.
For dichotomous outcome measures, both fixed-effect and ran-
dom-effects NMA models with binomial likelihood were fit to the
data, with comparisons between interventions expressed in terms
of ORs with 95% CrI.
For each outcome, NMA enabled us to calculate the probabil-
ity for each intervention to be at each possible rank. The Surface
Under the Cumulative RAnking curve (SUCRA) value, the mean
rankings (with 2.5% and 97.5% quantiles) of each intervention,
and the probability of each intervention to be the best (referred to
hereafter as ’Pr(best)’) were also estimated (Salanti 2011). Pr(best)
and SUCRA values range between 0 and 1, with values nearer 1 in-
dicative of preferred treatments. Values of smaller mean rank also
suggest preferred treatments. Further details regarding the meth-
ods and implementation of NMA are provided in the published
protocol (Burry 2015).
Unit of analysis issues
We used individual study participants in each trial arm as the unit
of analysis. We included all interventions relevant to this review. If
a trial involves multiple arms of the same drug class (e.g. multiple
atypical antipsychotics) compared to a control group, we planned
to merge data from the same drug class for pairwise comparisons.
Neither cluster-randomized trials nor cross-over trials were iden-
tified through the literature search. We did not anticipate cross-
over trials to evaluate delirium in the ICU, as this study design is
not typically used in the ICU.
Dealing with missing data
We conducted meta-analyses based on data available from our in-
cluded studies. For missing SDs associated with continuous out-
comes, we first contacted study authors for more information; we
made a maximum of three attempts.
Assessment of heterogeneity
An important aspect of NMA is examining included studies to
determine if they are sufficiently similar in terms of study design
and patient population. We describe each included trial in the
Characteristics of included studies tables. Within a treatment net-
work involving multiple interventions, heterogeneity can be the
result of an uneven distribution of important clinical and method-
ological effect modifiers across studies or across comparisons. We
assessed the presence of statistical heterogeneity by visual inspec-
tion of forest plots and by calculation of the I² statistic (Higgins
2003), as well as by the Chi² test for homogeneity (P < 0.10 deemed
significant). If the I² statistic was > 50%, we assessed the types and
sources of heterogeneity (clinical and methodological). We qual-
itatively assessed clinical heterogeneity by examining additional
delirium management strategies used in each trial (e.g. use of res-
cue medications or physical restraints to manage severe agitation,
non-drug strategies such as noise reduction or early mobilization).
We also assessed clinical heterogeneity by examining factors that
may influence delirium and sedation practices (for example, types
of sedatives and analgesics used, use of drugs known to increase
the risk of delirium, e.g. benzodiazepines, and definitions of out-
comes assessed).
Assessment of reporting biases
Reporting biases can occur due to an increased likelihood of pos-
itive (demonstration of effect) trials (large or small) being pub-
lished compared to negative (no effect demonstrated) trials. It is
difficult to estimate the number of unpublished delirium trials.
For direct comparisons in the network where a minimum of 10
studies were available, we reviewed comparison-adjusted funnel
plots to assess for small-study effects as signals of publication bias
(Salanti 2014).
Data synthesis
Methods for direct treatment comparisons
We performed conventional pairwise meta-analyses in Review
Manager 5.3 for all outcomes and comparisons that had at least
two studies available (Review Manager 2014). A variation of the
inverse-variance random-effects model was applied to continu-
ous outcomes (DerSimonian 1986), whereas the Mantel-Haenszel
random-effects model was applied to binary outcomes (DeMets
1987), allowing for variation within and between studies.
Methods for network meta-analysis (mixed treatment
comparisons)
NMA is a method of synthesizing evidence from trials addressing
the same question but involving multiple different interventions.
NMA combines direct and indirect evidence across a network of
RCTs into a single effect size for each pair of interventions. For a
given comparison (e.g. A vs B), direct evidence was provided by
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studies that compared two treatments head-to-head. Indirect evi-
dence for this comparison was provided by studies that compared
A versus C and B versus C (Caldwell 2005; Higgins 1996).
We followed established procedures to assess the validity of the as-
sumptions of homogeneity, similarity, and consistency (Donegan
2013). We performed NMAs within a Bayesian framework, assum-
ing a common between-study variance parameter across all com-
parisons and accounting for correlations in multi-arm studies (Lu
2006; Salanti 2011). A vague prior distribution for the between-
study variance parameter (specifically, Uniform (0, 3)) and vague
prior distribution for log ratio of means between each intervention
compared with placebo (specifically, Normal (0, 100)) were used
for all analyses. We reported findings when using the most recent
PRISMA Extension Statement for NMA (Hutton 2015). Two
review authors (WC, BH) performed NMAs with OpenBUGS
software (version 3.2.3, MRC Biostatistics Unit, Cambridge, UK)
(Lunn 2000; Spiegelhalter 2014). We expressed findings for con-
tinuous outcomes in terms of RoMs and findings for binary out-
comes in terms of ORs with corresponding 95% CrI (Dias 2011a;
Dias 2011b; Dias 2013). Network diagrams were drawn to depict
the evidence for each outcome. In the network diagrams, the size
of the treatment nodes reflects the number of participants ran-
domized to each treatment, and the thickness of the edges reflects
the number of studies informing each comparison.
We evaluated the adequacy of model fit by comparing the total
residual deviance to the number of unconstrained data points (i.e.
the total number of study arms); fit was adequate if these quantities
were close. Based on mean and SD values following transforma-
tion, fixed-effect and random-effects NMA models with Normal
Likelihood and the identity link were fit to the data (Dias 2011b).
Both fixed-effect (FE) and random-effects (RE) consistency mod-
els were fit, and we compared these models using the Deviance
Information Criterion (DIC), with lower value indicating better
model fit (Spiegelhalter 2002). We considered a difference of five
points or more indicative of an important difference. We also fit
unrelated means models to the data and compared DIC values
and posterior mean deviance contributions with those from con-
sistency models to detect violations of the consistency assumption.
We assessed model convergence with established methods includ-
ing inspection of Gelman-Rubin-Brooks diagnostics and poten-
tial scale reduction factors (Brooks 1998; Gelman 1996). As de-
scribed earlier, we also estimated SUCRA values, mean rankings,
and Pr(best) values for each intervention (Salanti 2011). For addi-
tional analyses, we planned to explore the impact of certain study
characteristics through subgroup analyses or meta-regression.
Subgroup analysis and investigation of heterogeneity
We planned to explore subgroup analyses or meta-regression anal-
yses or both, to assess the impact of covariates on findings to es-
tablish their robustness, if sufficient studies were available; specif-
ically:
1. age (< 65 years, ≥ 65 years);
2. different ICU populations (e.g. medical only, surgical only);
3. delirium subtype (e.g. hyperactive, hypoactive, mixed); or
4. use of co-interventions with non-drug approaches (e.g.
noise reduction, music therapy, early mobilization).
Sensitivity analysis
We planned to consider sensitivity analyses involving alternative
geometries of the network. Planned re-formulations of the network
included:
1. excluding studies with high risk of bias;
2. collapsing atypical and typical antipsychotics into one node;
3. splitting each node to reflect ‘low dose’ and ‘high dose’,
based on the median dose reported in trials; and
4. splitting each node to reflect fixed dosing and PRN (pro re
nata or as needed) only dosing.
We explored additional analyses after excluding studies that fo-
cused on subsyndromal delirium.
’Summary of findings’ tables and GRADE
In the ’Summary of findings’ tables, we present the specific re-
view outcomes duration of delirium, delirium-free and coma-free
days, days with coma, duration of mechanical ventilation, length
of ICU, and length of hospital stay, as recommended by Cochrane
(Higgins 2011; Schunemann 2011; Yepes-Nunez 2019). We used
the GRADE approach (https://gradepro.org/) to assess the quality
of the evidence for comparisons based on NMA. We graded the
quality of evidence for each outcome as ’high’, ’moderate’, ’low’, or
’very low’ using GRADEPro software (GRADEpro GDT), after
considering trial limitations (randomization, allocation conceal-
ment, and blinded outcome assessment), within-study directness
of evidence, heterogeneity, precision of effect estimates, and indi-
rectness. We did not assess risk of publication bias/small-study ef-
fects through funnel plots given the small number of studies avail-
able for any pairwise comparison. When we identified an issue
that we considered to be serious for each of the GRADE criteria,
we downgraded the quality of evidence and justified our decision
in the table footnotes. We assessed the extent of heterogeneity (i.e.
I² statistic) and examined imprecision based on the width of the
CI for treatment effect estimates.
R E S U L T S
Description of studies
Results of the search
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See Characteristics of included studies, Characteristics of excluded
studies, Characteristics of studies awaiting classification, and
Characteristics of ongoing studies.
The results of our search are outlined in Figure 1. The elec-
tronic database search yielded 7658 citations, and we identified
an additional 16 records through other sources. After we removed
duplicate items, 4461 unique citations remained. We excluded
4076 studies based on title and abstract, and we assessed the re-
maining 385 papers as full text. Fourteen studies met our inclu-
sion criteria (Al-Qadheeb 2016; Atalan 2013; Bakri 2015; Devlin
2010; Girard 2010a; Girard 2018; Hakim 2012; Needham 2016;
Page 2013; Page 2017; Reade 2009; Reade 2016; Skrobik 2004;
van Eijk 2010). Six studies await classification (NCT02366299;
NCT00429676; Emerson 2014; Peters 2015; Schoeffler 2012;
ISRCTN33122761) - three as conference abstracts (Emerson
2014; Peters 2015; Schoeffler 2012), and three as trial regis-
trations (NCT02366299; NCT00429676; ISRCTN33122761).
Ten studies are ongoing (NCT01811459; NCT03317067;
NCT02807467; NCT02216266; NCT02343575;
NCT00351299; NCT03628391; IRCT20121231011956N10;
IRCT20180911040998N1; NCT03392376), two of which have
published protocols (Louis 2018; Hollinger 2017).
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Figure 1. Study flow diagram.
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Included studies
See the Characteristics of included studies table.
Study population
The 14 included studies recruited 1844 adult participants, with
sample sizes ranging from 20 in Reade 2009 to 566 in Girard
2018. Seven studies enrolled more than 100 participants (Girard
2010a; Girard 2018; Hakim 2012; Needham 2016; Page 2013;
Page 2017; van Eijk 2010). Twelve studies enrolled a mix of med-
ical and surgical participants; two enrolled cardiovascular surgery
participants only (Atalan 2013; Hakim 2012).
Eight studies used the CAM-ICU to screen for delirium (Atalan
2013; Girard 2010a; Girard 2018; Needham 2016; Page 2013;
Page 2017; Reade 2016; van Eijk 2010); the remaining six
used the ICDSC (Al-Qadheeb 2016; Bakri 2015; Devlin 2010;
Hakim 2012; Reade 2009; Skrobik 2004). Five studies permit-
ted inclusion of patients at high risk of developing delirium (i.e.
delirium status not confirmed at study enrolment) (Al-Qadheeb
2016; Girard 2010a; Hakim 2012; Page 2013; Reade 2009). Of
these, two trials enrolled participants with subsyndromal delirium
(Al-Qadheeb 2016; Hakim 2012). One study enrolled mechan-
ically ventilated participants with specifically agitated delirium
(Reade 2009). Through written communication with the principal
investigator, we confirmed that all participants had at a minimum
subsyndromal delirium at enrolment, with 40% confirmed as
delirious (i.e. ICDSC > 4). The remaining studies enrolled a com-
bination of delirious and comatose participants (Girard 2010a;
Page 2013), or investigators confirmed delirium status before en-
rolment (Girard 2018). These trials all examined delirium during
ICU stay (and not thereafter).
Study design and setting
All trials but one were randomized (Skrobik 2004). Six trials
were multi-centre studies (Devlin 2010; Girard 2010a; Girard
2018; Needham 2016; Reade 2016; van Eijk 2010), and eight
were single-centre studies (Al-Qadheeb 2016; Atalan 2013; Bakri
2015; Hakim 2012; Page 2013; Page 2017; Reade 2009; Skrobik
2004). Six studies were conducted in North America - four exclu-
sively in the USA (Al-Qadheeb 2016; Girard 2010a; Girard 2018;
Needham 2016), one exclusively in Canada (Skrobik 2004), and
one in both Canada and the USA (Devlin 2010). The other stud-
ies took place in Australia and New Zealand (Reade 2009; Reade
2016), Egypt (Bakri 2015; Hakim 2012), the Netherlands (van
Eijk 2010), Turkey (Atalan 2013), and the UK (Page 2013; Page
2017).
Interventions and comparators
Ten trials were placebo-controlled (Al-Qadheeb 2016; Devlin
2010; Girard 2010a; Girard 2018; Hakim 2012; Needham 2016;
Page 2013; Page 2017; Reade 2016; van Eijk 2010). Four were
head-to-head comparisons of different drugs (Atalan 2013; Bakri
2015; Reade 2009; Skrobik 2004). Three included three study
groups (Bakri 2015; Girard 2010a; Girard 2018). Ten stud-
ied an antipsychotic intervention, predominantly haloperidol
(Al-Qadheeb 2016; Atalan 2013; Bakri 2015; Devlin 2010; Girard
2010a; Girard 2018; Hakim 2012; Page 2013; Reade 2009;
Skrobik 2004). Three studied alpha2 agonists (all used dexmedeto-
midine) (Bakri 2015; Reade 2009; Reade 2016). Two trials stud-
ied a statin (Needham 2016; Page 2017). The remaining trials
evaluated morphine (Atalan 2013), ondansetron (Bakri 2015), or
rivastigmine (van Eijk 2010). Ten trials titrated the study drug
based on symptoms or response (Atalan 2013; Bakri 2015; Devlin
2010; Girard 2010a; Girard 2018; Hakim 2012; Reade 2009;
Reade 2016; Skrobik 2004; van Eijk 2010); four used fixed drug
regimens (Al-Qadheeb 2016; Needham 2016; Page 2013; Page
2017).
The extent to which study medication was given also varied, with
some studies continuing drug for a fixed duration irrespective of
whether delirium had resolved and others protocolizing discontin-
uation of the study drug once the patient was no longer delirious
(Devlin 2010; Girard 2018; Page 2013). The duration of study
drug exposure varied across trials including maximum of 28 days
(Needham 2016; Page 2017), 14 days (Girard 2010a; Girard 2018;
Page 2013), 10 days (Al-Qadheeb 2016; Atalan 2013; Devlin
2010), seven days (Reade 2016), five days (Skrobik 2004), three
days (Bakri 2015), as long as deemed medically necessary (Reade
2009), until delirium resolution or hospital discharge (van Eijk
2010), or for 24 hours after ICDSC was zero (Hakim 2012).
Eleven trials allowed use of an additional drug for management
of breakthrough delirium symptoms or agitation (e.g. sedative,
antipsychotic) (Atalan 2013; Bakri 2015; Devlin 2010; Girard
2010a; Girard 2018; Hakim 2012; Page 2013; Reade 2009; Reade
2016; Skrobik 2004; van Eijk 2010).
Outcomes
Outcomes varied in terms of measurement and reporting. All but
two studies reported median (IQR) or mean (SD) for delirium
duration (Bakri 2015; Skrobik 2004). The planned primary out-
come defined as time from which delirium wasfirst identified to
when it was first resolved was rarely reported (Devlin 2010). Most
trials reported duration of delirium with variable definitions of
resolved delirium (e.g. one negative score, two consecutive days
with negative score, no definition provided). Therefore we chose
to pool the results as duration of delirium as reported by study
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authors. Five studies reported median (IQR) or mean (SD) for
number of days with coma (Girard 2010a; Girard 2018; Needham
2016; Page 2013; Page 2017); four reported median (IQR) or
mean (SD) for number of days alive without delirium or coma
(Girard 2010a; Girard 2018; Page 2013; Page 2017); eight re-
ported median (IQR) or mean (SD) for mechanical ventilation
duration (Al-Qadheeb 2016; Atalan 2013; Devlin 2010; Girard
2010a; Girard 2018; Needham 2016; Reade 2009; Reade 2016);
11 reported median (IQR) or mean (SD) for ICU length of stay
(Al-Qadheeb 2016; Atalan 2013; Devlin 2010; Girard 2010a;
Girard 2018; Hakim 2012; Needham 2016; Page 2013; Reade
2009; Reade 2016; van Eijk 2010); nine reported median (IQR)
or mean (SD) for hospital length of stay (Atalan 2013; Devlin
2010; Girard 2018; Hakim 2012; Needham 2016; Page 2013;
Page 2017; Reade 2016; van Eijk 2010); and 11 reported mor-
tality at various time points (Al-Qadheeb 2016; Atalan 2013;
Devlin 2010; Girard 2010a; Girard 2018; Hakim 2012; Needham
2016; Page 2013; Page 2017; Reade 2009; van Eijk 2010). Three
studies reported discharge disposition (Al-Qadheeb 2016; Devlin
2010; Reade 2016). Reported adverse events included arrhythmias
(Girard 2010a; Girard 2018; Page 2013; Reade 2009), extrapyra-
midal symptoms (Al-Qadheeb 2016; Devlin 2010; Girard 2010a;
Girard 2018; Hakim 2012; Page 2013; Skrobik 2004), use of
physical restraints (Reade 2009; van Eijk 2010), unintentional de-
vice removal (Al-Qadheeb 2016; Devlin 2010; Page 2013; Reade
2009; Reade 2016), and QTc prolongation (Al-Qadheeb 2016;
Bakri 2015; Devlin 2010; Girard 2010a; Girard 2018; Hakim
2012; Page 2013; Reade 2009).
For meta-analysis and network meta-analysis, we removed one
open-label trial from syntheses given what were judged to be spe-
cial features in the study population (i.e. cardiovascular surgery,
commonly associated with short ICU stays) and differences in
baseline characteristics between dexmedetomidine and haloperi-
dol arms despite randomization (Reade 2009).
Excluded studies
See Characteristics of excluded studies.
We excluded seven studies for the following reasons (Eremenko
2014; Khan 2019; Mailhot 2014; Pandharipande 2007; Riker
2009; Tagarakis 2012; Waszynski 2018): study design (Eremenko
2014; Pandharipande 2007; Riker 2009); no pharmacological in-
tervention (Khan 2019; Mailhot 2014; Waszynski 2018); and no
validated method to determine delirium (Tagarakis 2012).
Studies awaiting classification
See Characteristics of studies awaiting classification.
Six studies available as abstract - Emerson 2014, Peters 2015,
and Schoeffler 2012 - or as trial registration - NCT00429676,
ISRCTN33122761, and NCT02366299 - await classification due
to insufficient information. These studies evaluate an antipsy-
chotic (NCT00429676), clonidine (Schoeffler 2012), physostig-
mine (ISRCTN33122761), dexmedetomidine and propofol (
NCT02366299), a multi-component delirium management strat-
egy (Emerson 2014), and intranasal insulin aspart (Peters 2015).
Ongoing studies
See Characteristics of ongoing studies.
Ten studies
classified as ongoing studies will be monitored for incorporation
into future updates of this review (IRCT20121231011956N10;
IRCT20180911040998N1; NCT03392376; NCT01811459;
NCT03317067; NCT02807467; NCT02216266;




(NCT03317067; NCT02807467, NCT00351299), physostig-
mine (NCT02216266), and valproic acid (NCT02343575).
Risk of bias in included studies
We summarize risk of bias data in Figure 2 and Figure 3. Nine
trials scored low risk of bias across all domains (Al-Qadheeb 2016;
Devlin 2010; Girard 2010a; Girard 2018; Needham 2016; Page
2013; Page 2017; Reade 2016; van Eijk 2010).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We judged all studies but two - Atalan 2013 and Skrobik 2004 -
to have low risk of selection bias due to random sequence genera-
tion. Skrobik 2004 performed quasi-randomization (i.e. even/odd
enrolment day), and Atalan 2013 did not report the method of se-
quence generation. Twelve studies used computer-generated ran-
domization tables (Al-Qadheeb 2016; Bakri 2015; Devlin 2010;
Girard 2010a; Girard 2018; Hakim 2012; Page 2013; Needham
2016; Page 2017; Reade 2009; Reade 2016; van Eijk 2010). We
judged eleven studies to have adequate allocation concealment
via web-based programs or sealed opaque envelopes (Al-Qadheeb
2016; Devlin 2010; Girard 2010a; Girard 2018; Hakim 2012;
Needham 2016; Page 2013; Page 2017; Reade 2009; Reade 2016;
van Eijk 2010).
Blinding
Eleven studies have low risk of performance bias given blind design
and explicit discussion of blinded study participants, clinicians,
or study personnel (including outcome assessors) (Al-Qadheeb
2016; Bakri 2015; Devlin 2010; Girard 2010a; Girard 2018;
Hakim 2012; Needham 2016; Page 2013; Page 2017; Reade
2016; van Eijk 2010). We judged one study to have unclear risk
of blinding bias as no details of blinding were available (Atalan
2013). We judged two studies to have high risk of bias as these
trials lacked blinding (Reade 2009; Skrobik 2004). All trials but
one had blinded outcome assessment (Reade 2009).
Incomplete outcome data
We judged all studies but two to have low risk of attrition bias as
they accounted for all screened, enrolled, and randomized partici-
pants (Atalan 2013; Bakri 2015), and all except one employed an
intention-to-treat principle in their analyses (Skrobik 2004). Two
studies used a modified intention-to-treat analysis (e.g. modifica-
tion permitted to account for post-randomization circumstances
that prevented use of data from certain participants) (Reade 2016;
van Eijk 2010). We judged two studies to have unclear risk of attri-
tion bias because they did not include figures, tables, or text outlin-
ing the numbers of participants who were screened, enrolled, and
randomized, and/or who successfully completed the study proto-
col (Atalan 2013; Bakri 2015).
Selective reporting
We judged eleven studies to have low risk of reporting bias based
on examination of their respective trial registration or published
protocols (Al-Qadheeb 2016; Devlin 2010; Girard 2010a; Girard
2018; Hakim 2012; Needham 2016; Page 2013; Page 2017; Reade
2009; Reade 2016; van Eijk 2010). The remaining trials were
deemed at unclear risk, as trial registrations or protocols were not
available to confirm outcome reporting.
Other potential sources of bias
We judged all studies but two to have low risk of other potential
sources of bias (Atalan 2013; Bakri 2015). All studies cited fund-
ing sources, except Atalan 2013, which provided no funding de-
tails. Two studies were conducted without external funding (Bakri
2015; Hakim 2012). Study support for a pharmaceutical com-
pany was declared in seven studies; however all stated that these
companies had no involvement in study design, data collection,
analysis, or data reporting (Devlin 2010; Girard 2010a; Needham
2016; Reade 2009; Reade 2016; Skrobik 2004; van Eijk 2010).
Effects of interventions
See: Summary of findings for the main comparison Duration
of delirium; Summary of findings 2 Days with coma; Summary
of findings 3 Duration of mechanical ventilation; Summary of
findings 4 Length of ICU stay; Summary of findings 5 Length
of hospital stay; Summary of findings 6 QTc prolongation
See Summary of findings tables (Summary of findings for the
main comparison; Summary of findings 2; Summary of findings
3; Summary of findings 4; Summary of findings 5; Summary of
findings 6). The ’Summary of findings’ tables provide overall esti-
mates of treatment effects compared with placebo. We summarize
the quality of evidence for delirium duration, delirium-free and
coma-free days, duration of mechanical ventilation, and length of
ICU stay obtained through pairwise comparisons and NMA.
Geometry of evidence networks by endpoints
For all outcomes, most trials compared one active intervention
(drug) against placebo; trials involving comparisons between active
interventions were rare. The number of participants enrolled for
each active therapy was small in the networks compared to the
number enrolled for placebo comparisons. Figure 4 (panel A to F)
presents the network diagrams that indicate corresponding eligible
regimens in the evidence network for each outcome. Each line
links treatments directly compared across studies. Head-to-head
trials were available for 7/21 (33%) of the pairwise comparisons
for delirium duration, 6/15 (40%) for duration of mechanical
ventilation, 7/21 (33%) for hospital length of stay, 7/21 (33%)
for ICU length of stay, 4/6 (67%) for delirium-free and coma-free
days, and 4/6 (67%) for days in coma.
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Figure 4. Network diagrams of pairwise comparisons for the six outcomes with network meta-analyses.
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Primary outcome
1. Duration of delirium
Pairwise meta-analysis (direct comparisons)
Data from a total of 11 trials (n = 1530 participants) contributed
to the analysis of duration of delirium (Al-Qadheeb 2016; Atalan
2013; Devlin 2010; Girard 2010a; Girard 2018; Hakim 2012;
Needham 2016; Page 2013; Page 2017; Reade 2016; van Eijk
2010); ten RCTs (n = 1477 participants) were placebo-controlled.
Treatment effect estimates from pairwise meta-analyses are re-
ported in Analysis 1.1 and Figure 5. Pairwise meta-analyses showed
that the alpha2 agonist dexmedetomidine may be associated with
a shorter duration of delirium (ratio of means (RoM) 0.58, 95%
confidence interval (CI) 0.43 to 0.79; 71 participants; 1 study),
and the cholinesterase inhibitor rivastigmine may be associated
with a longer duration of delirium (RoM 1.84, 95% CI 1.25 to
2.69; 104 participants; 1 study) compared to placebo. The pair-
wise meta-analyses showed no effect on the duration of delirium
for typical antipsychotics (RoM 1.02, 95% CI 0.91 to 1.14; 608
participants; 4 studies), atypical antipsychotics (RoM 0.73, 95%
CI 0.49 to 1.11; 500 participants; 4 studies), or statins (RoM 1.07,
95% CI 0.91 to 1.25; 414 participants; 2 studies) compared to
placebo.
Figure 5. Forest plot of comparison: 1 Duration of delirium (log units), outcome: 1.1 Duration of delirium
(log units).
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NMA (combinations of direct and indirect comparisons)
The random-effects consistency model was an adequate fit, with
posterior total residual deviance of 27.33 (compared to 24 un-
constrained data points). The forest plot in Figure 6 presents the
ratio of means (RoM) estimates for each intervention compared to
placebo derived from the random-effects consistency model, along
with 95% credible intervals (CrIs). For all interventions compared
to placebo, 95% CrIs were wide and failed to rule out the possibil-
ity of no difference. The intervention with the smallest RoM (i.e.
most preferred) was the alpha2 agonist dexmedetomidine (RoM
0.58, 95% CrI 0.26 to 1.27; SUCRA 0.895; moderate-quality
evidence) (Table 1). In order of descending surface under the cu-
mulative ranking curve (SUCRA) values (best to worst; Table 2),
the next best interventions were atypical antipsychotics (RoM vs
placebo 0.80, 95% CrI 0.50 to 1.11; SUCRA 0.738; moderate-
quality evidence), opioids (RoM vs placebo 0.88, 95% CrI 0.37 to
2.01; SUCRA 0.578; very low-quality evidence), typical antipsy-
chotics (RoM vs placebo 0.96, 95% CrI 0.64 to 1.36; SUCRA
0.468; high-quality evidence), placebo (SUCRA 0.403), statins
(RoM vs placebo 1.05, 95% CrI 0.61 to 1.77; SUCRA 0.365;
moderate-quality evidence), and the cholinesterase inhibitor ri-
vastigmine (RoM vs placebo 1.84, 95% CrI 0.82 to 4.10; SUCRA
0.054; moderate-quality evidence). In addition to comparisons
versus placebo, Table 1 shows the comparisons between active in-
terventions. As an example of interpretation, the RoM estimate of
0.58 (95% CrI 0.26 to 1.27) in the lower triangle suggests a 42%
reduction in the mean duration of delirium with alpha2 agonists
compared to placebo. The corresponding probability estimate in
the upper triangle suggests a probability of 93.8% that alpha2 ago-
nists are better than placebo in terms of duration of delirium. The
between-study SD, as a measure of heterogeneity, was estimated
to be 0.29 (95% CrI 0.03 to 0.75). Comparison of DIC values be-
tween the random-effects consistency model (-14.66) and the cor-
responding random-effects unrelated means model (DIC -14.55),
as well as inspection of a scatterplot of posterior mean deviance
contributions from both models (Figure 7), suggested no viola-
tion of the consistency assumption. Our inspection of Gelman-
Rubin-Brooks diagnostics and potential scale reduction factors for
all NMAs confirmed convergence with 200,000 iterations in all
cases (among which 100,000 were burn-in).
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Figure 6. Findings from network meta-analysis: duration of delirium, delirium-free and coma-free days, and
days with coma.
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Figure 7. Consistency assumption check: posterior mean deviance contribution plots for RE consistency
model vs unrelated means model; they did not suggest violation of the consistency assumption.
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Secondary outcomes
1. a) Delirium-free and coma-free days
Pairwise meta-analysis (direct comparisons)
Data from a total of four trials (n = 950 participants) contributed
to the analysis of delirium-free and coma-free days (Girard 2010a;
Girard 2018; Page 2013; Page 2017). Studies were placebo-con-
trolled with antipsychotics - in Girard 2010a, Girard 2018, and
Page 2013 - or statins - in Page 2017 - as the intervention. No
pairwise comparison resulted in fewer delirium-free and coma-free
days (Analysis 2.1; Figure 8).
Figure 8. Forest plot of comparison: 2 Delirium-free and coma-free days (log units), outcome: 2.1 Delirium-
free and coma-free days.
NMA (combinations of direct and indirect comparisons)
The forest plot in Figure 6 presents estimates for all interven-
tions compared to placebo from the random-effects consistency
model. The random-effects consistency model was an adequate
fit, with posterior total residual deviance of 10.59 (compared to
10 unconstrained data points). The intervention with the largest
RoM was atypical antipsychotics (RoM vs placebo 1.31, 95% CrI
0.69 to 2.83; SUCRA 0.845; moderate-quality evidence). In or-
der of descending SUCRA values, the next best interventions were
typical antipsychotics (RoM vs placebo 1.14, 95% CrI 0.64 to
2.16; SUCRA 0.589; moderate-quality evidence), placebo (SU-
CRA 0.327), and statins (RoM vs placebo 0.90, 95% CrI 0.32
to 2.52; SUCRA 0.239; moderate-quality evidence). In addition
to comparisons versus placebo, comparisons between active inter-
ventions are provided in Table 3, and secondary measures of effect
are presented in Table 4. In all cases, 95% CrIs were wide and
failed to rule out the possibility of no difference. The between-
study SD, as a measure of heterogeneity, was estimated to be 0.37
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(95% CrI 0.02 to 1.42). Comparison of DIC values between the
random-effects consistency model (-11.23) and the corresponding
random-effects unrelated means model (DIC -11.26), as well as
inspection of a scatterplot of posterior mean deviance contribu-
tions from both models (Figure 7), did not suggest violation of
the consistency assumption.
1. b) Days with coma
Pairwise meta-analysis (direct comparisons)
Data from a total of five trials (n = 1222 participants) contributed
to the analysis of days with coma (Girard 2010a; Girard 2018;
Needham 2016; Page 2013; Page 2017). All five studies were
placebo-controlled, with antipsychotics (in Girard 2010a, Girard
2018, and Page 2013) or statins (in Needham 2016 and Page
2017) as the intervention group. No pairwise comparison resulted
in fewer days with coma (Analysis 3.1; Figure 9).
Figure 9. Forest plot of comparison: 3 Days with coma (log units), outcome: 3.1 Days with coma (log units).
NMA (combinations of direct and indirect comparisons)
The forest plot in Figure 6 presents estimates for each intervention
compared to placebo from the random-effects consistency model.
The random-effects consistency model was an adequate fit, with
a posterior total residual deviance of 12.34 (compared to 12 un-
constrained data points). The intervention with the smallest RoM
versus placebo was typical antipsychotics (RoM vs placebo 0.77,
95% CrI 0.43 to 1.29; SUCRA 0.820; low-quality evidence). In
order of descending SUCRA values, the next best interventions
were statins (RoM vs placebo 0.92, 95% CrI 0.49 to 1.80; SUCRA
0.481; moderate-quality evidence), atypical antipsychotics (RoM
vs placebo 0.94, 95% CrI 0.48 to 1.72; SUCRA 0.422; moderate-
quality evidence), and placebo (SUCRA 0.278). In addition to
comparisons versus placebo, comparisons between active interven-
tions are provided in Table 5, and secondary measures of effect are
presented in Table 6. In all cases, 95% CrIs were wide and failed to
rule out the possibility of no difference. The between-study SD,
as a measure of heterogeneity, was estimated to be 0.34 (95% CrI
0.03 to 1.08). Comparison of DIC values between the random-
effects consistency model (-5.32) and the corresponding random-
effects unrelated means model (-5.33), as well as inspection of a
scatterplot of posterior mean deviance contributions from both
models (Figure 7), did not suggest violation of the consistency
assumption.
2. Relapse of delirium (% patients)
No study reported data on this outcome.
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3. Resolution of delirium symptoms (e.g. hallucinations,
agitation)
No study reported data on resolution of delirium symptoms
as a specific outcome. Agitation was reported in three studies
(Al-Qadheeb 2016; Devlin 2010; Page 2013). Al-Qadheeb 2016
found that the haloperidol group spent fewer hours per study day
agitated (Sedation Agitation Scale ≥ 5) compared to the placebo
group (median 0 vs 2; P = 0.008). Similarly, Devlin 2010 found
that quetiapine was associated with fewer hours of agitation (SAS
≥ 5) compared to placebo (6 vs 36; P = 0.02). Page 2013 found
that a smaller proportion of participants had agitated Richmond
Agitation-Sedation Scale (RASS) scores (RASS > 2+) in the first
14 days of the study in the haloperidol group compared to the
placebo group (median 13% vs 20%; P = 0.0075).
4. Duration of mechanical ventilation
Pairwise meta-analysis (direct comparisons)
Data from a total of seven trials (n = 1167 participants) con-
tributed to the analysis of duration of mechanical ventilation
(Al-Qadheeb 2016; Atalan 2013; Devlin 2010; Girard 2010a;
Girard 2018; Needham 2016; Reade 2016); all but one study was
placebo-controlled (Atalan 2013). Trials evaluated dexmedeto-
midine (Reade 2016), antipsychotics (Al-Qadheeb 2016, Devlin
2010; Girard 2010a; Girard 2018), opioids (Atalan 2013), and
statins (Needham 2016). For meta-analysis and network meta-
analysis, we could not include Page 2013 or Reade 2009 in the
syntheses of mechanical ventilation duration. We excluded Page
2013 due to missing SD. We excluded Reade 2009 as the addition
of this trial resulted in problems with the consistency equation.
We judged there to be important differences in study populations
(i.e. cardiovascular surgery commonly associated with short ICU
stays) that explained the disruption of the consistency equation.
Amongst the pairwise comparisons versus placebo (Analysis 4.1;
Figure 10), dexmedetomidine was associated with a reduced dura-
tion of mechanical ventilation (RoM 0.55, 95% CI 0.41 to 0.75;
71 participants; 1 study), and typical antipsychotics (RoM 0.92,
95% CI 0.79 to 1.06; 515 participants; 3 studies), atypical an-
tipsychotics (RoM 0.98, 95% CI 0.84 to 1.34; 476 participants;
3 studies), and statins (RoM 1.09, 95% CI 0.90 to 1.34; 272 par-
ticipants; 1 study) did not.
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Figure 10. Forest plot of comparison: 4 Duration of mechanical ventilation (log units), outcome: 4.1
Duration of mechanical ventilation (log units).
NMA (combinations of direct and indirect comparisons)
The forest plot in Figure 11 presents RoM estimates for each inter-
vention compared to placebo from the random-effects consistency
model. The random-effects consistency model was an adequate
fit, with posterior total residual deviance of 14.13 (compared to
16 unconstrained data points). The intervention with the smallest
RoM versus placebo was dexmedetomidine (RoM 0.55, 95% CrI
0.34 to 0.89; SUCRA 0.974; moderate-quality evidence). In or-
der of descending SUCRA values, the next best interventions were
typical antipsychotics (RoM 0.93, 95% CI 0.72 to 1.24; SUCRA
0.576; moderate-quality evidence), atypical antipsychotics (RoM
0.98, 95% CI 0.71 to 1.28; SUCRA 0.440; moderate-quality evi-
dence), opioids (RoM vs placebo 0.99, 95% CrI 0.58 to 1.76; SU-
CRA 0.410; very low-quality evidence), placebo (SUCRA 0.377),
and statins (RoM vs placebo 1.10, 95% CrI 0.71 to 1.69; SUCRA
0.223; moderate-quality evidence). Comparisons between active
interventions are provided in Table 7, and secondary measures of
effect are presented in Table 8. The between-study SD, as a mea-
sure of heterogeneity, was estimated to be 0.14 (95% CrI 0.005
to 0.53). Comparison of DIC values between the random-effects
consistency model (-15.16) and the corresponding random-effects
unrelated means model (-15.24), as well as inspection of a scatter-
plot of posterior mean deviance contributions from both models
(Figure 7), did not suggest violation of the consistency assump-
tion.
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Figure 11. Findings from network meta-analysis: duration of mechanical ventilation, length of ICU and
hospital stay.
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5. a) Length of ICU stay
Pairwise meta-analysis (direct comparisons)
Data from a total of 10 trials (n = 1475 participants) contributed
to the analysis of length of ICU stay (Al-Qadheeb 2016; Atalan
2013; Devlin 2010; Girard 2010a; Girard 2018; Hakim 2012;
Needham 2016; Page 2013; Reade 2016; van Eijk 2010); all but
one trial were placebo-controlled (Atalan 2013). Atypical antipsy-
chotics were associated with significantly reduced length of ICU
stay (RoM 0.91, 95% CI 0.84 to 1.00; 577 participants; 4 stud-
ies), and the cholinesterase inhibitor rivastigmine was associated
with significantly increased length of ICU stay (RoM 2.18, 95%
CI 1.58 to 3.03; 104 participants; 1 study) compared to placebo
(Analysis 5.1; Figure 12). No difference was found for typical an-
tipsychotics (RoM 1.01, 95% CI 0.90 to 1.14; 618 participants;
4 studies), statins (RoM 1.06, 95% CI 0.91 to 1.23; 272 partic-
ipants; 1 study), or alpha2 agonists (RoM 0.80, 95% CI 0.59 to
1.08; 71 participants; 1 study) compared to placebo.
Figure 12. Forest plot of comparison: 5 Length of ICU stay (log units), outcome: 5.1 Length of ICU stay (log
units).
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NMA (combinations of direct and indirect comparisons)
The forest plot in Figure 11 presents RoM estimates for each inter-
vention compared to placebo from the random-effects consistency
model. The random-effects consistency model was an adequate fit,
with posterior total residual deviance of 20.45 (compared to 22
unconstrained data points). The cholinesterase inhibitor rivastig-
mine was found to have longer length of ICU stay compared to
placebo, and all remaining comparisons showed wide 95% CrIs
that failed to rule out the possibility of no difference. The interven-
tion with the smallest RoM versus placebo was dexmedetomidine
(RoM 0.80, 95% CrI 0.55 to 1.17; SUCRA 0.853; low-quality
evidence). In order of descending SUCRA values, the next best
interventions were atypical antipsychotics (RoM vs placebo 0.92,
95% CrI 0.80 to 1.08; SUCRA 0.709; high-quality evidence), opi-
oids (RoM vs placebo 0.92, 95% CrI 0.62 to 1.40; SUCRA 0.639;
very low-quality evidence), typical antipsychotics (RoM vs placebo
0.99, 95% CrI 0.85 to 1.17; SUCRA 0.496; moderate-quality ev-
idence), placebo (SUCRA 0.457), statins (RoM vs placebo 1.07,
95% CrI 0.81 to 1.41; SUCRA 0.344; low-quality evidence), and
cholinesterase inhibitors (RoM vs placebo 2.19, 95% CrI 1.47 to
3.27; SUCRA 0.002; moderate-quality evidence). Comparisons
between active interventions are provided in Table 9, and sec-
ondary measures of effect are presented in Table 10. The between-
study SD, as a measure of heterogeneity, was estimated to be 0.09
(95% CrI 0.003 to 0.28). Comparison of DIC values between the
random-effects consistency model (-27.94) and the correspond-
ing random-effects unrelated means model (-27.97), as well as in-
spection of a scatterplot of posterior mean deviance contributions
from both models (Figure 7), did not suggest violation of the con-
sistency assumption.
5. b) Length of hospital stay
Pairwise meta-analysis (direct comparisons)
Data from a total of nine trials (n = 1403 participants) contributed
to the analysis of length of hospital stay (Atalan 2013; Devlin 2010;
Girard 2018; Hakim 2012; Needham 2016; Page 2013; Page
2017; Reade 2016; van Eijk 2010); eight studies were placebo-
controlled. No pairwise comparison was statistically significant
(Analysis 6.1; Figure 13).
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Figure 13. Forest plot of comparison: 6 Length of hospital stay (log units), outcome: 6.1 Length of hospital
stay (log units).
NMA (combination of direct and indirect comparisons)
The forest plot in Figure 11 presents RoM estimates for each inter-
vention compared to placebo from the random-effects consistency
model. The random-effects consistency model was an adequate
fit, with a posterior total residual deviance of 19.07 (compared to
19 unconstrained data points). The intervention with the smallest
RoM versus placebo was typical antipsychotics (RoM 0.92, 95%
CrI 0.65 to 1.18; SUCRA 0.722; low-quality evidence). In order
of descending SUCRA values, the next best interventions were
atypical antipsychotics (RoM vs placebo 0.93, 95% CrI 0.69 to
1.16; SUCRA 0.693; moderate-quality evidence), statins (RoM
vs placebo 0.98, 95% CrI 0.69 to 1.30; SUCRA 0.537; moderate-
quality evidence), opioids (RoM vs placebo 0.97, 95% CrI 0.55
to 1.60; SUCRA 0.532; very low-quality evidence), placebo (SU-
CRA 0.435), dexmedetomidine (RoM vs placebo 1.10, 95% CrI
0.69 to 1.75; SUCRA 0.301; moderate-quality evidence), and ri-
vastigmine (RoM vs placebo 1.11, 95% CrI 0.70 to 1.77; SUCRA
0.280; moderate-quality evidence). Comparisons between active
interventions are provided in Table 11, and secondary measures
of effect are presented in Table 12. In all cases, 95% CrIs were
wide and failed to rule out the possibility of no difference. The
between-study SD, as a measure of heterogeneity, was estimated
to be 0.15 (95% CrI 0.005 to 0.53). Comparison of DIC values
between the random-effects consistency model (-27.19), and the
corresponding random-effects unrelated means model (-27.32), as
well as inspection of a scatterplot of posterior mean deviance con-
tributions from both models (Figure 7), did not suggest violation
of the consistency assumption.
6. Mortality
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Pairwise meta-analysis (direct comparisons)
Data from a total of 10 trials (n = 1584 participants) contributed to
the analysis of mortality (Al-Qadheeb 2016; Atalan 2013; Devlin
2010; Girard 2010a; Girard 2018; Hakim 2012; Needham 2016;
Page 2013; Page 2017; van Eijk 2010). Studies were placebo-con-
trolled with cholinesterase inhibitors, typical and atypical antipsy-
chotics, and statins as the interventions assessed, except for one
trial (Atalan 2013), which compared opioids with typical antipsy-
chotics. Mortality was reported at various time points and settings
(e.g. 14 day, 28 day, ICU, hospital). No comparisons were statis-
tically significant (Analysis 7.1; Figure 14).
Figure 14. Forest plot of comparison: 7 Mortality, outcome: 7.1 Mortality.
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NMA (combinations of direct and indirect comparisons)
We planned to perform an NMA for mortality. However, due to
variability in follow-up duration and settings across comparisons
in the network, NMA was judged by the research team to be inap-
propriate and thus was not pursued. The disconnected network of
interventions for the setting of ICU mortality alone (or hospital
mortality alone) made NMA infeasible.
7. Use of physical restraint
Two studies reported on physical restraint application but used
different outcome measures that were not amenable to meta-anal-
ysis. Reade 2009 reported that 8/10 participants in the antipsy-
chotic group were restrained compared to 9/10 participants in the
alpha2 agonist group (no statistical difference), and van Eijk 2010
reported the percentage of days on which participants were re-
strained (no difference between groups was observed: 1% placebo
and 1% cholinesterase inhibitor, respectively).
8. Hospital discharge disposition
Three studies reported on patient discharge disposition with in-
sufficient information for pooling (Al-Qadheeb 2016; Devlin
2010; Reade 2016). Devlin 2010 reported the combined out-
come of home or rehabilitation facility (89% quetiapine vs 56%
placebo; P = 0.06). Al-Qadheeb 2016 reported no overall statis-
tical difference in the percentage of participants discharged home
(41.2% haloperidol vs 26.5% placebo), to a rehabilitation facil-
ity (29.4% haloperidol vs 47.1% placebo), or to long-term care
(2.9% haloperidol vs 2.9% placebo). Finally, Reade 2016 reported
the percentage of participants transferred to rehabilitation facili-
ties (13.2% dexmedetomidine vs 9.7% placebo; P = 0.65).
9. Long-term cognitive outcome
This outcome was reported for only one trial (Page 2017). Study
investigators assessed cognitive outcomes at six months using the
Brief Test of Adult Cognition by Telephone (BTACT) (Lachman
2008). The BTACT assesses multiple dimensions central to effec-
tive cognitive functioning (e.g. episodic memory, reasoning, exec-
utive function). They also compared the Informant Questionnaire
on Cognitive Decline in the Elderly (IQCODE) at baseline ver-
sus data at six-month follow-up (Jorm 1994). BTACT composite
scores and differences between the IQCODE at baseline and at
six-month follow-up did not differ between the two groups.
10. Health-related quality of life
No study reported this outcome.
11. Adverse events - a) Akathisia
Pairwise meta-analysis (direct comparisons)
Akathisia was reported in two trials comparing antipsychotics to
placebo (Girard 2010a; Page 2013). The overall number of partic-
ipants was low (N = 242), as was the number of events. Akathisia
was assessed subjectively with a 10-cm visual analogue scale (Girard
2010a), or it was not specified how assessment was performed
(Page 2013). We found no differences in any of the drug pairwise
comparisons (Analysis 8.1; Figure 15). We assessed the evidence
as low quality.
Figure 15. Forest plot of comparison: 8 Akathisia, outcome: 8.1 Akathisia.
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NMA (combination of direct and indirect comparisons)
We did not conduct an NMA for this adverse event as only trials
investigating antipsychotic drugs reported on this outcome.
11. Adverse events - b) Arrhythmia and QTc prolongation
Pairwise meta-analysis (direct comparisons)
Arrhythmias were reported as an adverse event in four trials (Girard
2010a; Girard 2018; Page 2013; Reade 2009), and 828 partic-
ipants were analysed. These trials compared antipsychotics - in
Girard 2010a, Girard 2018, and Page 2013 - versus placebo or
dexmedetomidine - in Reade 2009. The number of included par-
ticipants was small, and events were rare. Only typical antipsy-
chotics compared with placebo were associated with significantly
increased odds of arrhythmias (OR 3.09, 95% CI 1.11 to 8.62)
amongst all pairwise comparisons (Analysis 9.1; Figure 16).
Figure 16. Forest plot of comparison: 9 Arrhythmias, outcome: 9.1 Arrhythmias.
QTc prolongation, measured by electrocardiogram, was reported
in seven studies (Al-Qadheeb 2016; Bakri 2015; Devlin 2010;
Girard 2010a; Girard 2018; Page 2013; Reade 2009), and 996
participants were analysed. Trials investigated antipsychotics com-
pared to placebo, ondansetron, and dexmedetomidine. The overall
number of participants was small, as was the number or reported
events. No comparisons were statistically significant (Analysis
10.1; Figure 17).
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Figure 17. Forest plot of comparison: 10 QTc prolongation, outcome: 10.1 QTc prolongation.
NMA (combination of direct and indirect comparisons)
We did not conduct an NMA for this adverse event.
11. Adverse events - c) Extrapyramidal side effects
Pairwise meta-analysis (direct comparisons)
Extrapyramidal side effects were assessed in six antipsychotic tri-
als (Al-Qadheeb 2016; Devlin 2010; Girard 2010a; Girard 2018;
Page 2013; Skrobik 2004), which included a total of 985 anal-
ysed participants. Extrapyramidal symptoms were assessed on the
modified Simpson-Angus Scale in five trials (Devlin 2010; Girard
2010a; Girard 2018; Page 2013; Skrobik 2004), and one trial
did not report the assessment method used (Al-Qadheeb 2016).
Pooled results showed no significant differences compared to
placebo (Analysis 11.1; Figure 18).
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Figure 18. Forest plot of comparison: 11 Extrapyramidal symptoms, outcome: 11.1 Extrapyramidal
symptoms.
NMA (combinations of direct and indirect comparisons)
We planned to perform an NMA for extrapyramidal side effects.
However, due to both the rare nature of events in this analysis and
violation of the consistency assumption, NMA was judged to be
inappropriate.
11. Adverse events - d) Seizures
No trial reported or examined seizures as an outcome.
Subgroup analyses
We planned to explore subgroup analyses or meta-regression anal-
yses, or both, to address the impact of age, ICU patient popula-
tion, delirium subtype, and use of non-drug co-interventions on
our findings to establish their robustness.
Neither subgroup analyses nor meta-regression analyses were fea-
sible to explore the delirium subtype (e.g. hyperactive, hypoactive,
mixed) and use of non-drug co-interventions. We did not have
a well-connected evidence network to perform subgroup analyses
for studies with mean participant age ≥ 65 years. Subgroup anal-
yses for studies with mean age < 65 years resulted in widened CIs/
CrIs for typical and atypical antipsychotics and disappearance of
opioids and cholinesterase inhibitors from the evidence network,
but did not provide different results compared to overall analyses.
Sensitivity analyses
We explored some sensitivity analyses involving alternative geome-
tries of the network. We did not end up with a well-connected
evidence network for each outcome once high risk of bias trials
were excluded. There were insufficient trials to conduct analyses
involving alternative geometries based on dose or frequency of
drug administration. Planned sensitivity analyses collapsing atyp-
ical and typical antipsychotics into one node did not provide dif-
ferent results compared to the overall analyses.
After exclusion of studies that focused on subsyndromal delirium
(Al-Qadheeb 2016; Hakim 2012), CIs/CrIs widened for typical
and atypical antipsychotics, but results were not different com-
pared to findings of the overall analyses.
Removal from analysis of studies with patients of low illness sever-
ity eliminated alpha2 agonists (dexmedetomidine) and opioids
(morphine) from the evidence network (Atalan 2013; Hakim
2012; Reade 2016), but results for the remaining interventions
were not different compared to findings of the overall analyses.
Reporting bias
We did not produce a funnel plot for each pairwise comparison.
To detect small-study effects by checking asymmetry per pairwise
comparison is not feasible due to the low number of identified
trials.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Outcome: days with coma
Patient or population: crit ically ill adult with conf irmed or at high risk of delirium
Settings: intensive care units in Australia and New Zealand, Canada, Egypt, Netherlands, Turkey, USA, UK
Intervention: any pharmacological intervent ion
Control: placebo or act ive comparator
Comparisons Illustrative comparative risks* (95% CI) Ratio of means (RoM)
based on log RoM esti-
mates from meta-anal-
ysis
(IV, random, 95% CI)
Number of participants
(studies)












Median number of days
with coma: 1 to 2 days
for placebo
1.53 days with coma
(95% CrI 0.86 to
2.57) corresponding to
2 days in the placebo
group
RoM: exp(-0.29) = 0.75
(95%CI 0.49 to 1.13);
log RoM: -0.29 (-0.71 to







SUCRA = 0.820, mean




Median number of days
with coma: 1 to 2 days
for placebo
1.88 days with coma
(95% CrI 0.96 to
3.43) corresponding to
2 days in the placebo
group
RoM: exp(0.06) = 1.06
(95%CI 0.88 to 1.30);
log RoM: 0.06 (-0.13 to







SUCRA = 0.422, mean




Mean number of days
with coma: 1.1 to 4.2
days for placebo
1.84 days with coma
(95% CrI 0.98 to
3.59) corresponding to
2 days in the placebo
group
RoM: exp(-0.10) = 0.90
(95%CI 0.73 to 1.12);
log RoM: -0.10 (-0.32 to







SUCRA = 0.481, mean














































































































* The basis for the assumed risk (e.g. the median control group risk across studies). The corresponding risk (and its 95%CrI) is calculated as the assumed risk mult iples the
ratio of means (and its 95% CrI) based on NMA.
CI: conf idence interval; CrI: credible interval; HMG-CoA: 5-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor; NMA: network meta-analysis; Pr(best): probability(best);
RoM: rat io of means; SUCRA: surface under the cumulat ive ranking curve
GRADE Working Group grades of evidence.
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aDowngraded one level for heterogeneity (I² of 50% to 75%, > 75% considered as medium and large heterogeneity).













































































































Outcome: duration of mechanical ventilation
Patient or population: crit ically ill adult with conf irmed or at high risk of delirium
Settings: intensive care units in Australia and New Zealand, Canada, Egypt, Netherlands, Turkey, USA, UK
Intervention: any pharmacological intervent ion
Control: placebo or act ive comparator
Comparisons Illustrative comparative risks* (95% CI) Ratio of means (RoM)
based on log RoM esti-
mates from meta-anal-
ysis
(IV, random, 95% CI)
Number of participants
(studies)












Median durat ion of me-
chanical vent ilat ion: 3
to 5 days for placebo
3.71 days of mechani-
cal vent ilat ion (95% CrI
2.89 to 4.94) corre-
sponding to 4 days in
the placebo group
RoM: exp(-0.08) = 0.92
(95% CI 0.79 to 1.06);
log RoM: -0.08 (-0.23 to







SUCRA = 0.576, mean





Median durat ion of me-
chanical vent ilat ion: 3
to 11 days for placebo
3.91 days of mechani-
cal vent ilat ion (95% CrI
2.85 to 5.10) corre-
sponding to 4 days in
the placebo group
RoM: exp(-0.02) = 0.98
(95% CI 0.84 to 1.34);
log RoM: -0.02 (-0.17 to







SUCRA = 0.440, mean




Mean durat ion of me-
chanical vent ilat ion: 11
days for placebo
4.38 days of mechani-
cal vent ilat ion (95% CrI
2.82 to 6.77) corre-
sponding to 4 days in
the placebo group
RoM: exp(0.09) = 1.09
(95% CI 0.90 to 1.34);
log RoM: 0.09 (-0.11 to







SUCRA = 0.223, mean
















































































































Median durat ion of me-
chanical vent ilat ion: 1.
846 days for placebo
2.21 days of mechani-
cal vent ilat ion (95% CrI
1.36 to 3.58) corre-
sponding to 4 days in
the placebo group
RoM: exp(-0.59) = 0.55
(95% CI 0.41 to 0.75);
log RoM: -0.59 (-0.89 to







SUCRA = 0.974, mean




No study reported this
comparison
3.96 days of mechani-
cal vent ilat ion (95% CrI
2.32 to 7.02) corre-










SUCRA = 0.410, mean
Pr(best) = 0.033, mean
rank = 3.95
* The basis for the assumed risk (e.g. the median control group risk across studies). The corresponding risk (and its 95%CrI) is calculated as the assumed risk mult iples the
ratio of means (and its 95% CrI) based on NMA.
CI: conf idence interval; CrI: credible interval; HMG-CoA: 5-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor; NMA: network meta-analysis; Pr(best): probability(best);
RoM: rat io of means; SUCRA: surface under the cumulat ive ranking curve
GRADE Working Group grades of evidence.
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aDowngraded one level for imprecision (wide credible interval).














































































































Outcome: length of ICU stay
Patient or population: crit ically ill adult with conf irmed or at high risk of delirium
Settings: intensive care units in Australia and New Zealand, Canada, Egypt, Netherlands, Turkey, USA, UK
Intervention: any pharmacological intervent ion
Control: placebo or act ive comparator
Comparisons Illustrative comparative risks* (95% CI) Ratio of means (RoM)
based on log RoM esti-
mates from meta-anal-
ysis
(IV, random, 95% CI)
Number of participants
(studies)












Median length of ICU
stay: 5 to 9 days for
placebo
7.92 days of ICU stay
(95% CrI 6.79 to
9.37) corresponding to
8 days in the placebo
group
RoM: exp(0.01) = 1.01
(95% CI 0.90 to 1.14);
log RoM: 0.01 (-0.11 to







SUCRA = 0.496, mean




Median length of ICU
stay: 3 to 16 days for
placebo
7.40 days of ICU stay
(95% CrI 6.37 to
8.66) corresponding to
8 days in the placebo
group
RoM: exp(-0.09) = 0.91
(95% CI 0.84 to 1.00);
log RoM: -0.09 (-0.18 to







SUCRA = 0.709, mean




Mean length of ICU
stay: 13 days for
placebo
8.54 days of ICU stay
(95% CrI 6.46 to
11.25) corresponding
to 8 days in the placebo
group
RoM: exp(0.06) = 1.06
(95% CI 0.91 to 1.23);
log RoM: 0.06 (-0.09 to







SUCRA = 0.344, mean
















































































































Median length of ICU
stay: 7.5 days for
placebo
6.43 days of ICU stay
(95% CrI 4.42 to
9.33) corresponding to
8 days in the placebo
group
RoM: exp(-0.22) = 0.80
(95% CI 0.59 to 1.08);
log RoM: -0.22 (-0.53 to







SUCRA = 0.853, mean





Median length of ICU
stay: 8 days for placebo
17.53 days of ICU stay
(95% CrI 11.76 to
26.14) corresponding
to 8 days in the placebo
group
RoM: exp(0.78) = 2.18
(95% CI 1.58 to 3.03);
log RoM: 0.78 (0.46 to







SUCRA = 0.002, mean




No study reported this
comparison
7.40 days of ICU stay
(95% CrI 4.95 to
11.24) corresponding










SUCRA = 0.639, mean
Pr(best) = 0.238, mean
rank = 3.17
* The basis for the assumed risk (e.g. the median control group risk across studies). The corresponding risk (and its 95%CrI) is calculated as the assumed risk mult iples the
ratio of means (and its 95% CrI) based on NMA.
CI: conf idence interval; CrI: credible interval; HMG-CoA: 5-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor; NMA: network meta-analysis; Pr(best): probability(best);
RoM: rat io of means; SUCRA: surface under the cumulat ive ranking curve
GRADE Working Group grades of evidence.
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aDowngraded one level for imprecision (wide credible interval).
bDowngraded one level for single trial with risk of bias and indirectness.














































































































Outcome: length of hospital stay
Patient or population: crit ically ill adult with conf irmed or at high risk of delirium
Settings: intensive care units in Australia and New Zealand, Canada, Egypt, Netherlands, Turkey, USA, UK
Intervention: any pharmacological intervent ion
Control: placebo or act ive comparator
Outcomes Illustrative comparative risks* (95% CI) Ratio of means (RoM)
based on log RoM esti-
mates from meta-anal-
ysis
(IV, random, 95% CI)
Number of participants
(studies)












Median length of hospi-
tal stay: 13 to 26 days
for placebo
16.48 days of hospi-
tal stay (95% CrI 11.74
to 21.29) correspond-
ing to 18 days in the
placebo group
RoM: exp(-0.12) = 0.89
(95% CI 0.68 to 1.15);
log RoM: -0.12 (-0.38 to







SUCRA = 0.722, mean




Median length of hospi-
tal stay: 6 to 26 days for
placebo
16.69 days of hospi-
tal stay (95% CrI 12.47
to 20.79) correspond-
ing to 18 days in the
placebo group
RoM: exp(-0.04) = 0.96
(95% CI 0.88 to 1.05);
log RoM: -0.04 (-0.13 to







SUCRA = 0.693, mean




Mean length of hospital
stay: 22 to 23.1 days for
placebo
17.55 days of hospi-
tal stay (95% CrI 12.45
to 23.47) correspond-
ing to 18 days in the
placebo group
RoM: exp(-0.01) = 0.99
(95% CI 0.88 to 1.13);
log RoM: -0.01 (-0.13 to







SUCRA = 0.537, mean
















































































































Median length of hospi-
tal stay: 12.5 days for
placebo
19.80 days of hospi-
tal stay (95% CrI 12.37
to 31.52) correspond-
ing to 18 days in the
placebo group
RoM: exp(0.09) = 1.09
(95% CI 0.84 to 1.42);
log RoM: 0.09 (-0.17 to







SUCRA = 0.301, mean





Median length of hos-
pital stay: 25 days for
placebo
20.00 days of hospi-
tal stay (95% CrI 12.64
to 31.93) correspond-
ing to 18 days in the
placebo group
RoM: exp(0.11) = 1.12
(95% CI 0.86 to 1.43);
log RoM: 0.11 (-0.15 to







SUCRA = 0.280, mean




No study reported this
comparison
17.51 days of hospital
stay (95%CrI 9.89 to 28.
78) corresponding to 18









SUCRA = 0.532, mean
Pr(best) = 0.225, mean
rank = 3.81
* The basis for the assumed risk (e.g. the median control group risk across studies). The corresponding risk (and its 95%CrI) is calculated as the assumed risk mult iples the
ratio of means (and its 95% CrI) based on NMA.
CI: conf idence interval; CrI: credible interval; HMG-CoA: 5-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor; NMA: network meta-analysis; Pr(best): probability(best);
RoM: rat io of means; SUCRA: surface under the cumulat ive ranking curve
GRADE Working Group grades of evidence.
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aDowngraded one level for heterogeneity (I² of 50% to 75%, > 75% considered as medium and large heterogeneity).
bDowngraded one level for imprecision (wide credible interval).
cDowngraded one level for single small t rial with risk of bias and indirectness.















































































































Patient or population: crit ically ill adult with conf irmed or at high risk of delirium
Settings: intensive care units in Australia and New Zealand, Canada, Egypt, Netherlands, Turkey, USA, UK
Intervention: any pharmacological intervent ion
Control: placebo or act ive comparator








Quality of the evidence
(GRADE)




62 per 1000 78 per 1000 1.26 (0.68 to 2.34)
I² = 0%
15 more per 1000








90 per 1000 118 per 1000 1.28 (0.45 to 3.66)
I² = 56%
22 more per 1000









114 per 1000 66 per 1000 0.55 (0.28 to 1.08)
I² = 0%
48 fewer per 1000








400 per 1000 400 per 1000 1.00 (0.17 to 5.98)
I² not applicable
0 fewer per 1000








0 per 1000 0 per 1000 OR not est imable
I² not applicable




* The basis for the assumed risk (e.g. the median control group risk across studies). The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in
the comparison group and the relative effect of the intervent ion (and its 95% CI).













































































































GRADE Working Group grades of evidence.
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aDowngraded one level for heterogeneity (I² of 50% to 75%, > 75% considered as medium and large heterogeneity).














































































































D I S C U S S I O N
Summary of main results
We identified 14 randomized controlled trials (RCTs) that en-
rolled 1844 adult participants which evaluated pharmacological
treatments for delirium in the intensive care unit (ICU). These
trials evaluated six different drug classes, primarily comparing one
active drug versus placebo. Most trials were small, enrolling fewer
than 100 participants. Nine trials scored low risk of bias across
all domains; the overall quality of evidence for each outcome was
assessed via the GRADE approach; quality ranged from low to
high.
Pairwise meta-analyses showed that only the alpha2 agonist
dexmedetomidine (vs placebo) significantly reduced the duration
of delirium in critically ill adults with delirium; this was based
on a single study with < 100 participants. Network meta-anal-
ysis shows that the smallest ratio of means (vs placebo) was as-
sociated with the alpha2 agonist dexmedetomidine, followed by
atypical antipsychotics. However, effect sizes for either of the drug
classes were neither statistically nor clinically significant. Among
secondary outcomes, network meta-analysis (NMA) revealed that
only dexmedetomidine was associated with a shorter duration of
mechanical ventilation, and that the cholinesterase (CHE) in-
hibitor rivastigmine was associated with longer ICU stay. Other-
wise, no pharmacological intervention was found to achieve sta-
tistical or clinical significance for the secondary outcomes. Analy-
ses of reported adverse drug events found that events were similar
to those seen with placebo. The 10 ongoing studies and the six
studies awaiting classification that we identified, once published
and assessed, may alter the conclusions of this review.
Please notice that the 95% credible intervals from Bayesian NMA
results are generally more conservative (wider) than the corre-
sponding 95% confidence intervals from pairwise meta-analyses.
If a pairwise comparison had at least one study contributing direct
evidence to NMA and resulted in a 95% credible interval that
ruled out the possibility of no difference, the corresponding 95%
confidence interval from pairwise meta-analysis was also signifi-
cant.
Overall completeness and applicability of
evidence
When we designed the protocol (Burry 2015), for several reasons
we anticipated at least 20 trials specifically investigating various
pharmacological interventions for the treatment of ICU delirium.
These reasons included the inclusion of delirium as a quality in-
dicator in care of the elderly, poor outcomes associated with delir-
ium in critically ill patients, and the number of registered trials,
as well as the strong recommendations for delirium prevention
and treatment provided in the Society of Critical Care Medicine’s
pain, agitation, and delirium guidelines (Barr 2013). Using strong
literature review methods, we identified only 14 published tri-
als that matched our review questions. However, we did identify
six studies awaiting classification and 10 ongoing trials, several of
which are large-scale, multi-centre trials. This suggests that this
topic will expand greatly in the next five years. We found that
most trials, and those ongoing, examined use of pharmacological
interventions commonly given in clinical practice, primarily an-
tipsychotics and the alpha2 agonist dexmedetomidine. We found
sufficient data to conduct pairwise comparisons and NMA to an-
swer our primary outcome of interest, but we could not analyse
some of the secondary outcomes that we deemed clinically im-
portant, as these outcomes were not investigated in any trial (i.e.
relapse, resolution of symptoms, long-term cognitive outcomes,
and health-related quality of life). Nor did we find sufficient in-
formation to conduct our planned subgroup analyses on age, ICU
population type, delirium subtype, or use of non-pharmacological
co-interventions.
Quality of the evidence
We scored the risk of bias for each trial and used GRADEpro
software to inform the generation of evidence quality statements.
Among the 14 RCTs included in this review, nine trials scored low
risk of bias across all domains. We judged available evidence to
range from low to high quality. Evidence for the primary outcome
- duration of delirium - was of moderate to high quality when
each drug class was compared to placebo. We most commonly
downgraded this evidence for imprecision.
Potential biases in the review process
This review followed Cochrane’s systematic review procedures
closely, with only minor amendments to the published proto-
col (Burry 2015). Our search was exhaustive without restrictions;
therefore we believe we have evaluated the available evidence in
full. The trials included in our review directly examined our cho-
sen population and the primary outcome - duration of delirium
- as their primary or secondary outcome. We had originally set
the primary outcome to be duration of delirium, defined as time
from which it wasfirst identified to when it was first resolved (i.e.
screened negative as defined by study authors (e.g. first negative
screen, two consecutive screenings)), and our secondary outcome
to be duration of delirium (as defined by study authors). We found
far more variability in the definition of the outcome used than we
had anticipated; thus we ended up reporting only the duration of
delirium for pooling of results. The definition applied by study
authors also varied, with some using 24 hours without delirium,
some 48 hours, and others not reporting the definition they ap-
plied.
For continuous outcomes, we approximated means and standard
deviations (SDs) from medians and interquartile ranges (IQRs)
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(Wan 2014) to make use of studies that reported only medians and
IQRs for some outcomes. Before all ratio of means (RoM) analyses,
we transformed means and SDs to the log scale (Higgins 2008)
to overcome various time windows across studies with existing
pairwise meta-analysis and NMA methods, and to make evidence
synthesis possible. The first transformation may not always yield
accurate RoM estimates for skewed outcomes in small studies.
Despite the robust properties of the second transformation for
skewed outcomes (Higgins 2008), interpretation of RoM analyses
is challenging. We did not approximate means and SDs using any
range-related formulae.
We are not aware of other potential sources of bias.
Agreements and disagreements with other
studies or reviews
This is the first NMA examining treatment of delirium for ICU
patients, and it is the first Cochrane systematic review examining
pharmacological interventions for ICU delirium. We identified
two recent systematic reviews examining antipsychotics for preven-
tion or treatment of delirium, or both, in any hospital population
(i.e. ICU and non-ICU) (Kishi 2016; Neufeld 2016). Our find-
ings regarding antipsychotics are consistent with those of Neufeld
2016, in that antipsychotics had no effect on delirium duration
when review authors pooled the results of treatment trials. Kishi
2016 conducted a review examining antipsychotics for preven-
tion or treatment of delirium, or both, in any hospital population,
including data from four studies that were unpublished or were
published in abstract form only. The review by Kishi reported re-
sponse rate (response rate at the study endpoint examining many
different severity and global scales) and did not report on duration
of delirium. Pooled results for response rate showed that antipsy-
chotics were superior to placebo and non-antipsychotic drugs. We
identified one Cochrane systematic review on alpha2 agonists for
long-term sedation during mechanical ventilation in critically ill
patients, which examined risk of delirium as a secondary outcome
(Chen 2015); review authors did not report on duration of delir-
ium nor on other delirium outcomes that we reported. The Chen
review found no evidence that dexmedetomidine decreased the
risk of delirium (risk ratio 0.85, 95% CI 0.63 to 1.14; seven stud-
ies; 1624 participants; low-quality evidence) compared to tradi-
tional sedatives.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In clinical practice, pharmacological interventions are commonly
administered to critically ill patients to manage their symptoms of
delirium (Burry 2017). We found evidence that the alpha2 ago-
nist dexmedetomidine may have some role in shortening delirium
duration, although this small effect was seen in pairwise analyses
based on a single small study compared with placebo, and was not
seen in the NMA results. No other pharmacological intervention
including antipsychotics, the most commonly prescribed drug for
delirium treatment, had any effect on delirium duration nor on
any of our a priori selected secondary outcomes. It is also im-
portant to note that the cholinesterase inhibitor rivastigmine was
associated with harm, and as such, guidelines suggest against its
use for treatment of ICU delirium. The 10 ongoing studies and
the six studies awaiting classification, once published and assessed,
may alter the conclusions of this review; therefore, their results are
much anticipated. The frequency of prescribing these drug classes
for critically ill adults with delirium and the non-significant find-
ings of our review should be considered at the bedside and should
be incorporated into future pain, agitation, and delirium guide-
lines.
Implications for research
We identified 10 ongoing studies, of which seven have a large
target enrolment number (100 to 1000 participants), suggesting
growing interest in the treatment of ICU delirium. These RCTs
should strengthen our results and may potentially alter the direc-
tion of our findings. For example, five ongoing trials are exam-
ining antipsychotics and three are examining the alpha2 agonist
dexmedetomidine - the drug classes found most promising in our
analysis - each trial with large target enrolment.
We note the promise of many new treatment trials on the hori-
zon; however, we must acknowledge the need to standardize out-
come reporting in ICU delirium trials to permit maximum pool-
ing and interpretation of results. We found far greater variability
in the definitions of study outcomes used than we had anticipated,
which led us to modify our primary outcome and to limit pool-
ing for some outcomes (e.g. mortality). We found no reporting
on some clinically important outcomes such as symptom man-
agement (e.g. treating agitation, stopping treatment interferences)
and long-term cognitive outcomes, and we found new outcomes
not listed in our protocol (e.g. number of days in coma) in multi-
ple new RCTs and ongoing trials. The Del-COrS (“Developmnt
of core outcome sets for effectiveness trial of interventions to pre-
vent and/or treat delirium”) Group is leading the development of
international consensus on outcomes for trials of intervention to
prevent and treat delirium in multiple patient populations (Rose
2017). Findings from this group should be used to guide future
ICU delirium trials.
We also found that RCTs in this review rarely reported on the use
of non-pharmacological strategies. Among the trials that we iden-
tified, all but one showed poor utilization of non-pharmacological
strategies. For example, early mobilization has been shown to re-
duce the duration of delirium (Barr 2013), and its use in practice is
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encouraged. Therefore, future trials should clearly describe the use
of such strategies in their methods and should report compliance
in their results. We also found poor reporting on the use of physi-
cal restraints - a non-pharmacological intervention associated with
delirium and prolonged duration of delirium (Rose 2016).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Al-Qadheeb 2016
Methods RCT comparing the efficacy and safety of low-dose haloperidol vs placebo for prevention
of conversion of subsyndromal delirium to delirium
Study took place in 3 ICUs (2 medical and 1 surgical) at a single academic medical
centre in the USA
Participants Participants included 68 critically ill patients diagnosed with subsyndromal delirium
(ICDSC score 1 to 3) (N = 34 haloperidol, mean age 61.7 ± 16.9 years, 18/34 (52.
9%) male; N = 34 placebo, mean age 59.3 ± 14.9 years, 20/34 (58.8%) male) who were
mechanically ventilated
Study enrolment between September 2010 and August 2013
Interventions Participants received 1 mg intravenous haloperidol or placebo every 6 hours until
the occurrence of delirium (ICDSC score ≥ 4), a maximum of 10 days of treatment,
discharge from the ICU, or an adverse effect necessitating study drug discontinuation
Each dose of the study drug was administered by the bedside nurse as a slow intra-
venous push over 1 minute into a preexisting IV catheter and then was flushed with 10
mL of D5W
All other decisions regarding sedation, analgesia, and ventilation were left to the discretion
of the ICU team
Assessment: delirium status was determined based on the previous 24 hours of nursing
assessments using the SAS and ICDSC
Non-drug strategies: an early mobilization protocol was implemented in 1 of 3 ICUs
part-way through the study (% ever receiving early mobilization was low). All patients
were managed with the same daily awakening spontaneous breathing trial protocol
Outcomes Primary (measured during study drug administration)
1. Incidence of delirium (ICDSC score ≥ 4) during period of study drug
administration
Secondary delirium outcomes (measured during ICU admission)
1. Incidence of delirium during ICU admission
2. Time to delirium occurrence
3. Proportion of 12-hour nursing shifts without delirium, and duration of delirium
(in those who progressed from subsyndromal form)
4. Hours per study day spent agitated
5. Proportion of 12-hour ICU shifts without coma and without coma or delirium,
and among study days where a continuous sedative was administered
6. Proportion of days daily awakening protocol criteria were met and daily
awakening was completed
7. Participants ever receiving early mobilization
8. Use of dexmedetomidine or non-study antipsychotic drug
9. Days of mechanical ventilation
10. Duration of both ICU and hospital stay
11. ICU and hospital death
12. Discharge disposition categorized as home, rehabilitation facility, chronic care
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1. Study was funded by the National Institutes of Health (Grant no.
1R15AG034915-01A1) and the National Institute on Aging
Registration
1. Study was registered at clinicaltrials.gov under NCT01174290
Study authors were not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomized in blocks of 4
in a 1:1 ratio by means of a computer-gen-
erated random numbers table. Treatment
allocation was known only to the investi-
gational pharmacist
Allocation concealment (selection bias) Low risk States treatment allocation was known only
to the investigational pharmacist. Elec-
tronic randomization was performed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treatment allocation was known only
to the investigational pharmacist. Partici-
pants, clinicians, and all study personnel
were blinded to study drug assignment.
Each study dose was prepared by the inves-
tigational pharmacy so an identical look-
ing 0.5-mL tuberculin syringe contained 0.
2 mL of haloperidol 1 mg or 5% dextrose
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinicians, investigators, participants, and
their families remained blinded to treat-
ment allocation. A study investigator con-
firmed the presence of delirium with the
bedside nurse using the ICDSC assess-
ment. The presence of delirium was sub-
sequently confirmed by a consulting psy-
chiatrist. Discordance between the psychi-
atric consultation and the bedside nurse
and study investigator’s ICDSC assess-
ments was resolved through consensus
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomized participants were included
in the analysis. Data were analysed accord-
ing to an intention-to-treat approach
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Al-Qadheeb 2016 (Continued)
Selective reporting (reporting bias) Low risk All outcomes reported in methods were in-
cluded in results. Data were presented for
all participants included in the analysis
Other bias Low risk Use of dexmedetomidine and non-study
antipsychotic drugs was not permitted un-
less deemed medically necessary
An early mobilization protocol was imple-
mented in 1 of 3 ICUs part-way through
the study (% ever receiving early mobiliza-
tion was low). All participants were man-
aged with the same daily awakening spon-
taneous breathing trial protocol
Sample size calculation was provided
Atalan 2013
Methods RCT comparing the efficacy of haloperidol vs morphine for treatment of postoperative
delirium
Study took place in a single ICU at a community hospital in Turkey
Participants Participants included 53 (N = 26 haloperidol, mean age 66.00 ± 8.39 years, 21/26
(80.8%) male; N = 27 morphine, mean age 65.74 ± 9.67 years, 18/27 (66.7%) male)
patients who underwent cardiac surgery, with or without cardiopulmonary bypass, and
were diagnosed with hyperactive delirium using the CAM-ICU and RASS (to determine
subtype)
Study enrolment between January 2010 and July 2012
Interventions Participants received 5 mg haloperidol or 5 mg morphine sulphate intramuscularly
every hour until adequate sedation (RASS -1 to + 1) was achieved. Participants who
were still agitated despite administration of 20 mg/d morphine or 20 mg/d haloperidol
received 2.5 mg lorazepam orally, twice daily
Assessment: delirium status (CAM-ICU) was determined every 12 hours until discharge
from hospital or for a maximum of 10 days following surgery. Participants were consid-
ered delirium-free after a period of 24 hours without symptoms
Non-drug strategies: not reported
Outcomes Primary (measured at completion of study drug)
1. Duration of delirium
Secondary (measured at completion of study drug)
1. Duration of delirium
2. Total daily medication doses
3. Need for additional sedative drug
4. RASS scores
5. Percentage of patients maintaining target RASS score
6. Incidence of re-intubation
7. Repeat surgery and ICU re-admission
8. Length of ICU and hospital stay
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Atalan 2013 (Continued)
9. Hospital mortality rate
Notes Funding
1. The funding source for this study was not mentioned
Registration
1. No trial registration number was identified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The manuscript stated that participants
were randomized to 2 groups but provided
no specific details on the method used
Allocation concealment (selection bias) Unclear risk No details were provided on the method
of randomization or concealment used. At-
tempts to obtain details from study authors
were not successful
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details were provided on the method of
drug preparation and dispensing used. At-
temtps to obtain details from study authors
were not successful
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abnormal or delirious behaviour was
recorded by the bedside nurse and reviewed
by the research team. Clinical evaluation
was performed by the intensivist and the
consulting psychiatrist, who were blinded
to study group assignment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No flow chart was included to report the
numbers of screened vs randomized partic-
ipants
Selective reporting (reporting bias) Unclear risk All outcomes reported in methods were in-
cluded in results. Data presented for all
participants were included in the analysis.
However without a published protocol or
trial registration, it is unknown if all out-
comes were reported as planned
Other bias Unclear risk The funding source for the study was not
mentioned
All participants were permitted rescue lo-
razepam
Sample size calculation was not provided
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Bakri 2015
Methods RCT comparing the efficacy of dexmedetomidine, ondansetron, and haloperidol for
treatment of postoperative delirium
Study took place in a single 24-bed ICU (mixed medical and surgical) in Saudi Arabia
Participants Participants included 96 (N = 32 dexmedetomidine, mean age 31 ± 4 years, 29/32
(91% male); N = 32 ondansetron, mean age 32 ± 5 years, 30/32 (94%) male, N = 32
haloperidol, mean age 30 ± 7 years, 28/32 (88%) male) critically ill trauma patients
diagnosed with postoperative delirium (ICDSC score ≥ 4)
Study enrolment between 2011 and 2013
Interventions Participants received 1 µg/kg dexmedetomidine, 4 mg ondansetron, or 5 mg haloperi-
dol, administered as a continuous intravenous infusion over 20 minutes. Study drug was
started after delirium was diagnosed and was given twice daily for 3 consecutive days
Treating physicians were allowed to prescribe rescue haloperidol for all groups
Assessment: ICDSC was administered twice daily
Non-drug strategies: not reported
Outcomes Primary outcome (measured day 3)
1. Number of patients with delirium
Secondary outcomes (measured day 3)
1. Number of patients requiring rescue haloperidol
2. Mean dose of rescue haloperidol
Notes Funding
1. The study was carried out without external funding
Registration
1. No trial registration number was included in the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly allocated to 3
equal groups according to a computer-gen-
erated random numbers sequence
Allocation concealment (selection bias) Unclear risk Method of concealment was not reported
and was not available from study authors
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study medications were prepared by physi-
cians who were not part of the research
team. All study drug was administered as a
continuous infusion over a 20-minute pe-
riod to maintain blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data were collected by researchers blinded
to study allocation. Participants were man-
aged by ICU staff not included in the
study. ICU nurses conducted delirium as-
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Bakri 2015 (Continued)
sessments as part of the standard of care
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No flow chart was included to report num-
bers of screened vs randomized participants
Selective reporting (reporting bias) Unclear risk All outcomes reported in methods were in-
cluded in results. Data presented for all
participants were included in the analysis.
However without a published protocol or
trial registration, it is unknown if all out-
comes were reported as planned
Other bias Unclear risk All participants were permitted rescue
haloperidol. Use of rescue haloperidol was
an outcome
Sample size calculation was not reported
Devlin 2010
Methods RCT comparing the efficacy and safety of quetiapine vs placebo for treatment of delirium
Study took place in 3 ICUs (mixed medical and surgical) at 3 academic medical centres
- 2 in the USA and 1 in Canada
Participants Participants included 36 (N = 18 quetiapine, mean age 62.4 ± 14 years, 51% male; N =
18 placebo, mean age 63.6 ± 15.3 years, 56% male) critically ill patients with diagnosis
of delirium (ICDSC score ≥ 4), requiring as needed haloperidol and tolerating enteral
nutrition without a complicating neurological condition
Study enrolment between April 2006 and August 2008
Interventions Participants received an initial dose of 50 mg quetiapine or placebo given orally or via
nasogastric/enteral feeding tube. Daily titration of 50-mg increments every 12 hours (to
maximum 200 mg every 12 hours) was permitted if participant received at least 1 dose
of as needed haloperidol
All participants were permitted as needed intravenous haloperidol (1 to 10 mg), admin-
istered up to every 2 hours. Study drug was continued until delirium resolution (based
on clinical judgement of attending intensivist), 10 days of treatment, ICU discharge, or
occurrence of an adverse event attributable to study drug and warranting its discontin-
uation
Assessment: delirium status was determined by every nursing shift using the ICDSC
Non-drug strategies: not reported
Outcomes Primary (measured at completion of study drug)
1. Time to first resolution of delirium, defined as time (in hours) from
administration of first study dose to ICDSC ≤ 3
Secondary efficacy outcomes (measured at completion of study drug)
1. Total hours in delirium
2. Total hours spent “deeply sedated” (SAS ≤ 2) or agitated (SAS ≥ 5)
3. Episodes of participant-initiated device removal
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Devlin 2010 (Continued)
4. Use of haloperidol (number of doses, total dose, days of treatment)
5. Use of sedatives and analgesics
6. Duration of study drug
7. Average daily and maximum study drug dose
8. Duration of mechanical ventilation
9. Length of both ICU and hospital stay
10. Hospital mortality
11. Discharge disposition categorized as home, rehabilitation facility, chronic care
facility, or death
Notes Funding
1. The study was funded in part by the Society of Critical Care Medicine’s Joseph F.
Dasta Critical Care Pharmacy Research Award
2. Un unrestricted grant was received from AstraZeneca Pharmaceuticals
Post-hoc analysis of the trial compared duration and time to first resolution of individual
delirium symptoms from participants in the original study (Devlin 2011)
Registration
1. No trial registration number was included in the manuscript
Study authors were contacted for clarification and responded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned in blocks of 4 to
1 to the 2 groups in a 1:1 ratio by means
of a computer-generated random numbers
table. A different randomization schedule
was used at each site. Treatment allocation
was known only to the investigational phar-
macist at each site
Allocation concealment (selection bias) Low risk Treatment allocation was known only to
the investigational pharmacist at each site.
Electronic randomization was performed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and all study personnel were
blinded to study drug assignment. Tablets
were identical to one another, even when
crushed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and all study personnel were
blinded to study drug assignment. Delir-
ium assessments were completed by ICU
nurses as part of the standard of care
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were analysed using the intention-to-
treat principle. All randomized participants
were included in the analysis
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Selective reporting (reporting bias) Low risk Data presented for all participants were in-
cluded in the analysis
No trial registration was reported; however
the original REB application was obtained
from the study author
Other bias Low risk All participants were permitted rescue
haloperidol
Sample size calculation was reported
Girard 2010a
Methods RCT comparing haloperidol, ziprasidone, and placebo on the number of days alive and
without delirium or coma among ICU patients (49% of all patients were delirious at
enrolment, and 35% were comatose)
Study took place in 6 ICUs (mixed medical and surgical) at 6 tertiary care centres in
the USA
Participants Participants included 101 (N = 35 haloperidol, median age 51 (IQR 35 to 59) years,
20/35 (57% male); N = 30 ziprasidone, median age 54 (IQR 47 to 66), 21/30 (70%)
male; N = 36 placebo, median age 56 (IQR 43 to 68), 22/36 (61%) male) mechanically
ventilated, critically ill patients with an abnormal level of consciousness or receiving
sedative or analgesic medications
Study enrolment between February 2005 and July 2007
Interventions Participants received 5 mg haloperidol (as a solution containing 1 mg/mL), 40 mg
ziprasidone (as a solution containing 8 mg/mL), or placebo (as a 5-mL solution). In
patients without gastric access, study drug was given via 0.5-mL intramuscular injection
(to a maximum of 8 doses). If QTc remained < 500 ms, the second dose of study drug
was administered 12 hours after the first, and subsequent doses were given every 6 hours
until a change in frequency was warranted. If 2 consecutive assessments for delirium/
coma were negative, drug frequency was decreased to every 8 hours, and the drug was
discontinued if no delirium or coma was noted for 48 hours. Study drug was reduced
if patients remained over-sedated (RASS ≥ 2 levels deeper than target score) despite
discontinuation of sedatives. Study drug was restarted or increased in frequency when
over-sedation was resolved. Study drug was restarted (if discontinued prior) or increased
to the previously effective dose if delirium recurred. Study drug was discontinued if
extrapyramidal symptoms (≥ 3 points on 3 or more categories of the Simpson-Angus
Scale) or QTc prolongation (> 500 ms) occurred and was restarted only if these were
resolved
All patients stopped study drug on day 14 regardless of clinical status
Other treatments including approaches to sedation were determined by the managing
ICU team. Daily spontaneous awakening trials were common but were not protocolized
An open-label antipsychotic was strongly discouraged during the trial but could be used
if the ICU team considered it necessary for breakthrough agitation
Assessment: brain dysfunction was assessed twice daily using CAM-ICU and RASS
Non-drug strategies: none of the ICUs used formalized non-pharmacological interven-
tions to prevent or treat delirium
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Outcomes Primary
1. Number of days alive without coma or delirium (over 21 study days)
Secondary
1. Daily delirium risk
2. Duration of delirium
3. Duration of coma
4. Number of days alive and breathing without assistance (in 21 study days) (i.e.
ventilator-free days)
5. Time to ICU and hospital discharge
6. All-cause 21-day survival
Notes Funding
1. Study was investigator-initiated
2. Study drug was provided by Pfizer Inc., which had no role in the design or
conduct of the trial
Dr Girard received support from
1. National Institutes of Health (HL007123)
2. Hartford Geriatrics Health Outcomes Research Scholars Award Program
3. Vanderbilt Physician Scientist Development Program
4. VA Tennessee Valley Geriatric Research, Education, and Clinical Center
(GRECC)
Dr Pandharipande received support from
1. VA Clinical Science Research and Development Service (VA Career Development
Award)
2. ASCCA-FAER-Abbott Physician Scientist Award
3. Vanderbilt Physician Scientist Development Program
Dr Ely received support from
1. VA Clinical Science Research and Development Service (VA Merit Review Award)
2. VA Tennessee Valley GRECC
3. National Institutes of Health (AG027472)
Registration
1. Study was registered at clinicaltrials.gov under NCT00096863
Study authors were not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned in a 1:
1:1 manner via a computer-generated, per-
muted block randomization scheme strati-
fied according to study centre
Allocation concealment (selection bias) Low risk A co-ordinating centre biostatistician des-
ignated treatment group assignments on a
list that was provided only to the investi-
gational pharmacists at each study centre,
who referred to their unique list to deter-
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mine group assignment after each patient
was enrolled
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk This was a double-blind study. Except for
the pharmacist, neither study personnel
nor participants were aware of treatment
group assignment. Participants received 1
of the 3 colourless, odourless, and tasteless
study drugs
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded trained study personnel evaluated
participants twice daily for acute brain dys-
function, diagnosing delirium with CAM-
ICU
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were analysed via an intention-to-
treat principle. 2 participants were ex-
cluded after randomization, before study
drug was administered, because of ventric-
ular tachycardia. No outcome data could
be collected for these 2 participants after
their withdrawal
Selective reporting (reporting bias) Low risk All outcomes reported in methods were in-
cluded in results. Data presented for all par-
ticipants were included in the analysis
Other bias Low risk Open-label antipsychotic administration
was strongly discouraged during the trial
but could be provided if the clinical team
considered it necessary for breakthrough
delirium and agitation. Pfizer Inc. had no
role in the design or conduct of the trial;
in the collection, analysis, or interpretation
of data; nor in the preparation, review, ap-
proval, or publication strategy of the study
manuscript
Girard 2018
Methods RCT comparing haloperidol, ziprasidone, and placebo on the number of days alive and
without delirium or coma in ICU patients
Study took place in 16 ICUs (mixed medical and surgical) in the United States
Participants Adult (≥ 18 years) medical/surgical ICU participants on mechanical or non-invasive
positive-pressure ventilation and/or requiring vasopressors due to shock, or an intra-
aortic balloon pump, and diagnosed with delirium by CAM-ICU
Participants included 566 (N = 189 haloperidol, median age 61 (IQR 51 to 69) years,
44% female); N = 183 ziprasidone, median age 61 (IQR 50 to 69), 43% male; N = 179
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placebo, median age 59 (IQR 52 to 67), 42% female)
Study enrolment between December 2011 and August 2017
To minimize the time between onset of delirium and randomization, informed consent
was often obtained before the onset of delirium
Interventions Participants were randomized to receive haloperidol (up to 10 mg every 12 hours,
administered by intravenous bolus over up to 5 minutes at concentrations of 5 mg/mL)
, ziprasidone (up to 20 mg every 12 hours, administered by intravenous bolus over up
to 5 minutes at concentrations of 10 mg/mL), or placebo (up to 10 mg every 12 hours,
administered by intravenous bolus over up to 5 minutes). Participants will be treated
until delirium has resolved for 48 hours, or when 14 days of treatment have elapsed,
whichever occurs first
All patients stopped study drug on day 14 regardless of clinical status
Open-label antipsychotic use was permitted (21%; no differences between groups)
Assessment: brain dysfunction was assessed twice daily using CAM-ICU and RASS
Non-drug strategies: all ICUs used formalized non-pharmacological interventions to
prevent or treat delirium - specifically, the ABCDE treatment bundle (assess, prevent,
and manage pain; both spontaneous awakening and breathing trials; choice of analgesia
and sedation; assess, prevent, and manage delirium; and early mobility and exercise).
Compliance was > 88% in each study group
Outcomes Primary
1. Days alive without delirium or coma
Secondary
1. 30-day, 90-day, and 1-year survival
2. Delirium duration
3. ICU and hospital length of stay
4. Ventilator-free days
5. ICU and hospital re-admission
6. Neuropsychological dysfunction
7. Quality of life
8. Post-traumatic stress disorder
9. QTc prolongation
10. Extrapyramidal symptoms
11. Neuroleptic malignant syndrome
Notes MIND-USA study: modifying the impact of ICU-associated neurological dysfunction
Funding
1. Study was investigator-initiated
2. National Institutes of Health and VA Geriatric Research Education and Clincial
Center provided funding
Registration
1. Study was registered at clinicaltrials.gov under NCT01211522
2. Study was FDA-approved because the intravenous routes of drug administration
and the indication for delirium were not approved
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Participants were randomly assigned in a 1:
1:1 manner via a computer-generated, per-
muted block randomization scheme strati-
fied according to study centre
Allocation concealment (selection bias) Low risk A co-ordinating centre biostatistician des-
ignated treatment group assignments on a
list that was provided only to the investi-
gational pharmacists at each study centre,
who referred to their unique list to deter-
mine group assignment after each patient
was enrolled
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk This was a double-blind study. Except for
the pharmacist, neither study personnel
nor participants were aware of treatment
group assignment. Study drugs were iden-
tical colourless preparations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded trained study personnel evaluated
participants twice daily for acute brain dys-
function, diagnosing delirium using CAM-
ICU
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes reported in methods were in-
cluded in results. Data presented for all par-
ticipants were included in the analysis
Selective reporting (reporting bias) Low risk All outcomes reported in methods were in-
cluded in results. Data presented for all
participants were included in the analysis.
The trial was registered in advance. The
statistical plan was registered at Open Sci-
ence Framework (https://osf.io/mq38r) be-
fore the trial group assignments were un-
masked
Other bias Low risk Open-label antipsychotic administration
was strongly discouraged during the trial
but could be used if the clinical team con-
sidered it necessary for breakthrough delir-
ium and agitation. There was no difference
between study groups in the use of open-
label antipsychotics
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Methods RCT comparing risperidone and placebo for prevention of conversion of subsyndromal
delirium to delirium
Study took place in a single cardiosurgical ICU in Egypt
Participants Participants included 101 elderly (aged ≥ 65) (N = 51 risperidone, mean age not
provided, 33/51 male; N = 50 placebo, mean age not provided, 36/50 male) on-pump
cardiac surgery patients with diagnosis of postsurgical subsyndromal delirium (ICDSC
score 1 to 3)
Study enrolment between December 2007 and November 2010
Interventions Participants with subsyndromal delirium (ICDSC score 1 to 3) received oral 0.5 mg
risperidone or placebo every 12 hours until 24 hours after subsidence of subsyndromal
delirium (ICDSC score of 0) or development of frank delirium (ICDSC ≥ 4). Among
delirious participants, treatment allocation was revealed, and placebo-treated patients
were started on 0.5 mg oral risperidone every 12 hours. If symptoms remained uncon-
trolled, the dose was increased to a maximum of 4 mg/d. Among delirious risperidone-
treated patients, the dose was increased until symptoms were controlled or a maximum
dose of 4 mg/d was attained. Haloperidol was used in both groups if symptoms were not
controlled with maximal risperidone dose. Haloperidol was started at 0.5 mg every 8
hours and could be increased to 10 mg/d if needed. Haloperidol dose could be doubled
every 24 hours until symptoms were controlled or the maximum dosage was attained
Rescue medications were continued for 24 hours after a score of 0 was achieved on the
ICDSC
Assessment:screening for subsyndromal delirium was done using the ICDSC, began 4
hours after extubation in the ICU, and was continued for every 8-hour nursing shift
thereafter, including after discharge to the cardiosurgical ward
Non-drug strategies: not reported
Outcomes Primary (end of study)
1. Incidence of delirium
Secondary (end of study)
1. Duration and severity of delirium
2. Length of ICU and hospital stay
3. Occurrence of adverse events (e.g. extrapyramidal symptoms)
Notes Funding
1. Support for the study was provided solely by institutional and/or departmental
sources
Registration
1. No trial registration number was included in the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomized by a clini-
cal pharmacist in a 1:1 ratio via a com-
puter-generated random numbers list cre-
ated with GraphPad StatMate v.1.01i soft-
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ware (Graph-Pad Software Inc., San Diego,
CA, USA) using permuted blocks of size 4
Allocation concealment (selection bias) Low risk Allocation group codes were typed and
were kept at the pharmacy in sealed en-
velopes. Treatment concealment was main-
tained until recruitment, data collection,
and analysis were completed, unless an
emergency warranted otherwise and was re-
quested by an attending physician
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk This was a double-blind study. Test drugs
were prepared by the hospital’s pharmacy
and were identical in appearance and
odour. Drugs were dispensed in identical
containers sealed and numbered according
to the random number list
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk 4 intensivists and 3 ward physicians, who
were blinded to group allocation, were
charged with screening participants for
subsyndromal delirium using the ICDSC.
Randomized participants were assessed by
a blinded observer using the ICDSC, and
those scoring > 3 were evaluated by a
blinded psychiatrist to confirm delirium
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were analysed using an intention-to-
treat principle. All randomized participants
were included in the analysis
Selective reporting (reporting bias) Unclear risk All outcomes reported in methods were in-
cluded in results. Data presented for all
participants were included in the analysis.
However without a published protocol or
trial registration, it is unknown if all out-
comes were reported as planned
Other bias Low risk All participants were permitted rescue
haloperidol
Sample size calculation was provided
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Methods Ancillary study to an RCT of rosuvastatin vs placebo for delirium
Study took place in 35 ICUs (mixed medical and surgical) in the USA
Participants Participants included 272 (N = 137 rosuvastatin, mean age 52 ± 18 years, 72/137 (53%)
male; N = 135 placebo, mean age 52 ± 16 years, 65/135 (48%) male) adult ICU patients
meeting criteria for acute respiratory distress syndrome, receiving mechanical ventilation
through an endotracheal tube, and meeting criteria for systemic inflammatory response
with a known or suspected infection
Study enrolment between Janurary 2010 and November 2013
Interventions Participants received a 40-mg loading dose of rosuvastatin (and a daily 20-mg dose) or
placebo at randomization until 3 days after discharge from intensive care, study day 28,
or death, whichever occurred first
Delirium was assessed daily by clinical or research personnel using the CAM-ICU
Outcomes Primary
1. Daily delirium status in intensive care up to 28 days
Secondary
1. Cognitive function at 6 months and 12 months
Notes Funding was provided by:
1. National Heart, Lung and Blood Institute
2. Johns Hopkins Institute for Clinical and Translational Research
3. AstraZeneca
The funders had no role in study design; collection, analysis, and interpretation of data;
writing of the report; or the decision to submit for publication
This is an ancillary study of the SAILS trial (https://clinicaltrials.gov/ct2/show/
NCT00979121) - a randomized controlled trial assessing mortality and ventilator-free
days for rosuvastatin vs placebo in patients with sepsis-associated acute respiratory dis-
tress syndrome
SAILS was stopped early because of futility, after recruiting 745 of 1000 patients, with
no significant differences in short-term mortality, ventilator-free days, or intensive care
unit-free days
Additional unpublished data were provided by study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned in per-
muted blocks of 8, with stratification by
hospital, via a web-based system
Allocation concealment (selection bias) Low risk Participants were randomly assigned in per-
muted blocks of 8, with stratification by
hospital, via a web-based system. Each re-
search co-ordinator used a unique personal
identification number to access the system.
Treatment assignment and individual sub-
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ject identification numbers were assigned.
An emailed confirmation to the study site
followed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drug was blinded by an identical ap-
pearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This was a double-blind study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary analysis was done for the inten-
tion-to-treat population, with participants
contributing to the model on days when
delirium could be assessed (i.e. no coma)
Selective reporting (reporting bias) Low risk All outcomes reported in methods were in-
cluded in results. Additional data were pro-
vided by study authors for this review
Other bias Low risk The funders had no role in study design;
collection, analysis, and interpretation of
data; writing of the report; or the decision
to submit for publication
Page 2013
Methods RCT comparing haloperidol vs placebo on the duration of delirium coma
Study took place in a single ICU (mixed medical and surgical) in the UK
Participants Participants included 141 (N = 71 haloperidol, mean age 67.9 ± 16.5 years, 37/71
(52%) male; N = 70 placebo, mean age 68.7 ± 14.9 years, 45/70 (64%) male) critically
ill patients requiring mechanical ventilation within 72 hours of ICU admission
Study enrolment between November 2010 and September 2012
Interventions Participants received haloperidol 2.5 mg or an equal volume of 0.9% saline, intra-
venously, every 8 hours
Study drug was discontinued
1. Upon ICU discharge
2. When the patient was delirium-free for 2 consecutive days
3. After a maximum of 14 days of treatment, whichever occurred first
If a patient screened positive for delirium again within the 14-day study period, the study
drug was re-administered. Patients were kept on fentanyl and propofol infusions, titrated
to a RASS of 0 to -1, unless deeper sedation was required. If a patient was over-sedated,
study drug dose was halved; if over-sedation lasted longer than 24 hours, study drug was
stopped. If a patient developed acute agitation (RASS +2 or higher), reversible causes
were investigated and treated. If the agitation did not resolve, the patient was allowed
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up to 10 mg intravenous haloperidol in a 24-hour period (2.5- to 5.0-mg doses)
Delirium status was assessed via the CAM-ICU twice during each 12-hour shift, with a
minimum of 4 hours between 2 consecutive assessments. Delirium was defined if RASS
was -2 to +4 and CAM-ICU was positive
Outcomes Primary
1. Number of delirium-free and coma-free days, defined as the number of days in
the first 14 days after randomization during which the patient was alive without
delirium and was not in coma
Secondary
1. Number of delirium-free and coma-free days to day 28
2. Ventilator-free days from randomization to day 28
3. 28-day mortality
4. Length of ICU and hospital stay
5. Safety with regard to prolonged QTc
6. Extrapyramidal effects
7. Serious adverse events attributed to study drug
Notes Funding
1. National Institute for Health Research provided funding
The sponsor of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. Additional study outcomes were published in
abstract form (page 2015). This analysis served to determine long-term survival, quality
of life, and cost-effectiveness of the use of haloperidol in the original trial
Registration
1. Trial was registered with the International Standard Randomised Controlled Trial
Registry under number ISRCTN83567338
Study authors were contacted for clarification; they provided the requested information
Erratum in Lancet Respir Med 2013 Oct;1(8):592
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A nurse from the operating theatre post-
anaesthetic care unit, who was independent
of the ICU clinical and research staff, allo-
cated participants in a 1:1 ratio using ran-
dom permuted blocks of sizes 4 and 6 and
a centralized, secure web-based randomiza-
tion service
Allocation concealment (selection bias) Low risk Study was randomized via a centralized, se-
cure web-based randomization service
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugs were prepared in the PACU,
which was separate from the ICU, in iden-
tical syringes by an independent member
of the PACU nursing staff, who adminis-
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tered the drug
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All ICU clinical and research staff, legal rep-
resentatives, and participants were masked
to study drug. The data monitoring and sa-
fety committee reviewed blinded data re-
ports. Statisticians were not masked to al-
location
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were analysed according to an inten-
tion-to-treat principle. 1 participant in the
placebo group was withdrawn after failure
to obtain consent to continue or use col-
lected data; this patient’s data were not in-
cluded in the final analysis
Selective reporting (reporting bias) Low risk All outcomes reported in methods were in-
cluded in results. Data presented for all par-
ticipants were included in the analysis
Other bias Low risk The sponsor of the study had no role in
study design, data collection, data analysis,
data interpretation, or writing of the report
Page 2017
Methods RCT comparing simvastatin vs placebo on duration of delirium coma
Study took place in a single ICU (mixed medical and surgical) in the UK
Participants Participants included 142 (N = 71 simvastatin, mean age 61.9 ± 15.3 years, 45/71
(63%) male; N = 71 placebo, mean age 62.1 ± 17.3 years, 37/71 (52%) male) critically
ill patients requiring mechanical ventilation within 72 hours of ICU admission
Study enrolment between February 2013 and January 2015
Interventions Participants received 80 mg simvastatin or placebo within 72 hours of admission to the
ICU, irrespective of the presence of coma or delirium. Study drug was given daily, orally
or by feeding tube. Treatment was discontinued at ICU discharge, after a maximum
of 28 days, at death, with creatine kinase concentrations > 10 times the upper limit of
normal, with alanine transaminase concentrations > 8 times the upper limit of normal,
with development of a clinical condition requiring immediate treatment with statins,
upon discontinuation of active medical treatment, with request for discontinuation by
patient or legal representative, or upon request for discontinuation by attending clinician
or contraindication to enteral drug administration. Patients were kept on fentanyl and
propofol infusions, titrated to a RASS of 0 to -1, unless deeper sedation was required
Delirium status was assessed via the CAM-ICU twice during each 12-hour shift, with a
minimum of 4 hours between 2 consecutive assessments. Delirium was defined if RASS
was -2 to +4 and CAM-ICU was positive
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Outcomes Primary
1. Number of delirium-free and coma-free days, defined as the number of days in
the first 14 days after randomization during which the patient was alive without
delirium and not in coma
Secondary
1. Delirium-free and coma-free days to day 28
2. Ventilator-free days to day 28
3. Mortality at 6 months
4. Length of ICU and hospital stay
5. Safety with regard to elevated creatine kinase and alanine transaminase
concentrations
6. Serious adverse events
Notes Funding
1. The National Institute for Health Research provided funding
Sponsored by
1. The study was sponsored by West Hertfordshire Hospitals National Health
Service Trust
Co-ordinated by
1. The study was co-ordinated by the Northern Ireland Clinical Trials Unit
Registration
1. The trial was registered with the International Standard Randomised Controlled
Trial Registry under number ISRCTN89079989
Study authors were contacted for clarification, and requested information was provided
Erratum in Corrections (Lancet Respir Med 2018)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study statistician generated the ran-
domization schedule in advance using
nQuery Advisor version 4.0; randomiza-
tion was done by variable block sizes of 2,
4, 6, and 8, without stratification
Allocation concealment (selection bias) Low risk No details were provided pertaining to
the individual responsible for randomizing
participants. Patient drug packs were pre-
pared by Victoria Pharmaceuticals (Belfast,
Northern Ireland) according to the pre-ar-
ranged randomization schedule and were
distributed to the hospital pharmacy, which
stored the packs in a secure area and dis-
pensed them to the ICU as required. Each
pack was numbered with a unique patient
trial identifier that had been allocated to
each participant at the time of random as-
signment to a group
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk This was a double-blind study. Simvastatin
or placebo tablets were packaged in white
opaque high-density polyethylene plastic
containers sealed with a tamper-evident
seal. Placebo and simvastatin tablets were
indistinguishable when crushed and dis-
persed in water for enteral administration
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All ICU clinical and research staff, legal rep-
resentatives, and participants were masked
to study drug. The data monitoring and sa-
fety committee reviewed blinded data re-
ports. Statisticians were not masked to al-
location
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were analysed according to an inten-
tion-to-treat principle. All randomized par-
ticipants were included in the primary anal-
ysis
Selective reporting (reporting bias) Low risk All outcomes reported in methods were in-
cluded in results. Data presented for all par-
ticipants were included in the analysis
Other bias Low risk The funder of the study had no role in study
design, data collection, data analysis, data
interpretation, or writing of the report
Reade 2009
Methods RCT comparing haloperidol vs dexmedetomidine in facilitating extubation for patients
with severe agitation
Study took place in a single 20-bed ICU (mixed medical and surgical) at a university
hospital in Australia
Participants Participants included 20 (N = 10 haloperidol, median age 68.5 (IQR 43 to 78) years,
80% male; N = 10 dexmedetomidine, median age 52 (IQR 42 to 69) years, 90% male)
mechanically ventilated, critically ill patients who could not be extubated because their
level of agitation (e.g. RASS score ≥ 2) required such a high dose of sedative drug (40%
haloperidol group delirious at enrolment, 30% dexmedetomidine, using ICDSC ≥ 4;
100% haloperidol group at least subsyndromal delirium at enrolment, 80% dexmedeto-
midine, using ICDSC ≥ 0)
Study enrolment between April 2006 and August 2008
Interventions Participants received dexmedetomidine, started as an intravenous infusion of 0.2 to
0.7 mcg/kg/h (option of providing a loading dose of 1.0 µg/kg IV over a 20-minute
period), or haloperidol, started as an intravenous infusion of 0.5 to 2.0 mg/h (option
of providing a loading dose of 2.5 mg). Nurses adjusted infusion rates as necessary (re-
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assessing at least every 4 hours), with the aim of minimizing psychomotor agitation
and achieving a RASS score of 0. Treatment was continued for as long as was deemed
necessary by the treating physician, including following extubation. There was no strict
protocol outlining the titration of either drug. Dexmedetomidine was not available in
the hospital’s formulary; once it was stopped, it could not be restarted. Haloperidol could
however be administered for as long as needed
The bedside nurse was responsible for transitioning the patient from mechanical to
spontaneous ventilation as early as possible and through assessments done every 4 hours
Outcomes Primary
1. Time from start of study drug to extubation
Secondary efficacy outcomes
1. Time from start of study drug to ICU discharge
2. Time to attain satisfactory sedation score
3. Need for additional sedative and analgesic drugs
Secondary safety outcomes
1. Change in QTc interval
2. Duration and rate of vasopressor or inotropic support
3. Re-intubation
Notes Funding was provided by
1. Australian College of Critical Care Nurses
2. Australian and New Zealand College of Anaesthetists
Dexmedetomidine was supplied free of charge by the manufacturer, Hospira, which had
no other involvement in the study
Registration
1. Study was registered at clinicaltrials.gov under NCT00505804
Study authors were contracted and clarifications were provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated random-number se-
quence was used. Numbered envelopes
contained a card indicating allocation
Allocation concealment (selection bias) Low risk Participants were allocated via numbered
envelopes into which a card indicating pa-
tient allocation had been placed according
to a computer-generated random numbers
sequence
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study used an open-label study design.
Clinical personnel were not blinded to the
study drug
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study used an open-label study design
and was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomized participants were included
in the analysis. No eligible participants’
relatives refused consent, and no patients
were lost to follow-up. 1 participant in
the haloperidol group stopped the drug at
physician request
Selective reporting (reporting bias) Low risk All outcomes reported in methods were in-
cluded in results. Data presented for all par-
ticipants were included in the analysis
Other bias Low risk Dexmedetomidine was supplied free of
charge by the manufacturer, Hospira,
which had no other involvement in the
study
Reade 2016
Methods RCT comparing dexmedetomidine vs placebo in facilitating extubation for patients with
agitated delirium
Study took place in 15 ICUs (14 mixed medical-surgical and 1 primarily cardiac post-
operative) in Australia and New Zealand
Participants Participants included 71 (N = 39 dexmedetomidine, median age 58 (IQR 47 to 65)
years, 28/39 (71.8%) male; N = 32 placebo, median age 56.5 (IQR 46 to 69.5) years,
25/32 (78.1%) male) patients who required continued mechanical ventilation because
their level of agitation was so severe that reducing sedation or extubation was deemed
unsafe
Participants met the following criteria during the 4 hours before randomization
1. Need for mechanical restraint, antipsychotic or sedative medication, or both
restraint and medication
2. Positive CAM-ICU score
3. Motor Activity Assessment Scale (MAAS) score ≥ 5, confirming psychomotor
agitation
Study enrolment between May 2011 and December 2013
Interventions Participants received intravenous dexmedetomidine or placebo (saline), started at a dose
of 0.5 µg/kg/h (option of 1.0 µg/kg bolus over 20 minutes). Study drug was titrated by
the bedside nurse between 0 and 1.5 µg/kg/h to achieve RASS score of 0 or to physician-
prescribed target. After 48 hours of study drug infusion, the treating physician could
prescribe open-label dexmedetomidine and the study drug was stopped. More than 7
days of infusion of study drug was considered treatment failure, at which point study
drug was stopped and open-label dexmedetomidine was started
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Outcomes Primary
1. Number of ventilator-free hours, defined as the number of hours alive and free of
invasive mechanical ventilation during first 7 days after randomization, during the
incident ICU admission
Secondary
1. Time to extubation
2. Time to satisfactory sedation (RASS -2 to 1)
3. Time to satisfactory agitation score (MAAS score 2 to 4)
4. Proportion of study time with a satisfactory MAAS score
5. Period until nurse thought it was time to extubate
6. Time to first negative CAM-ICU
7. Time with positive CAM-ICU
8. Use of sedative and antipsychotic medications
9. Tracheostomy
10. Re-intubation
11. Daily SOFA score
12. Length of ICU and hospital stay
Notes Funding
1. The study was funded in part by Hospira Australia through an unrestricted grant
of AUD 25,000 plus free study drug supply
2. Individual site funding was supplemented by grants from the Wellington Hospital
Research Office and the Austin Hospital Intensive Care Specialists Trust Fund
The sponsoring pharmaceutical company (Hospira Australia) decided against extend-
ing funding and provision of study drug beyond a date that had been earlier agreed.
Consequently, the trial was terminated prematurely in December 2013, after 74 patients
had been randomized. The funders had no role in the design and conduct of the study;
collection, management, analysis, and interpretation of data; preparation or approval of
the manuscript; or decision to submit the manuscript for publication
Registration
1. Study was registered at clinicaltrials.gov under NCT01151865
Study authors were contacted for clarification and provided requested details
Erratum in Expanded Explanation of the Sample Size Calcualtion (JAMA 2016)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomized, stratified by
site and age (< 55 years and ≥ 55 years), in
concealed permuted blocks of 2 to 6 by a
computer-generated algorithm accessed via
Internet connection to the Australian and
New Zealand Research Centre at Monash
University
Allocation concealment (selection bias) Low risk Participants were randomized in concealed
permuted blocks of 2 to 6 by a computer-
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generated algorithm accessed via Internet
connection to the Australian and New
Zealand Research Centre at Monash Uni-
versity. Unblinded pharmacists or nurses
not involved in the care of study partici-
pants prepared study drug in identically la-
belled syringes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk This was a double-blind study. Participants
randomized to placebo received an identi-
cally labelled infusion of saline at an equiv-
alent rate. Physicians and nurses treating
study participants and the study staff at
each site remained blinded to group alloca-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Frequency of delirium screening was not
mentioned. Bedside nurses performed
delirium assessments. The decision to extu-
bate was determined by senior ICU physi-
cians, taking into account assessments of
bedside nurses. This decision was not part
of the protocol but instead was tailored
to individual patient circumstances, with a
physician constantly present at each ICU
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were analysed through modified in-
tention-to-treat analyses. Modification was
permitted to account for post-randomiza-
tion circumstances that prevented use of
data from certain participants. Because no
data for the primary outcome were missing
and less than 5% was missing for all sec-
ondary outcomes, no data imputation was
performed
Selective reporting (reporting bias) Low risk All outcomes reported in methods were in-
cluded in results. Data presented for all par-
ticipants were included in the analysis
Other bias Low risk The funders had no role in the design and
conduct of the study; collection, manage-
ment, analysis, and interpretation of data;
preparation or approval of the manuscript;
or the decision to submit the manuscript
for publication
80Pharmacological interventions for the treatment of delirium in critically ill adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Skrobik 2004
Methods RCT comparing olanzapine vs haloperidol for treatment of delirium
Study took place: single 16-bed tertiary care university-affiliated ICU (mixed medical-
surgical) in Canada
Participants Participants included 73 (N = 45 haloperidol, mean age 63.26 ± 11.66 years, 31/45
male; N = 28 olanzapine, mean age 67.50 ± 6.04 years, 22/28 male) critically ill patients
admitted to the ICU for longer than 24 hours and diagnosed with delirium (ICDSC ≥
4, confirmed by DSM-IV criteria)
Study enrolment July 2000 to September 2001
Interventions The intensivist prescribed haloperidol or olanzapine PO (or via feeding tube, if nec-
essary) within 2 hours of delirium diagnosis. Haloperidol was initiated at 2.5 to 5 mg
every 8 hours, and olanzapine was begun at 5 mg daily. Patients over 60 years of age
received a lower initial dosage (haloperidol 0.5 to 1 mg, or olanzapine 2.5 mg). Subse-
quent titration was based on clinical judgement. Clinicians and nurses titrated sedatives
to targeted RASS score, and use of rescue IV haloperidol was left to the discretion of the
treating intensivist
The Delirium Index (DI) was administered by 1 of 2 research nurses and a physician at
baseline and daily for up to 5 days
Outcomes 1. Vital signs
2. Liver function tests
3. Daily dose of antipsychotic study medication
4. Daily dose “rescue haloperidol”
5. Daily dose of sedatives
6. If used specifically for sedation, daily dose of anti-Parkinsonian medication
prescribed for extrapyramidal symptoms
7. Delirium Index score (primary outcome)
8. Daily worst RASS score, obtained at least once every 8-hour shift
9. Extrapyramidal symptoms, based on the Ross-Chouinard and Simpson Angus
scales, administered by a physician
Notes Funding
1. A (peer-reviewed) grant was received from the Zyprexa fund, Eli-Lilly, North
America, but the funder was not involved in study design or analysis
Registration
No trial registration number was included in the manuscript
Study authors were contacted for clarifications and provided requested information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomization was performed on an even/
odd day basis
Allocation concealment (selection bias) High risk Method of allocation concealment was not
reported
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treating physicians and nurses were not
blinded to the assigned drug
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective evaluations were performed on a
daily basis by a clinician or a research nurse
blinded to the dispensed medication
Incomplete outcome data (attrition bias)
All outcomes
Low risk Informed consent was obtained for 80
participants; of these, the treating physi-
cian withdrew 3 participants, status was
changed to “no active treatment” for 2,
drug interaction was suspected for 1, and
data for 1 were lost. 73 participants were
included in the final analysis
Selective reporting (reporting bias) Unclear risk Published protocol or trial registration was
not available
Other bias Low risk Participants who developed agitation dur-
ing the study were permitted intravenous
haloperidol administration (recorded as
“rescue haloperidol”)
van Eijk 2010
Methods RCT comparing rivastigmine vs placebo as an adjunct to haloperidol for treatment of
delirium
Study took place in 6 ICUs in the Netherlands
Participants Participants included 104 (N = 54 rivastigmine, mean age 68.0 ± 11.4 years, 38/54
(70%) male; N = 50 placebo, mean age 70.0 ± 12.2 years, 29/50 (58%) male) critically
ill patients diagnosed with delirium according to the CAM-ICU and expected to remain
in the ICU for at least 48 hours
Study enrolment between November 2008 and January 2010
Interventions Participants received rivastigmine or placebo twice daily. Rivastigmine was delivered in
a 2-mg/mL solution
The dosing regimen for rivastigmine was as follows
1. Study days 1 to 3: 0.75 mL twice daily
2. Study days 4 to 6: 1.5 mL twice daily
3. Study days 7 to 9: 2.25 mL twice daily
4. Study days 10 onward: 3.0 mL twice daily.
Once delirium was resolved or participants were discharged from hospital, the dose
regimen was reversed and study drug was tapered off over 3 days. If a possible side effect
occurred during treatment, study drug was reduced until the side effect was resolved, or
was stopped if the side effect persisted for longer than 3 days. Participants with persistent
side effects were followed until an endpoint was reached (end of delirium, discharge from
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hospital, or death)
Delirium was assessed daily using the CAM-ICU until 3 days after study drug cessation.
The CAM was used if the patient was discharged to a regular ward. All participants
received usual care including frequent orientation, physical therapy, and exercise. Par-
ticipants ≥ 70 years of age received 1 mg intravenous haloperidol 3x/d, and those aged
≤ 69 years received 2.5 mg intravenous haloperidol 3x/d. Participants were allowed to
receive 1 mg intravenous lorazepam at night (22:00). The treating physician could adjust
treatment with haloperidol or a benzodiazepine, similar to usual care. Rescue haloperidol
(2.5 mg if ≥ 70 years, and 5 mg ≤ 69 years) was recommended in the event of persistent
agitation and was repeated every 30 minutes if needed. If haloperidol proved ineffective,
1 mg/kg per hour intravenous propofol was administered. In the event that propofol
was contraindicated, 5 mg per hour intravenous midazolam was used instead. The dose
of propofol or midazolam was increased until the participant was calm but was tapered
every 12 hours thereafter. Study drug was continued during sedation
Outcomes Primary
1. Duration of delirium during hospital admission (i.e. in the ICU and hospital
wards combined)
Secondary
1. Percentage of fixation days (i.e. proportion of study days on which patient was
restrained by arms, legs, or both)
2. Number of self-removed catheters
3. Severity of delirium
4. Use of psychoactive drugs
5. ICU and hospital length of stay
Other outcomes
1. Total dose of study drug
2. Number of study days
3. Mortality during treatment and at 90-day follow-up
Notes Funding
1. ZonMw, the Netherlands Brain Foundation provided funding
2. Novartis supplied the study drug, information about the study drug, and empty
bottles for placebo
None of the funding sources had any role in the design or conduct of the study
Registration
1. Study was registered at clinicaltrials.gov under NCT00704301
Study authors were not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomized in a 1:1 ra-
tio. The randomization sequence was com-
puter generated by the trial pharmacist and
was stratified by study centre. The leading
pharmacist held a list of study codes, which
could be broken at any time if deemed nec-
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essary by the treating physician
Allocation concealment (selection bias) Low risk The trial pharmacist consecutively num-
bered the bottles according to the random-
ization sequence to conceal allocation of
the next participant in the sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Once eligibility of participants was con-
firmed, the investigator used bottles of the
study drug consecutively to mask every pa-
tient and families, medical staff, and inves-
tigators from treatment allocation. All cen-
tres received batches of 10 identical bottles,
5 of which contained a solution of the study
drug and 5 of which contained a placebo so-
lution. The solutions had identical colour,
smell, taste, and viscosity
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This was a double-blind study
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5 participants were withdrawn from the
study by their families (1 on rivastigmine
and 4 on placebo), leading to a modi-
fied intention-to-treat analysis of 54 partic-
ipants on rivastigmine and 50 on placebo.
Data were censored for 16 participants who
died and for 19 participants who were dis-
charged from hospital while still delirious
Selective reporting (reporting bias) Low risk All outcomes reported in methods were in-
cluded in results. Data presented for all par-
ticipants were included in the analysis
Other bias Low risk All included participants received usual
care, which included frequent orientation,
physical therapy, and exercise. The treat-
ing physician could adjust treatment with
haloperidol or a benzodiazepine, similar to
usual care. In case of persistent severe agita-
tion, rescue haloperidol was recommended
ZonMw and the Netherlands Brain Foun-
dation did not contribute to study design,
data collection, data analysis, data inter-
pretation, writing of the report, or the de-
cision to submit for publication. Novartis
had no role in the decision to conduct the
study or to stop it early; nor in study de-
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sign, data collection, data analysis, data in-
terpretation, writing of the report, or the
decision to submit for publication
CAM-ICU: Confusion Assessment Method for the ICU.
DI: Delirium Index.
D5W: 5% dextrose in water.
ICDSC: Intensive Care Delirium Screening Checklist.
ICU: intensive care unit.
IQR: interquartile range.
MAAS: Motor Activity Assessment Scale.
QTc: measure of time between start of the Q wave and end of the T wave in the heart’s electrical cycle corrected for heart rate.
RASS: Richmond Agitation-Sedation Scale.
RCT: randomized controlled trial.
REB: research ethics board.
SAILS: Statins for Acutely Injured Lungs from Sepsis trial.
SAS: Riker Sedation-Agitation Scale.
SOFA: Sequential Organ Failure Assessment.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Eremenko 2014 This study is not a randomized controlled trial. Participants in the intervention group received dexmedetomi-
dine, some exclusively; others also received haloperidol and midazolam. Patients in the control group received
haloperidol intramuscularly and intravenously, separately and in combination with benzodiazepines
Khan 2019 The experimental intervention (vs usual care) included a multi-component pharmacological management of
delirium bundle, consisting of reducing exposure to 20 definite anticholinergic medications and benzodi-
azepines and prescribing low-dose haloperidol. The usual care group could also receive haloperidol. A full
study protocol was published (Campbell 2011)
Mailhot 2014 The intervention had no pharmacological component. The experimental intervention included mentoring
family members about delirium management behaviours and offering support for their implementation
Pandharipande 2007 The purpose of this study was to examine the sedative effects of 2 different drugs. Although delirium was a
reported secondary outcome for this trial, the focus of the trial was not delirium treatment
Riker 2009 The purpose of this study was to examine efficacy and safety of prolonged sedation with dexmedetomidine
vs midazolam for mechanically ventilated patients. Although delirium was a reported secondary outcome for
this trial, the focus of the trial was not delirium treatment
Tagarakis 2012 This study did not use a validated delirium screening tool. For detection of delirium, study authors used a 4-
point scale (0 - normal; 1 - patient with restlessness and mild confusion but co-operative; 2 - patient disoriented
but co-operative, memory gaps; 3 - patient disoriented and unco-operative with augmented mobility that
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could put him in danger; 4 - patient totally disoriented, violent, and aggressive, presence of hallucinations)
Waszynski 2018 This study evaluated delirious participants, but no study drug was administered to either group
Characteristics of studies awaiting assessment [ordered by study ID]
Emerson 2014
Methods Randomized trial comparing the effectiveness of a delirium management team vs standard of care in the treatment
of delirium
Study took place in 3 medical-surgical ICUs in the United States
Participants Adult (> 18 years) ICU patients diagnosed with delirium via the CAM-ICU
Interventions Participants received standard delirium care or management via a team consisting of a physician, a clinical pharmacist,
and a registered nurse delirium co-ordinator. Participants in the intervention group were assessed daily over the course
of their ICU stay for non-pharmacological and pharmacological interventions. Per hospital initiative, a delirium
prevention bundle and early mobilization administered by exercise physiologists were provided to all patients in the
study
Outcomes Primary
1. Duration of delirium
Secondary
1. Duration of mechanical ventilation
2. ICU and hospital length of stay
Notes Study status unknown. Study was published in abstract form under the title “Impact of a collaborative multidisci-
plinary team on ICU delirium” (Emerson 2014). Several attempts to contact the principal study investigator (kemer-
son1@stlukeshealth.org) were unsuccessful
ISRCTN33122761
Methods Randomized trial comparing physostigmine salicylate vs placebo in the treatment of delirium
Single centre in Germany
Participants Adult (18 to < 90 years) ICU patients who had undergone elective aortocoronary bypass under mild hypothermia
(34°C) and were diagnosed with delirium via the CAM-ICU
Interventions Participants received physostigmine 0.03 mg per kg body weight administered intravenously or matched placebo
Outcomes Primary
1. CAM-ICU status 30 minutes after drug administration
Secondary
1. CAM-ICU status 120 minutes after drug administration
2. Serum anticholinergic activity 60 minutes after drug administration
3. RASS score 30 and 120 minutes after drug administration
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4. Adverse events
5. Vital signs 10, 20, 30, 60, and 120 minutes after drug administration
Notes Study is stated as complete but does not appear to be published
Study started in December 2008 and was registered under the name “Efficacy and tolerability of physostigmine
salicylate for treatment of post-operative delirium after aortocoronary-bypass operation (ACVB): a prospective,
double-blind, placebo-controlled, 2 parallel-groups, phase III study”
Sponsor: Dr Franz Köhler Chemie GmbH (Germany)
Study registered: at isrctn.com under ISRCTN33122761
Several attempts to contact the principal study investigator were unsuccessful (Markus.Verch@med.uni-heidelberg.de)
NCT00429676
Methods Randomized trial comparing standard sedation to standard sedation with add-on haloperidol for duration of me-
chanical ventilation in patients with delirium
Single ICU in the USA
Participants Adult (> 18 years) patients requiring mechanical ventilation within 24 hours of ICU admission and diagnosed with
delirium via the CAM-ICU
Interventions Participants received a standard of care sedation protocol with or without add-on haloperidol. Haloperidol dose was
administered via a titration protocol guided by nursing assessment of delirium using the CAM-ICU
Outcomes Primary
1. Number of ventilator-free days (in 28 days of study)
Secondary
1. Duration of delirium
2. Hospital length of stay
3. Cost of hospitalization
4. 28-day mortality
5. Use of sedatives
6. Serum markers of delirium (e.g. neuron-specific enolase)
7. Cognitive-function scores at ICU discharge, hospital discharge, and 6-month follow-up
Notes Study is complete but unpublished
Study was started in December 2005 and was registered under the name “A randomised prospective pilot study of
haloperidol in addition to standard sedation in mechanically ventilated patients with delirium”
Sponsor: University of Colorado, Denver
Study registered: clinicaltrials.gov under NCT00429676
Principal investigator was contacted and was not able to share data for inclusion in this review
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Methods Randomized trial comparing effects of dexmedetomidine and propofol on delirium and neuroinflammation in
patients with systemic inflammatory response syndrome (SIRS)
No study location details provided
Participants Adult (18 to < 80 years) participants diagnosed with delirium





Notes Study status unknown. Study registered in February 2015 and listed as not yet recruiting. Study status have not been
updated since that time
Sponsor: Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy
Study registered: at clinicaltrials.gov under NCT02366299
Unable to contact principal investigator
Peters 2015
Methods Randomized trial comparing intranasal insulin aspart vs placebo in the treatment of delirium
Single-centre study in the USA
Participants Adult (> 18 years) participants diagnosed with delirium via the CAM-ICU
Interventions Participants received a single intranasal dose of 40 units insulin aspart or 0.4 mL normal saline at the time of delirium
diagnosis. Delirium was reassessed 15 minutes later and daily until discharge
Outcomes Primary
1. Duration of delirium
Secondary
1. Not listed in the abstract
Notes Study status unknown. Study was published in abstract form under the title “Therapeutic effects of intranasal insulin
aspart on cognitive function in postoperative delirium” (Peters 2015). Several attempts to contact the principal study
investigator (l-peters@onu.edu) were unsuccessful
Schoeffler 2012
Methods Randomized trial comparing clonidine vs placebo in the treatment of delirium
Single centre in the USA
Participants Adult (> 18 years) trauma patients admitted to the ICU > 24 hours, meeting criteria for extubation, declared stable
from a neurological, respiratory, and cardiovascular standpoint to receive clonidine, and diagnosed with delirium via
the CAM-ICU
88Pharmacological interventions for the treatment of delirium in critically ill adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Schoeffler 2012 (Continued)
Interventions Participants received an oral loading dose of 0.3 mg clonidine or matched placebo, along with a transdermal clonidine
patch of the same dose with patch overlay (patch overlay alone in placebo group). 12 hours later, a final dose of 0.3
mg clonidine or matched placebo was given
Outcomes Primary
1. Duration of mechanical ventilation
Secondary
1. Incidence and duration of delirium, time to successful spontaneous breathing trial
Notes Study is stated as terminated in June 2017 due to difficulty recruiting participants
Study was started in May 2010 and was registered under the name “A randomized double blinded placebo controlled
trial of transdermal clonidine for adjuvant sedation in ventilated trauma patients experiencing delirium”
Interim study results published in abstract form (Schoeffler 2012)
Sponsor: Memorial Health University Medical Center (Savannah, Georgia)
Study registered: at clinicaltrials.gov under NCT01139996
Principal investigator was contacted and was not able to share data for inclusion in this review (
schoeme1@memorialhealth.com)
CAM-ICU: Confusion Assessment Method for the ICU.
ICU: intensive care unit.
RASS: Richmond Agitation-Sedation Scale.
Characteristics of ongoing studies [ordered by study ID]
IRCT20121231011956N10
Trial name or title Comparison of the effectiveness of haloperidol and quetiapine for delirium in the emergency department and
intensive care unit
Methods Single-site, double-blind, randomized study taking place in Iran. Target enrolment: 100 participants
Participants Adult (> 18 years) patients admitted to the Emergency Department or ICU and diagnosed with delirium via
DSM criteria
Interventions Participants randomized to receive haloperidol (5 mg IM daily) or quetiapine (25 mg PO daily)
Outcomes Primary
1. Delirium severity (DRS-R-98)
Secondary
1. None stated
Starting date March 2018
Contact information Morteza Talebi Doluee (talebidm@mums.ac.ir)
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Notes Study recruitment is complete
Funding source: Mashhad University of Medical Sciences
Sponsor: Mashhad University of Medical Sciences
Study registered: at https://en.irct.ir/trial/29718
IRCT20180911040998N1
Trial name or title Comparison of the effect of quetiapine and haloperidol on the treatment of delirium in ICU
Methods Single-site, double-blind, randomized study taking place in Iran. Target enrolment: 60 participants
Participants Adult (> 18 years) ICU patients diagnosed with delirium via DSM criteria
Interventions Participants randomized to receive injected haloperidol (2.5 mg/d) or quetiapine (25 mg twice daily)
Outcomes Primary
1. Sedation (RASS)
2. Illness severity (APACHE II)
Secondary
1. None listed
Starting date February 2018
Contact information Alireza Kamali (alikamaliir@yahoo.com)
Notes Study is currently recruiting
Funding source: Arak University of Medical Sciences
Sponsor: Arak University of Medical Sciences
Study registered: at https://en.irct.ir/trial/33804
NCT00351299
Trial name or title Study of dexmedetomidine as an effective sedative to treat acute ICU delirium
Methods Single-site, double-blind, randomized study taking place in the United States. Target enrolment: 53 partici-
pants
Participants Adult (≥ 18 years) ICU patients diagnosed with delirium via the CAM-ICU
Interventions Participants randomized to receive an infusion of dexmedetomidine (0.3 to 0.7 mcg/kg/h) or standard of care




1. Duration of mechanical ventilation
2. ICU and hospital length of stay
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3. Ease of management noted by nursing staff
4. Hospital mortality
Starting date January 2006
Contact information Namrata Patil (npatil@partners.org)
Gerald Weinhouse (gweinhouse@partners.org)
Notes This study is complete; 5- and 7-year follow-up data are being collected as of September 2014 (communication
with principal investigators)
Study sponsor: Brigham and Women’s Hospital
Study registered: at clinicaltrials.gov under NCT00351299
NCT01811459
Trial name or title Randomized trial comparing haloperidol, quetiapine, and placebo in the pharmacological treatment of delir-
ium (Haloquet)
Methods Single-site, quadruple-blind, randomized placebo-controlled study taking place in Canada. Target enrolment:
107 participants
Participants Adult (≥ 18 years) ICU patients diagnosed with delirium by a psychiatrist (DSM criteria)
Interventions Participants randomized to 1 mg intravenous haloperidol and oral placebo, 50 mg oral quetiapine and
intravenous placebo, or intravenous and oral placebo
As needed 2 mg intravenous doses of haloperidol permitted every 30 minutes to all participants until delirium
symptoms resolve. Incremental titration (1 mg haloperidol or 50 mg quetiapine) permitted twice daily if
2 doses of as needed haloperidol were given in the previous 24 hours. Additional rescue doses of 5 mg of
intravenous haloperidol were permitted every 30 minutes to all participants if agreed by the treating physician
Treatment continued until:
1. delirium resolution
2. 21 days of treatment
3. ICU discharge; or
4. life-threatening adverse event potentially attributable to the study drug
Outcomes Primary
1. Time to first resolution of delirium
Secondary
1. Days of delirium, duration of delirium
2. Severity of delirium
3. ICU and hospital mortality
4. ICU and hospital length of stay
5. Duration of mechanical ventilation
6. Time spent deeply sedated (i.e. RASS < 3)
7. Episodes of subject-initiated device removal
8. Use of as needed and rescue haloperidol therapy
9. Average daily and maximum total antipsychotic doses (haloperidol equivalents)
10. Duration of study drug administration
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11. Use of benzodiazepines
12. Use of opioids
13. QTc prolongation
14. Extrapyramidal symptoms
15. Neuroleptic malignant syndrome
Starting date February 2013
Contact information Nicholas Bergeron (nbergeron@yahoo.com)
Marie-Pierre Leduc (marie-pierre.leduc.chum@ssss.gouv.qc.ca)
Notes Study recruitment complete and data analysis phase in progress as of December 2017 (communication with
principal investigators)
Sponsor: Centre Hopitalier de l’Université de Montréal
Study registered: at clinicaltrials.gov under NCT01811459
NCT02216266
Trial name or title Monocentre, double-blind, randomised, placebo-controlled study to evaluate physostigmine for the treatment
of delirium in perioperative intensive care medicine
Methods Single-site, triple-blind, randomized placebo-controlled study taking place in Germany. Target enrolment:
120 participants
Participants Adult (18 to < 85 years) ICU patients post elective or emergency heart surgery (with or without extracorporeal
circulation) diagnosed with delirium via the CAM-ICU
Interventions Participants randomized to receive physostigmine or placebo, administered intravenously at a dose of 24 mg
+ 25 minutes at 0.04 mg/kg
Outcomes Primary
1. Change in delirium symptoms measured by RASS
Secondary
1. Duration of mechanical ventilation
2. Change in spontaneous EEG and auditory evoked potential
3. Heart rate variability
4. Muscular force (via force gauge)
5. Adverse events.
Starting date April 2014
Contact information Bertram Scheller (bertram.scheller@kgu.de)
Notes Study status unknown, but last updated as recruiting on 10 March 2017
Study sponsor: PD Dr Bertram Scheller
Study registered: at clinicaltrials.gov under NCT02216266
92Pharmacological interventions for the treatment of delirium in critically ill adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02343575
Trial name or title Valproic acid for treatment of hyperactive or mixed delirium in ICU
Methods Single-site, quadruple-blind, randomized placebo-controlled study taking place in the United States. Target
enrolment: 30 participants
Participants Adult (≥ 18 years) ICU patients diagnosed with hyperactive or mixed delirium via the CAM-ICU
Interventions Participants randomized to receive valproic acid or matched placebo, started at 500 mg twice daily (oral or
via nasogastric tube)
If additional symptom control needed, increases permitted every 24 hours
1. 500 mg in the morning and 1000 mg at night
2. 500 mg in the morning and 1500 mg at night
3. 500 mg in the morning and 2000 mg at night.
All participants permitted as needed rescue haloperidol 2 to 5 mg given intravenously every 4 hours
Outcomes Primary
1. Time to delirium resolution
Secondary
1. Use of as needed antipsychotics (haloperidol and other)
2. Mortality
3. Adverse events
4. Delirium intensity (via ICDSC)
5. ICU and hospital length of stay
Starting date January 2015
Contact information Yelizaveta Sher, Stanford University
Jose R Maldonado, Stanford University
Notes Study is currently suspended due to loss of research staff
Study sponsor: Stanford University
Study registered: at clinicaltrials.gov under NCT02343575
NCT02807467
Trial name or title Comparison of propofol and dexmedetomidine to treat hyperactive and mixed ICU delirium: the Basel
ProDex randomised trial
Methods Single-site, open-label, randomized study taking place in Switzerland. Target enrolment: 318 participants
Participants Adult (≥ 18 years) ICU patients diagnosed with hyperactive or mixed delirium via ICDSC
Interventions Participants randomized to receive a continuous infusion of dexmedetomidine (200µg/2mL) or propofol (1%
1g/100mL) between the hours of 20:00 and 06:00. Rescue haloperidol (administered intravenously) used for
daytime symptoms of delirium. The dexmedetomidine or propofol infusion was repeated nightly until full
resolution of delirium
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NCT02807467 (Continued)
Outcomes Primary
1. Duration of delirium
Secondary
1. Number of delirium-free days (28 days)
2. 28-day mortality
3. Delirium severity
4. Duration of mechanical ventilation
5. Use of rescue haloperidol
6. Length of ICU stay
7. Length of hospital stay
8. Level of sedation (measured by RASS)
Starting date January 2017
Contact information Alexa Hollinger (alexa.hollinger@usb.ch)
Martin Siegemund (martin.siegemund@usb.ch)
Notes Study is currently recruiting
Study sponsor: University Hospital, Basel, Switzerland
Full protocol published and study registered at clinicaltrials.gov under NCT02807467 (Hollinger 2017)
NCT03317067
Trial name or title Effects of dexmedetomidine on delirium duration of non-intubated ICU patients (4D trial)
Methods Multi-site, double-blind, randomized, placebo-controlled trials taking place in France. Target enrolment: 300
participants
Participants Adult (> 18 years), non-intubated ICU patients diagnosed with delirium (via CAM-ICU and RASS)
Interventions Participants randomized to receive dexmedetomidine or placebo (NaCL 0.9%) via continuous infusion
Outcomes Primary
1. Duration of agitation (in hours)
2. Duration of delirium (in days)
3. Delay between inclusion and intubation requirement to control delirium with deep sedation
Secondary
1. Length of ICU stay (days)
2. Number of ventilator-free days
3. Adverse effects (e.g. pneumonia)
4. Duration of mechanical restraint
5. Occurrence of tachycardia and hypotension
6. All-cause mortality
Starting date December 2017
Contact information Patrick Lacarin (placarin@chu-clermontferrand.fr)
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NCT03317067 (Continued)
Notes Study is currently recruiting
Study sponsor: University Hospital, Clermont-Ferrand
Full protocol published and study registered at clinicaltrials.gov under NCT03317067 (Louis 2018)
NCT03392376
Trial name or title Agents intervening against delirium in intensive care unit (AID-ICU)
Methods Multi-site (23), quadruple-blind, randomized placebo-controlled trial taking place in Denmark, Finland,
Germany, Italy, Norway, and Spain. Target enrolment: 1000 patients
Participants Acutely admitted adult (> 18 years) patients diagnosed with delirium via the CAM-ICU or ICDSC
Interventions Participants randomized to receive haloperidol (2.5 mg IV thrice daily with additional, as needed doses up to
a maximum of 20 mg/d) or placebo (0.5 mL IV isotonic saline thrice daily, with additional, as needed doses
up to a maximum of 4 mL/d)
Outcomes Primary
1. Days alive out of the hospital within 90 days post randomization
Secondary
1. Number of days alive without delirium or coma in the ICU
2. Number of patients with 1 or more serious adverse reactions or the total number of serious adverse
reactions to haloperidol compared with placebo, or both
3. Usage of escape medicine and dosage of escape medicine per patient
4. Number of days alive without mechanical ventilation within 90 days post randomization
5. Mortality
6. Quality of life (EQ-5D-5L total score 1 year post randomization)
7. Quality of life (EQ-Visual Analogue Scale 1 year post randomization)
8. Cognitive function 1 year after randomization (at selected sites)
9. Executive function 1 year after randomization (at selected sites)
10. Health economics analysis
11. Cognitive function at admission
Starting date 12 June 2018
Contact information Lone Musaeus Poulsen, MD (lmp@regionsjaelland.dk)
Nina Christine Andersen-Ranberg, MD (ncan@regionsjaelland.dk)
Notes Subset of sites currently recruiting
Study sponsor: Zealand University Hospital
Study registered: at https://clinicaltrials.gov/ct2/show/NCT03392376
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NCT03628391
Trial name or title Efficacy of halopeRIdol to decrease the burden of Delirium In adult Critically ill patiEnts: a prospective
randomized multi-center double-blind placebo-controlled clinical trial (EuRIDICE)
Methods Multi-site (6), quadruple-blind, randomized placebo-controlled trial taking place in the Netherlands. Target
enrolment: 742 participants
Participants Adult (≥ 18 years) participants admitted to 1 of 6 participating ICUs and diagnosed with delirium by the
CAM-ICU or ICDSC ≥ 4
Interventions Participants randomized to receive haloperidol, starting with 2.5 mg IV q8h and titrated to a maximum of 5
mg IV q8h, or placebo
Outcomes Primary
1. Numbers of delirium-free and coma-free days in the ICU
Secondary
1. Time to delirium resolution
2. 28-day and 1-year mortality
3. Time to readiness of ICU discharge
4. Adverse drug reaction (e.g. QTc prolongation, arrhythmias, extrapyramidal symptoms)
5. Patient and family well-being (ICU Memory Tool)
6. Delirium Experience Questionnaire (DEQ)
7. Caregiver Strain Index at discharge and 3 months after randomization
8. Incidence of post-traumatic stress disorder in participants and family 3 months after randomization
9. Maximum ICU mobility scale
10. Quality of sleep (Richards-Campbell Sleep Questionnaire)
11. 3- and 12-month cognitive function (Montreal Cognitive Assessment)
12. Rey Auditory Verbal Learning Test
13. Semantic Fluency Digit Span
14. Trailmaking Tests A and B
15. Boston Naming Test
16. Hospital Anxiety and Depression Scale
17. 3- and 12-month functional outcomes and quality of life (Short Form-36)
18. Workload experienced by ICU nurses while caring for delirious patients (based on Delirium
Experience Questionnaire)
Starting date February 2018
Contact information Mathieu van der Jagt (m.vanderjagt@erasmusmc.nl)
Notes Study is currently recruiting
Study sponsor: Erasmus Medical Center Rotterdam
Study funded by: ZonMw
Study registered: at https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003115-20/NL
APACHE: Acute Physiology and Chronic Healh Evaluation.
CAM-ICU: Confusion Assessment Method for the ICU.
DRS-R-98: Delirium Rating Scale - Revised - 98.
DSM: Diagnostic and Statistical Manual.
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EEG: electroencephalography.
EQ-5D-5L: EuroQoL Group Quality of Life Based on 5 Dimensions - 5-Level Scale.
ICDSC: Intensive Care Delirium Screening Checklist.
ICU: intensive care unit.
QTc: measure of time between start of the Q wave and end of the T wave in the heart’s electrical cycle corrected for heart rate.
RASS: Richmond Agitation-Sedation Scale.
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D A T A A N D A N A L Y S E S
Comparison 1. Duration of delirium (log ratio of means scale)




participants Statistical method Effect size
1 Duration of delirium (log units) 11 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Typical AP vs placebo 4 608 Mean Difference (IV, Random, 95% CI) 0.02 [-0.09, 0.13]
1.2 Atypical AP vs placebo 4 500 Mean Difference (IV, Random, 95% CI) -0.31 [-0.71, 0.10]
1.3 Statin vs placebo 2 414 Mean Difference (IV, Random, 95% CI) 0.07 [-0.09, 0.22]
1.4 Alpha-2 agonist vs placebo 1 71 Mean Difference (IV, Random, 95% CI) -0.55 [-0.85, -0.24]
1.5 Cholinesterase inhibitor
vs placebo
1 104 Mean Difference (IV, Random, 95% CI) 0.61 [0.22, 0.99]
1.6 Typical AP vs atypical AP 2 447 Mean Difference (IV, Random, 95% CI) 0.05 [-0.07, 0.17]
1.7 Typical AP vs opioid 1 53 Mean Difference (IV, Random, 95% CI) 0.09 [-0.17, 0.34]
Comparison 2. Delirium-free and coma-free days (log ratio of means scale)




participants Statistical method Effect size
1 Delirium-free and coma-free
days
4 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Typical AP vs placebo 3 588 Mean Difference (IV, Random, 95% CI) 0.13 [-0.08, 0.34]
1.2 Atypical AP vs placebo 2 440 Mean Difference (IV, Random, 95% CI) 0.36 [-0.15, 0.87]
1.3 Statin vs placebo 1 142 Mean Difference (IV, Random, 95% CI) -0.11 [-0.33, 0.11]
1.4 Typical AP vs atypical AP 2 447 Mean Difference (IV, Random, 95% CI) -0.08 [-0.21, 0.05]
Comparison 3. Days with coma (log ratio of means scale)




participants Statistical method Effect size
1 Days with coma (log units) 5 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Typical AP vs placebo 3 588 Mean Difference (IV, Random, 95% CI) -0.29 [-0.71, 0.12]
1.2 Atypical AP vs placebo 2 440 Mean Difference (IV, Random, 95% CI) 0.06 [-0.13, 0.26]
1.3 Statin vs placebo 2 414 Mean Difference (IV, Random, 95% CI) -0.10 [-0.32, 0.11]
1.4 Typical AP vs atypical AP 2 447 Mean Difference (IV, Random, 95% CI) -0.15 [-0.34, 0.04]
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Comparison 4. Duration of mechanical ventilation (log ratio of means scale)




participants Statistical method Effect size
1 Duration of mechanical
ventilation (log units)
7 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Typical AP vs placebo 3 515 Mean Difference (IV, Random, 95% CI) -0.08 [-0.23, 0.06]
1.2 Atypical AP vs placebo 3 476 Mean Difference (IV, Random, 95% CI) -0.02 [-0.17, 0.14]
1.3 Statin vs placebo 1 272 Mean Difference (IV, Random, 95% CI) 0.09 [-0.11, 0.29]
1.4 Alpha-2 agonist vs placebo 1 71 Mean Difference (IV, Random, 95% CI) -0.59 [-0.89, -0.29]
1.5 Typical AP vs atypical AP 2 447 Mean Difference (IV, Random, 95% CI) -0.17 [-0.67, 0.33]
1.6 Typical AP vs opioid 1 53 Mean Difference (IV, Random, 95% CI) -0.06 [-0.37, 0.24]
Comparison 5. Length of ICU stay (log ratio of means scale)




participants Statistical method Effect size
1 Length of ICU stay (log units) 10 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Typical AP vs placebo 4 618 Mean Difference (IV, Random, 95% CI) 0.01 [-0.11, 0.13]
1.2 Atypical AP vs placebo 4 577 Mean Difference (IV, Random, 95% CI) -0.09 [-0.18, -0.00]
1.3 Statin vs placebo 1 272 Mean Difference (IV, Random, 95% CI) 0.06 [-0.09, 0.21]
1.4 Alpha-2 agonist vs placebo 1 71 Mean Difference (IV, Random, 95% CI) -0.22 [-0.53, 0.08]
1.5 Cholinesterase inhibitor
vs placebo
1 104 Mean Difference (IV, Random, 95% CI) 0.78 [0.46, 1.11]
1.6 Typical AP vs atypical AP 2 447 Mean Difference (IV, Random, 95% CI) 0.01 [-0.13, 0.16]
1.7 Typical AP vs opioid 1 53 Mean Difference (IV, Random, 95% CI) 0.07 [-0.24, 0.37]
Comparison 6. Length of hospital stay (log ratio of means scale)




participants Statistical method Effect size
1 Length of hospital stay (log
units)
9 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Typical AP vs placebo 2 479 Mean Difference (IV, Random, 95% CI) -0.12 [-0.38, 0.14]
1.2 Atypical AP vs placebo 3 511 Mean Difference (IV, Random, 95% CI) -0.04 [-0.13, 0.05]
1.3 Statin vs placebo 2 369 Mean Difference (IV, Random, 95% CI) -0.01 [-0.13, 0.12]
1.4 Alpha-2 agonist vs placebo 1 71 Mean Difference (IV, Random, 95% CI) 0.09 [-0.17, 0.35]
1.5 Cholinesterase Inhibitor
vs placebo
1 104 Mean Difference (IV, Random, 95% CI) 0.11 [-0.15, 0.36]
1.6 Typical AP vs atypical AP 1 382 Mean Difference (IV, Random, 95% CI) 0.04 [-0.09, 0.17]
1.7 Typical AP vs opioid 1 53 Mean Difference (IV, Random, 95% CI) -0.06 [-0.26, 0.13]
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Comparison 7. Mortality




participants Statistical method Effect size
1 Mortality 10 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Typical AP vs placebo 4 656 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.69, 1.40]
1.2 Atypical AP vs placebo 4 577 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.66, 1.52]
1.3 Cholinesterase inhibitor
vs placebo
1 104 Odds Ratio (M-H, Random, 95% CI) 1.77 [0.74, 4.26]
1.4 Statin vs placebo 2 414 Odds Ratio (M-H, Random, 95% CI) 1.42 [0.84, 2.39]
1.5 Typical AP vs opioid 1 53 Odds Ratio (M-H, Random, 95% CI) 2.17 [0.18, 25.46]
1.6 Typical AP vs atypical AP 2 447 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.59, 1.39]
Comparison 8. Akathisia




participants Statistical method Effect size
1 Akathisia 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Typical AP vs placebo 2 212 Odds Ratio (M-H, Random, 95% CI) 1.34 [0.49, 3.67]
1.2 Atypical AP vs placebo 1 66 Odds Ratio (M-H, Random, 95% CI) 1.04 [0.31, 3.50]
1.3 Typical AP vs atypical AP 1 65 Odds Ratio (M-H, Random, 95% CI) 1.6 [0.50, 5.09]
Comparison 9. Arrhythmias




participants Statistical method Effect size
1 Arrhythmias 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Typical AP vs placebo 3 588 Odds Ratio (M-H, Random, 95% CI) 3.09 [1.11, 8.62]
1.2 Atypical AP vs placebo 2 440 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Alpha-2 agonist vs typical
AP
1 20 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.11, 8.95]
1.4 Typical AP vs atypical AP 2 447 Odds Ratio (M-H, Random, 95% CI) 5.0 [0.24, 104.84]
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Comparison 10. QTc prolongation




participants Statistical method Effect size
1 QTc prolongation 8 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Typical AP vs placebo 4 656 Odds Ratio (M-H, Random, 95% CI) 1.26 [0.68, 2.34]
1.2 Atypical AP vs placebo 4 577 Odds Ratio (M-H, Random, 95% CI) 1.28 [0.45, 3.66]
1.3 Typical AP vs atypical AP 2 447 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.28, 1.08]
1.4 Alpha-2 agonist vs typical
AP
1 20 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.17, 5.98]
1.5 Alpha-2 agonist vs 5HT3
inhibitor
1 64 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 11. Extrapyramidal symptoms




participants Statistical method Effect size
1 Extrapyramidal symptoms 6 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Typical AP vs placebo 4 656 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.26, 2.21]
1.2 Atypical AP vs placebo 3 476 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.11, 1.97]
1.3 Typical AP vs atypical AP 3 520 Odds Ratio (M-H, Random, 95% CI) 2.22 [0.59, 8.38]
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Analysis 1.1. Comparison 1 Duration of delirium (log ratio of means scale), Outcome 1 Duration of
delirium (log units).
Review: Pharmacological interventions for the treatment of delirium in critically ill adults
Comparison: 1 Duration of delirium (log ratio of means scale)
Outcome: 1 Duration of delirium (log units)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Typical AP vs placebo
Al-Qadheeb 2016 0.786557 (0.348542) 12 8 0.95 (0.551065) 6.8 % -0.16 [ -0.59, 0.27 ]
Girard 2010a 35 1.1737 (0.765033) 36 1.15 (0.683787) 11.0 % 0.02 [ -0.32, 0.36 ]
Girard 2018 1.434712 (0.654136) 192 184 1.43 (0.684853) 68.4 % 0.00 [ -0.13, 0.14 ]
Page 2013 1.353901 (0.872582) 71 70 1.16 (0.950214) 13.8 % 0.20 [ -0.11, 0.50 ]
Subtotal (95% CI) 310 298 100.0 % 0.02 [ -0.09, 0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.06, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
2 Atypical AP vs placebo
Devlin 2010 0.114652 (1.014737) 18 18 1.37 (0.750244) 19.4 % -1.25 [ -1.84, -0.67 ]
Girard 2010a 1.193458 (0.833051) 30 36 1.15 (0.683787) 25.5 % 0.04 [ -0.33, 0.41 ]
Girard 2018 1.375082 (0.622148) 190 184 1.43 (0.684853) 31.4 % -0.06 [ -0.19, 0.07 ]
Hakim 2012 0.93939 (0.564308) 7 17 1.18 (0.239057) 23.7 % -0.24 [ -0.67, 0.20 ]
Subtotal (95% CI) 245 255 100.0 % -0.31 [ -0.71, 0.10 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 16.35, df = 3 (P = 0.00096); I2 =82%
Test for overall effect: Z = 1.49 (P = 0.14)
3 Statin vs placebo
Needham 2016 1.965497 (0.758813) 137 135 1.85 (0.792892) 67.3 % 0.12 [ -0.07, 0.30 ]
Page 2017 1.540953 (0.79416) 71 71 1.59 (0.814702) 32.7 % -0.04 [ -0.31, 0.22 ]
Subtotal (95% CI) 208 206 100.0 % 0.07 [ -0.09, 0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
4 Alpha-2 agonist vs placebo
Reade 2016 0.327005 (0.682072) 39 32 0.87 (0.637477) 100.0 % -0.55 [ -0.85, -0.24 ]
Subtotal (95% CI) 39 32 100.0 % -0.55 [ -0.85, -0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.48 (P = 0.00050)
5 Cholinesterase inhibitor vs placebo
van Eijk 2010 1.541946 (0.944381) 54 50 0.93 (1.054784) 100.0 % 0.61 [ 0.22, 0.99 ]
-2 -1 0 1 2
Favour intervention drug Favour placebo/comparator
(Continued . . . )
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(. . . Continued)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 54 50 100.0 % 0.61 [ 0.22, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.09 (P = 0.0020)
6 Typical AP vs atypical AP
Girard 2010a 35 1.1737 (0.765033) 30 1.19 (0.833051) 9.7 % -0.02 [ -0.41, 0.37 ]
Girard 2018 1.434712 (0.654136) 192 190 1.38 (0.622148) 90.3 % 0.06 [ -0.07, 0.19 ]
Subtotal (95% CI) 227 220 100.0 % 0.05 [ -0.07, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
7 Typical AP vs opioid
Atalan 2013 0.237431 (0.465875) 26 27 0.15 (0.494212) 100.0 % 0.09 [ -0.17, 0.34 ]
Subtotal (95% CI) 26 27 100.0 % 0.09 [ -0.17, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
-2 -1 0 1 2
Favour intervention drug Favour placebo/comparator
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Analysis 2.1. Comparison 2 Delirium-free and coma-free days (log ratio of means scale), Outcome 1
Delirium-free and coma-free days.
Review: Pharmacological interventions for the treatment of delirium in critically ill adults
Comparison: 2 Delirium-free and coma-free days (log ratio of means scale)
Outcome: 1 Delirium-free and coma-free days





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Typical AP vs placebo
Girard 2010a 2.324299 (0.655248) 35 36 1.89 (0.944114) 21.5 % 0.44 [ 0.06, 0.81 ]
Girard 2018 1.667557 (0.662589) 192 184 1.59 (0.709929) 52.4 % 0.08 [ -0.06, 0.22 ]
Page 2013 2.183788 (0.97857) 71 70 2.21 (0.982871) 26.2 % -0.03 [ -0.35, 0.29 ]
Subtotal (95% CI) 298 290 100.0 % 0.13 [ -0.08, 0.34 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.79, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Atypical AP vs placebo
Girard 2010a 2.532383 (0.467017) 30 36 1.89 (0.944114) 45.0 % 0.65 [ 0.30, 1.00 ]
Girard 2018 1.714767 (0.635855) 190 184 1.59 (0.709929) 55.0 % 0.13 [ -0.01, 0.26 ]
Subtotal (95% CI) 220 220 100.0 % 0.36 [ -0.15, 0.87 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 7.32, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.39 (P = 0.16)
3 Statin vs placebo
Page 2017 2.421079 (0.691637) 71 71 2.53 (0.637269) 100.0 % -0.11 [ -0.33, 0.11 ]
Subtotal (95% CI) 71 71 100.0 % -0.11 [ -0.33, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
4 Typical AP vs atypical AP
Girard 2010a 2.324299 (0.655248) 35 30 2.53 (0.467017) 20.8 % -0.21 [ -0.48, 0.07 ]
Girard 2018 1.667557 (0.662589) 192 190 1.71 (0.635855) 79.2 % -0.05 [ -0.18, 0.08 ]
Subtotal (95% CI) 227 220 100.0 % -0.08 [ -0.21, 0.05 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.08, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 1.24 (P = 0.22)
-1 -0.5 0 0.5 1
Favour placebo/comparator Favour intervention drug
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Analysis 3.1. Comparison 3 Days with coma (log ratio of means scale), Outcome 1 Days with coma (log
units).
Review: Pharmacological interventions for the treatment of delirium in critically ill adults
Comparison: 3 Days with coma (log ratio of means scale)
Outcome: 1 Days with coma (log units)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Typical AP vs placebo
Girard 2010a 0.082734 (1.10491) 35 36 0.19 (1.148189) 26.6 % -0.11 [ -0.63, 0.42 ]
Girard 2018 192 -0.0308 (1.000804) 184 0.05 (1.036661) 41.3 % -0.08 [ -0.29, 0.12 ]
Page 2013 -1.31398 (1.347972) 71 70 -0.6 (1.091531) 32.1 % -0.72 [ -1.12, -0.31 ]
Subtotal (95% CI) 298 290 100.0 % -0.29 [ -0.71, 0.12 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 7.70, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 1.37 (P = 0.17)
2 Atypical AP vs placebo
Girard 2010a 0.077779 (1.109386) 30 36 0.19 (1.148189) 12.5 % -0.11 [ -0.66, 0.44 ]
Girard 2018 0.139465 (1.002386) 190 184 0.05 (1.036661) 87.5 % 0.09 [ -0.12, 0.30 ]
Subtotal (95% CI) 220 220 100.0 % 0.06 [ -0.13, 0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
3 Statin vs placebo
Needham 2016 0.684993 (1.101808) 137 135 0.86 (1.071333) 67.2 % -0.18 [ -0.43, 0.08 ]
Page 2017 -0.514873 (1.104702) 71 71 -0.56 (1.141176) 32.8 % 0.04 [ -0.33, 0.41 ]
Subtotal (95% CI) 208 206 100.0 % -0.10 [ -0.32, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
4 Typical AP vs atypical AP
Girard 2010a 0.082734 (1.10491) 35 30 0.08 (1.109386) 12.2 % 0.00 [ -0.54, 0.54 ]
Girard 2018 192 -0.0308 (1.000804) 190 0.14 (1.002386) 87.8 % -0.17 [ -0.37, 0.03 ]
Subtotal (95% CI) 227 220 100.0 % -0.15 [ -0.34, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
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Analysis 4.1. Comparison 4 Duration of mechanical ventilation (log ratio of means scale), Outcome 1
Duration of mechanical ventilation (log units).
Review: Pharmacological interventions for the treatment of delirium in critically ill adults
Comparison: 4 Duration of mechanical ventilation (log ratio of means scale)
Outcome: 1 Duration of mechanical ventilation (log units)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Typical AP vs placebo
Al-Qadheeb 2016 1.403657 (0.58631) 34 34 1.46 (0.650339) 24.1 % -0.06 [ -0.35, 0.24 ]
Girard 2010a 1.526706 (0.872197) 35 36 1.44 (0.870241) 12.7 % 0.09 [ -0.32, 0.49 ]
Girard 2018 0.630596 (0.967487) 192 184 0.75 (0.830312) 63.1 % -0.12 [ -0.31, 0.06 ]
Subtotal (95% CI) 261 254 100.0 % -0.08 [ -0.23, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
2 Atypical AP vs placebo
Devlin 2010 1.966623 (0.928733) 18 18 2.16 (1.028537) 5.7 % -0.19 [ -0.83, 0.45 ]
Girard 2010a 1.395246 (0.970994) 30 36 1.44 (0.870241) 11.6 % -0.05 [ -0.49, 0.40 ]
Girard 2018 0.754028 (0.830162) 190 184 0.75 (0.830312) 82.7 % 0.00 [ -0.17, 0.17 ]
Subtotal (95% CI) 238 238 100.0 % -0.02 [ -0.17, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
3 Statin vs placebo
Needham 2016 2.096709 (0.776126) 137 135 2.01 (0.885403) 100.0 % 0.09 [ -0.11, 0.29 ]
Subtotal (95% CI) 137 135 100.0 % 0.09 [ -0.11, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
4 Alpha-2 agonist vs placebo
Reade 2016 -0.10727 (0.311908) 39 32 0.49 (0.82052) 100.0 % -0.59 [ -0.89, -0.29 ]
Subtotal (95% CI) 39 32 100.0 % -0.59 [ -0.89, -0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.87 (P = 0.00011)
5 Typical AP vs atypical AP
Girard 2010a 1.526706 (0.872197) 35 30 1.4 (0.970994) 41.4 % 0.13 [ -0.32, 0.58 ]
Girard 2018 0.630596 (0.967487) 192 190 1.02 (0.610693) 58.6 % -0.39 [ -0.55, -0.22 ]
Subtotal (95% CI) 227 220 100.0 % -0.17 [ -0.67, 0.33 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 4.48, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.68 (P = 0.50)
-1 -0.5 0 0.5 1
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
6 Typical AP vs opioid
Atalan 2013 -0.88569 (0.401691) 26 27 -0.82 (0.703039) 100.0 % -0.06 [ -0.37, 0.24 ]
Subtotal (95% CI) 26 27 100.0 % -0.06 [ -0.37, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
-1 -0.5 0 0.5 1
Favour intervention drug Favour placebo/comparator
Analysis 5.1. Comparison 5 Length of ICU stay (log ratio of means scale), Outcome 1 Length of ICU stay
(log units).
Review: Pharmacological interventions for the treatment of delirium in critically ill adults
Comparison: 5 Length of ICU stay (log ratio of means scale)
Outcome: 1 Length of ICU stay (log units)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Typical AP vs placebo
Al-Qadheeb 2016 1.706781 (0.474084) 34 34 1.75 (0.538862) 24.2 % -0.05 [ -0.29, 0.20 ]
Girard 2010a 2.117637 (0.706381) 35 36 1.88 (0.649501) 14.1 % 0.24 [ -0.08, 0.55 ]
Girard 2018 192 1.56582 (0.871883) 184 1.59 (0.902044) 43.7 % -0.02 [ -0.20, 0.16 ]
Page 2013 2.041365 (0.647961) 52 51 2.06 (0.789272) 18.0 % -0.01 [ -0.29, 0.26 ]
Subtotal (95% CI) 313 305 100.0 % 0.01 [ -0.11, 0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.31, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Atypical AP vs placebo
Devlin 2010 2.617369 (0.55717) 18 18 2.79 (0.669273) 5.0 % -0.17 [ -0.57, 0.23 ]
Girard 2010a 1.935537 (0.767433) 30 36 1.88 (0.649501) 6.7 % 0.05 [ -0.29, 0.40 ]
Girard 2018 1.585925 (0.720974) 190 184 1.59 (0.902044) 29.4 % 0.00 [ -0.17, 0.17 ]
-1 -0.5 0 0.5 1
Favour intervention drug Favour placebo/comparator
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hakim 2012 0.79652 (0.318678) 51 50 0.94 (0.280623) 58.9 % -0.14 [ -0.26, -0.03 ]
Subtotal (95% CI) 289 288 100.0 % -0.09 [ -0.18, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.81, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
3 Statin vs placebo
Needham 2016 2.432935 (0.642063) 137 135 2.37 (0.625749) 100.0 % 0.06 [ -0.09, 0.21 ]
Subtotal (95% CI) 137 135 100.0 % 0.06 [ -0.09, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
4 Alpha-2 agonist vs placebo
Reade 2016 1.660084 (0.673774) 39 32 1.88 (0.617916) 100.0 % -0.22 [ -0.53, 0.08 ]
Subtotal (95% CI) 39 32 100.0 % -0.22 [ -0.53, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
5 Cholinesterase inhibitor vs placebo
van Eijk 2010 2.599378 (0.76288) 54 50 1.81 (0.915231) 100.0 % 0.78 [ 0.46, 1.11 ]
Subtotal (95% CI) 54 50 100.0 % 0.78 [ 0.46, 1.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.73 (P < 0.00001)
6 Typical AP vs atypical AP
Girard 2010a 2.117637 (0.706381) 35 30 1.94 (0.767433) 16.7 % 0.18 [ -0.18, 0.54 ]
Girard 2018 192 1.56582 (0.871883) 190 1.59 (0.720974) 83.3 % -0.02 [ -0.18, 0.14 ]
Subtotal (95% CI) 227 220 100.0 % 0.01 [ -0.13, 0.16 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.01, df = 1 (P = 0.32); I2 =1%
Test for overall effect: Z = 0.18 (P = 0.86)
7 Typical AP vs opioid
Atalan 2013 0.997134 (0.632161) 26 27 0.93 (0.488628) 100.0 % 0.07 [ -0.24, 0.37 ]
Subtotal (95% CI) 26 27 100.0 % 0.07 [ -0.24, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
-1 -0.5 0 0.5 1
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Analysis 6.1. Comparison 6 Length of hospital stay (log ratio of means scale), Outcome 1 Length of hospital
stay (log units).
Review: Pharmacological interventions for the treatment of delirium in critically ill adults
Comparison: 6 Length of hospital stay (log ratio of means scale)
Outcome: 1 Length of hospital stay (log units)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Typical AP vs placebo
Girard 2018 2.449205 (0.653273) 192 184 2.46 (0.678189) 57.6 % -0.01 [ -0.14, 0.13 ]
Page 2013 2.817905 (0.636427) 52 51 3.09 (0.636206) 42.4 % -0.28 [ -0.52, -0.03 ]
Subtotal (95% CI) 244 235 100.0 % -0.12 [ -0.38, 0.14 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.54, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.91 (P = 0.36)
2 Atypical AP vs placebo
Devlin 2010 2.882889 (0.689937) 18 18 3.16 (0.730315) 3.5 % -0.27 [ -0.74, 0.19 ]
Girard 2018 190 2.41059 (0.639327) 184 2.46 (0.678189) 42.6 % -0.05 [ -0.18, 0.09 ]
Hakim 2012 1.76043 (0.250316) 51 50 1.78 (0.350518) 53.8 % -0.02 [ -0.14, 0.10 ]
Subtotal (95% CI) 259 252 100.0 % -0.04 [ -0.13, 0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.05, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
3 Statin vs placebo
Needham 2016 2.941296 (0.547259) 137 135 2.92 (0.583102) 83.7 % 0.02 [ -0.11, 0.15 ]
Page 2017 2.780427 (0.857935) 47 50 2.93 (0.654742) 16.3 % -0.15 [ -0.45, 0.16 ]
Subtotal (95% CI) 184 185 100.0 % -0.01 [ -0.13, 0.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.92)
4 Alpha-2 agonist vs placebo
Reade 2016 2.563956 (0.493196) 39 32 2.47 (0.599287) 100.0 % 0.09 [ -0.17, 0.35 ]
Subtotal (95% CI) 39 32 100.0 % 0.09 [ -0.17, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
5 Cholinesterase Inhibitor vs placebo
van Eijk 2010 3.239838 (0.743868) 54 50 3.13 (0.571853) 100.0 % 0.11 [ -0.15, 0.36 ]
Subtotal (95% CI) 54 50 100.0 % 0.11 [ -0.15, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
6 Typical AP vs atypical AP
-1 -0.5 0 0.5 1
Favour intervention drug Favour placebo/comparator
(Continued . . . )
109Pharmacological interventions for the treatment of delirium in critically ill adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Girard 2018 2.449205 (0.653273) 192 190 2.41 (0.639327) 100.0 % 0.04 [ -0.09, 0.17 ]
Subtotal (95% CI) 192 190 100.0 % 0.04 [ -0.09, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
7 Typical AP vs opioid
Atalan 2013 2.069579 (0.387767) 26 27 2.13 (0.338346) 100.0 % -0.06 [ -0.26, 0.13 ]
Subtotal (95% CI) 26 27 100.0 % -0.06 [ -0.26, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
-1 -0.5 0 0.5 1
Favour intervention drug Favour placebo/comparator
Analysis 7.1. Comparison 7 Mortality, Outcome 1 Mortality.
Review: Pharmacological interventions for the treatment of delirium in critically ill adults
Comparison: 7 Mortality
Outcome: 1 Mortality








1 Typical AP vs placebo
Al-Qadheeb 2016 9/34 7/34 9.9 % 1.39 [ 0.45, 4.29 ]
Girard 2010a 4/35 6/36 6.8 % 0.65 [ 0.17, 2.52 ]
Girard 2018 50/192 50/184 60.2 % 0.94 [ 0.60, 1.49 ]
Page 2013 20/71 19/70 23.1 % 1.05 [ 0.50, 2.20 ]
Subtotal (95% CI) 332 324 100.0 % 0.98 [ 0.69, 1.40 ]
Total events: 83 (Intervention Drug), 82 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
2 Atypical AP vs placebo
0.02 0.1 1 10 50
Favour intervention drug Favour placebo/comparator
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Devlin 2010 2/18 3/18 4.6 % 0.63 [ 0.09, 4.28 ]
Girard 2010a 4/30 6/36 9.1 % 0.77 [ 0.20, 3.03 ]
Girard 2018 53/190 50/184 83.3 % 1.04 [ 0.66, 1.63 ]
Hakim 2012 2/51 1/50 2.9 % 2.00 [ 0.18, 22.78 ]
Subtotal (95% CI) 289 288 100.0 % 1.00 [ 0.66, 1.52 ]
Total events: 61 (Intervention Drug), 60 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
3 Cholinesterase inhibitor vs placebo
van Eijk 2010 18/54 11/50 100.0 % 1.77 [ 0.74, 4.26 ]
Subtotal (95% CI) 54 50 100.0 % 1.77 [ 0.74, 4.26 ]
Total events: 18 (Intervention Drug), 11 (Placebo/Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
4 Statin vs placebo
Needham 2016 14/137 12/135 41.9 % 1.17 [ 0.52, 2.62 ]
Page 2017 30/71 22/71 58.1 % 1.63 [ 0.82, 3.25 ]
Subtotal (95% CI) 208 206 100.0 % 1.42 [ 0.84, 2.39 ]
Total events: 44 (Intervention Drug), 34 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
5 Typical AP vs opioid
Atalan 2013 2/26 1/27 100.0 % 2.17 [ 0.18, 25.46 ]
Subtotal (95% CI) 26 27 100.0 % 2.17 [ 0.18, 25.46 ]
Total events: 2 (Intervention Drug), 1 (Placebo/Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
6 Typical AP vs atypical AP
Girard 2010a 4/35 4/30 8.5 % 0.84 [ 0.19, 3.69 ]
Girard 2018 50/192 53/190 91.5 % 0.91 [ 0.58, 1.43 ]
Subtotal (95% CI) 227 220 100.0 % 0.90 [ 0.59, 1.39 ]
Total events: 54 (Intervention Drug), 57 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
0.02 0.1 1 10 50
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Analysis 8.1. Comparison 8 Akathisia, Outcome 1 Akathisia.
Review: Pharmacological interventions for the treatment of delirium in critically ill adults
Comparison: 8 Akathisia
Outcome: 1 Akathisia








1 Typical AP vs placebo
Girard 2010a 10/35 7/36 82.8 % 1.66 [ 0.55, 5.00 ]
Page 2013 1/71 2/70 17.2 % 0.49 [ 0.04, 5.48 ]
Subtotal (95% CI) 106 106 100.0 % 1.34 [ 0.49, 3.67 ]
Total events: 11 (Intervention Drug), 9 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Atypical AP vs placebo
Girard 2010a 6/30 7/36 100.0 % 1.04 [ 0.31, 3.50 ]
Subtotal (95% CI) 30 36 100.0 % 1.04 [ 0.31, 3.50 ]
Total events: 6 (Intervention Drug), 7 (Placebo/Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
3 Typical AP vs atypical AP
Girard 2010a 10/35 6/30 100.0 % 1.60 [ 0.50, 5.09 ]
Subtotal (95% CI) 35 30 100.0 % 1.60 [ 0.50, 5.09 ]
Total events: 10 (Intervention Drug), 6 (Placebo/Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
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Analysis 9.1. Comparison 9 Arrhythmias, Outcome 1 Arrhythmias.
Review: Pharmacological interventions for the treatment of delirium in critically ill adults
Comparison: 9 Arrhythmias
Outcome: 1 Arrhythmias








1 Typical AP vs placebo
Girard 2010a 0/35 0/36 Not estimable
Girard 2018 2/192 0/184 11.4 % 4.84 [ 0.23, 101.55 ]
Page 2013 13/71 5/70 88.6 % 2.91 [ 0.98, 8.67 ]
Subtotal (95% CI) 298 290 100.0 % 3.09 [ 1.11, 8.62 ]
Total events: 15 (Intervention Drug), 5 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.031)
2 Atypical AP vs placebo
Girard 2010a 0/30 0/36 Not estimable
Girard 2018 0/190 0/184 Not estimable
Subtotal (95% CI) 220 220 Not estimable
Total events: 0 (Intervention Drug), 0 (Placebo/Comparator)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Alpha-2 agonist vs typical AP
Reade 2009 2/10 2/10 100.0 % 1.00 [ 0.11, 8.95 ]
Subtotal (95% CI) 10 10 100.0 % 1.00 [ 0.11, 8.95 ]
Total events: 2 (Intervention Drug), 2 (Placebo/Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Typical AP vs atypical AP
Girard 2010a 0/35 0/30 Not estimable
Girard 2018 2/192 0/190 100.0 % 5.00 [ 0.24, 104.84 ]
Subtotal (95% CI) 227 220 100.0 % 5.00 [ 0.24, 104.84 ]
Total events: 2 (Intervention Drug), 0 (Placebo/Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
0.01 0.1 1 10 100
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Analysis 10.1. Comparison 10 QTc prolongation, Outcome 1 QTc prolongation.
Review: Pharmacological interventions for the treatment of delirium in critically ill adults
Comparison: 10 QTc prolongation
Outcome: 1 QTc prolongation








1 Typical AP vs placebo
Al-Qadheeb 2016 4/34 1/34 7.5 % 4.40 [ 0.47, 41.60 ]
Girard 2010a 2/35 3/36 11.0 % 0.67 [ 0.10, 4.25 ]
Girard 2018 13/192 10/184 52.5 % 1.26 [ 0.54, 2.96 ]
Page 2013 7/71 6/70 29.0 % 1.17 [ 0.37, 3.66 ]
Subtotal (95% CI) 332 324 100.0 % 1.26 [ 0.68, 2.34 ]
Total events: 26 (Intervention Drug), 20 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Atypical AP vs placebo
Devlin 2010 9/18 13/18 29.2 % 0.38 [ 0.10, 1.54 ]
Girard 2010a 5/30 3/36 26.4 % 2.20 [ 0.48, 10.09 ]
Girard 2018 20/190 10/184 44.4 % 2.05 [ 0.93, 4.50 ]
Hakim 2012 0/51 0/50 Not estimable
Subtotal (95% CI) 289 288 100.0 % 1.28 [ 0.45, 3.66 ]
Total events: 34 (Intervention Drug), 26 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.48; Chi2 = 4.55, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 0.46 (P = 0.64)
3 Typical AP vs atypical AP
Girard 2010a 2/35 5/30 15.2 % 0.30 [ 0.05, 1.69 ]
Girard 2018 13/192 20/190 84.8 % 0.62 [ 0.30, 1.28 ]
Subtotal (95% CI) 227 220 100.0 % 0.55 [ 0.28, 1.08 ]
Total events: 15 (Intervention Drug), 25 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
4 Alpha-2 agonist vs typical AP
Reade 2009 4/10 4/10 100.0 % 1.00 [ 0.17, 5.98 ]
Subtotal (95% CI) 10 10 100.0 % 1.00 [ 0.17, 5.98 ]
Total events: 4 (Intervention Drug), 4 (Placebo/Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
0.02 0.1 1 10 50
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5 Alpha-2 agonist vs 5HT3 inhibitor
Bakri 2015 0/32 0/32 Not estimable
Subtotal (95% CI) 32 32 Not estimable
Total events: 0 (Intervention Drug), 0 (Placebo/Comparator)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.02 0.1 1 10 50
Favour intervention drug Favour placebo/comparator
Analysis 11.1. Comparison 11 Extrapyramidal symptoms, Outcome 1 Extrapyramidal symptoms.
Review: Pharmacological interventions for the treatment of delirium in critically ill adults
Comparison: 11 Extrapyramidal symptoms
Outcome: 1 Extrapyramidal symptoms








1 Typical AP vs placebo
Al-Qadheeb 2016 1/34 0/34 11.1 % 3.09 [ 0.12, 78.55 ]
Girard 2010a 4/35 6/36 62.7 % 0.65 [ 0.17, 2.52 ]
Girard 2018 1/192 1/184 15.0 % 0.96 [ 0.06, 15.43 ]
Page 2013 0/71 1/70 11.2 % 0.32 [ 0.01, 8.09 ]
Subtotal (95% CI) 332 324 100.0 % 0.75 [ 0.26, 2.21 ]
Total events: 6 (Intervention Drug), 8 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.07, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Atypical AP vs placebo
Devlin 2010 0/18 0/18 Not estimable
Girard 2010a 2/30 6/36 73.2 % 0.36 [ 0.07, 1.92 ]
0.01 0.1 1 10 100
Favour intervention drug Favour placebo/comparator
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Girard 2018 1/190 1/184 26.8 % 0.97 [ 0.06, 15.60 ]
Subtotal (95% CI) 238 238 100.0 % 0.47 [ 0.11, 1.97 ]
Total events: 3 (Intervention Drug), 7 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
3 Typical AP vs atypical AP
Girard 2010a 4/35 2/30 56.3 % 1.81 [ 0.31, 10.63 ]
Girard 2018 1/192 1/190 22.9 % 0.99 [ 0.06, 15.94 ]
Skrobik 2004 6/45 0/28 20.8 % 9.38 [ 0.51, 173.30 ]
Subtotal (95% CI) 272 248 100.0 % 2.22 [ 0.59, 8.38 ]
Total events: 11 (Intervention Drug), 3 (Placebo/Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.41, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
0.01 0.1 1 10 100
Favour intervention drug Favour placebo/comparator
A D D I T I O N A L T A B L E S
Table 1. Duration of delirium: league table of posterior median pairwise RoM and 95% CrI (lower triangle), and pairwise
probabilities that a treatment is better than another (upper triangle)
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Table 1. Duration of delirium: league table of posterior median pairwise RoM and 95% CrI (lower triangle), and pairwise
















RoM: ratio of means.
A complete summary of estimates for efficacy from the random-effects (RE) consistency model assuming vague priors is displayed.
Treatments other than placebo are in the order of decreasing surface under the cumulative ranking curve (SUCRA) value from upper
left to lower right. For each comparison, the lower/right-most treatment is the reference treatment. For example, the RoM estimate of
0.58 (95% CrI 0.26 to 1.27) in the lower triangle suggests a 42% reduction in the mean duration of delirium with alpha2 agonists
compared to placebo. The corresponding probability estimate in the upper triangle suggests a probability of 93.8% that alpha2 agonists
are better than placebo in terms of duration of delirium. Estimates which ruled out the possibility of no difference based on pairwise
RoM estimates are shown in bold font.
Table 2. Duration of delirium: mean SUCRA value, mean probability to be the best, and mean rank for each treatment
RE consistency model
Mean SUCRA Mean Pr(best) Mean ranka
Alpha2 agonist 0.895 0.717 1.63 (1 to 6)
Atypical antipsychotic 0.738 0.114 2.57 (1 to 5)
Opioid 0.578 0.129 3.53 (1 to 7)
Typical antipsychotic 0.468 0.010 4.19 (2 to 6)
Placebo 0.403 0.001 4.58 (3 to 6)
Statin 0.365 0.023 4.81 (2 to 7)
CHE inhibitor 0.054 0.006 6.68 (3 to 7)




SUCRA: surface under the cumulative ranking curve.
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Table 3. Delirium- and coma-free days: league table of posterior median pairwise RoM and 95% (lower triangle), and pairwise





















RoM: ratio of means.
A complete summary of estimates for efficacy from the random-effects (RE) consistency model assuming vague priors is displayed.
Treatments other than placebo are in the order of decreasing surface under the cumulative ranking curve (SUCRA) value from upper
left to lower right. For each comparison, the lower/right-most treatment is the reference treatment. For example, the RoM estimate of
1.31 (95% credible interval (CrI) 0.69 to 2.83) in the lower triangle suggests a 31% increase in mean delirium- and coma-free days
with atypical antipsychotics compared to placebo. The corresponding probability estimate in the upper triangle suggests a probability
of 89.8% that atypical antipsychotics are better than placebo in terms of delirium- and coma-free days.
Table 4. Delirium- and coma-free days: mean SUCRA value, mean probability to be the best, and mean rank for each treatment
RE consistency model
Mean SUCRA Mean Pr(best) Mean ranka
Atypical antipsychotic 0.845 0.690 1.46 (1 to 4)
Typical antipsychotic 0.589 0.160 2.23 (1 to 4)
Placebo 0.327 0.033 3.02 (1 to 4)
Statin 0.239 0.116 3.28 (1 to 4)
aMean rank with 2.5% and 97.5% quantiles in parentheses.
Pr: probability.
RE: random-effects.
SUCRA: surface under the cumulative ranking curve.
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Table 5. Days with coma: league table of posterior median pairwise RoM and 95% CrI (lower triangle), and pairwise






















RoM: ratio of means.
A complete summary of estimates for efficacy from the random-effects (RE) consistency model assuming vague priors is displayed.
Treatments other than placebo are in the order of decreasing surface under the cumulative ranking curve (SUCRA) value from upper
left to lower right. For each comparison, the lower/right-most treatment is the reference treatment. For example, the RoM estimate of
0.77 (95% CrI 0.43 to 1.29) in the lower triangle suggests a 23% reduction in mean coma days with typical antipsychotics compared
to placebo. The corresponding probability estimate in the upper triangle suggests a probability of 90.5% that typical antipsychotics are
better than placebo in terms of days with coma.
Table 6. Days with coma: mean SUCRA values, mean probability to be the best, and mean rank for each treatment
RE consistency model
Mean SUCRA Mean Pr(best) Mean ranka
Typical antipsychotic 0.820 0.620 1.54 (1 to 4)
Statin 0.481 0.222 2.56 (1 to 4)
Atypical antipsychotic 0.422 0.132 2.73 (1 to 4)
Placebo 0.278 0.026 3.17 (1 to 4)
aMean rank with 2.5% and 97.5% quantiles in parentheses.
Pr: probability.
RE: random-effects.
SUCRA: surface under the cumulative ranking curve
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Table 7. Duration of mechanical ventilation: league table of posterior median pairwise RoM and 95% CrI (lower triangle),
and pairwise probabilities that a treatment is better than another (upper triangle)
Alpha2
agonist









































RoM: ratio of means.
A complete summary of estimates for efficacy from the random-effects (RE) consistency model assuming vague priors is displayed.
Treatments other than placebo are in the order of decreasing surface under the cumulative ranking curve (SUCRA) value from upper
left to lower right. For each comparison, the lower/right-most treatment is the reference treatment. For example, the RoM estimate
of 0.55 (95% CrI 0.34 to 0.89) in the lower triangle suggests a 45% reduction in the mean duration of mechanical ventilation with
alpha2 agonists compared to placebo. The corresponding probability estimate in the upper triangle suggests a probability of 98.6%
that alpha2 agonists are better than placebo for the duration of mechanical ventilation. Estimates which ruled out the possibility of no
difference based on pairwise RoM estimates are shown in bold font.
Table 8. Duration of mechanical ventilation: mean SUCRA values, mean probability to be the best, and mean rank for each
treatment
RE consistency model
Mean SUCRA Mean Pr(best) Mean ranka
Alpha2 agonists 0.974 0.931 1.13 (1 to 3)
Typical antipsychotic 0.576 0.009 3.12 (2 to 6)
Atypical antipsychotic 0.440 0.012 3.80 (2 to 6)
Opioid 0.410 0.033 3.95 (1 to 6)
Placebo 0.377 0.001 4.11 (2 to 6)
120Pharmacological interventions for the treatment of delirium in critically ill adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 8. Duration of mechanical ventilation: mean SUCRA values, mean probability to be the best, and mean rank for each
treatment (Continued)
Statin 0.223 0.014 4.88 (2 to 6)
aMean rank with 2.5% and 97.5% quantiles in parentheses.
Pr: probability.
RE: random-effects.
SUCRA: surface under the cumulative ranking curve.
Table 9. Length of ICU stay: league table of posterior median pairwise RoM and 95% CrI (lower triangle), and pairwise
probabilities that a treatment is better than another (upper triangle)























































ICU: intensive care unit.
RoM: ratio of means.
A complete summary of estimates for efficacy from the random-effects (RE) consistency model assuming vague priors is displayed.
Treatments other than placebo are in the order of decreasing surface under the cumulative ranking curve (SUCRA) value from upper
left to lower right. For each comparison, the lower/right-most treatment is the reference treatment. For example, the RoM estimate of
0.80 (95% CrI 0.55 to 1.17) in the lower triangle suggests a 20% reduction in mean length of ICU stay with alpha2 agonists compared
to placebo. The corresponding probability estimate in the upper triangle suggests a probability of 88.6% that alpha2 agonists are better
than placebo for the length of ICU stay. Estimates which ruled out the possibility of no difference based on pairwise RoM estimates
are shown in bold font.
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Table 10. Length of ICU stay: mean SUCRA value, mean probability to be the best, and mean rank for each treatment
RE consistency model
Mean SUCRA Mean Pr(best) Mean ranka
Alpha2 agonists 0.853 0.608 1.88 (1 to 6)
Atypical antipsychotic 0.709 0.106 2.75 (1 to 5)
Opioid 0.639 0.238 3.17 (1 to 6)
Typical antipsychotic 0.496 0.014 4.02 (2 to 6)
Placebo 0.457 0.004 4.26 (2 to 6)
Statin 0.344 0.030 4.93 (1 to 6)
CHE inhibitor 0.002 0.000 6.99 (7 to 7)
aMean rank with 2.5% and 97.5% quantiles in parentheses.
CHE: cholinesterase.
ICU: intensive care unit.
Pr: probability.
RE: random-effects.
SUCRA: surface under the cumulative ranking curve.
Table 11. Length of hospital stay: league table of posterior median pairwise RoM and 95% CrI (lower triangle), and pairwise
probabilities that a treatment is better than another (upper triangle)
Typical
antipsychotic
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Table 11. Length of hospital stay: league table of posterior median pairwise RoM and 95% CrI (lower triangle), and pairwise
















RoM: ratio of means.
Treatments other than placebo are in the order of decreasing surface under the cumulative ranking curve (SUCRA) value from
upper left to lower right. For each comparison, the lower/right-most treatment is the reference treatment. For example, the RoM
estimate of 0.92 (95% CrI 0.65 to 1.18) in the lower triangle suggests an 8% reduction in mean length of hospital stay with typical
antipsychotics compared to placebo. The corresponding probability estimate in the upper triangle suggests a probability of 82% that
typical antipsychotics are better than placebo for length of hospital stay.
Table 12. Length of hospital stay: mean SUCRA value, mean probability to be the best, and mean rank for each treatment
RE consistency model
Mean SUCRA Mean Pr(best) Mean ranka
Typical antipsychotic 0.722 0.235 2.67 (1 to 6)
Atypical antipsychotic 0.693 0.218 2.84 (1 to 6)
Statin 0.537 0.147 3.78 (1 to 7)
Opioid 0.532 0.225 3.81 (1 to 7)
Placebo 0.435 0.008 4.39 (2 to 6)
Alpha2 agonists 0.301 0.090 5.19 (1 to 7)
CHE inhibitor 0.280 0.078 5.32 (1 to 7)




SUCRA: surface under the cumulative ranking curve.
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A P P E N D I C E S
Appendix 1. RCT Search Strategy: Ovid MEDLINE®, Ovid MEDLINE® In-Process & Other Non-
Indexed Citations, Embase Classic+Embase, and PsycINFO
Search Strategy:
--------------------------------------------------------------------------------
1 ((postoperati* or post-operati* or postsurg* or post-surg*) adj1 (“cognitive dysfunction” or “brain dysfunction”)).tw.
2 Intensive Care Units/
3 Burn Units/
4 Coronary Care Units/
5 Respiratory Care Units/
6 exp Intensive Care Units, Pediatric/
7 exp Critical Care/
8 ((intensive or critical or acute) adj3 care).tw.
9 (ICU or ICUs or NICU or NICUs or PICU or PICUs or SICU or SICUs or CCU or CCUs).tw.
10 (burn$1 adj3 (unit$1 or centre$1 or center$1)).tw.
11 ((cardiac or coronary or heart) adj3 (unit$1 or centre$1 or center$1)).tw.
12 (respiratory adj3 (unit$1 or centre$1 or center$1)).tw.
13 ((surgical or surger*) adj3 (unit$1 or centre$1 or center$1)).tw.
14 Postoperative Care/
15 Postoperative Complications/
16 (postoperati* or post-operati* or postsurg* or post-surg*).tw.
17 Critical Illness/





23 (psychos* adj3 (toxic* or exogenous* or chemical* or drug or drugs or medication* or substance*)).tw.
24 (acute brain adj (dysfunction* or failure* or syndrome*)).tw.
25 (cloud* adj3 consciousness*).tw.
26 clouded state*.tw.





32 19 and 31
33 1 or 32
34 (controlled clinical trial or randomized controlled trial).pt.
35 clinical trials as topic.sh.
36 (randomi#ed or randomly or RCT$1 or placebo*).tw.
37 ((singl* or doubl* or trebl* or tripl*) adj (mask* or blind* or dumm*)).tw.
38 trial.ti.
39 or/34-38
40 33 and 39
41 exp Animals/ not (exp Animals/ and Humans/)
42 40 not 41
43 (comment or editorial or interview or letter or news).pt.
44 42 not 43
45 44 use prmz
46 remove duplicates from 45 [MEDLINE RECORDS]
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47 postoperative delirium/
48 postoperative cognitive dysfunction/
49 ((postoperati* or post-operati* or postsurg* or post-surg*) adj1 (“cognitive dysfunction” or “brain dysfunction”)).tw.
50 intensive care psychosis/
51 or/47-50
52 intensive care unit/
53 burn unit/
54 coronary care unit/
55 intensive care/
56 ((intensive or critical or acute) adj3 care).tw.
57 (ICU or ICUs or NICU or NICUs or PICU or PICUs or SICU or SICUs or CCU or CCUs).tw.
58 (burn$1 adj3 (unit$1 or centre$1 or center$1)).tw.
59 ((cardiac or coronary or heart) adj3 (unit$1 or centre$1 or center$1)).tw.
60 (respiratory adj3 (unit$1 or centre$1 or center$1)).tw.
61 ((surgical or surger*) adj3 (unit$1 or centre$1 or center$1)).tw.
62 postoperative care/
63 postoperative complication/
64 (postoperati* or post-operati* or postsurg* or post-surg*).tw.
65 critical illness/




70 (psychos* adj3 (toxic* or exogenous* or chemical* or drug or drugs or medication* or substance*)).tw.
71 (acute brain adj (dysfunction* or failure* or syndrome*)).tw.
72 (cloud* adj3 consciousness*).tw.
73 clouded state*.tw.




78 67 and 77
79 51 or 78
80 randomized controlled trial/ or controlled clinical trial/
81 exp “clinical trial (topic)”/
82 (randomi#ed or randomly or RCT$1 or placebo*).tw.
83 ((singl* or doubl* or trebl* or tripl*) adj (mask* or blind* or dumm*)).tw.
84 trial.ti.
85 or/80-84
86 79 and 85
87 exp animal experimentation/ or exp models animal/ or exp animal experiment/ or nonhuman/ or exp vertebrate/
88 exp humans/ or exp human experimentation/ or exp human experiment/
89 87 not 88
90 86 not 89
91 (editorial or letter).pt.
92 90 not 91
93 92 use emczd
94 remove duplicates from 93 [EMBASE RECORDS]
95 ((postoperati* or post-operati* or postsurg* or post surg*) adj1 (“cognitive dysfunction” or “brain dysfunction”)).tw.
96 exp intensive care/
97 ((intensive or critical or acute) adj3 care).tw.
98 (ICU or ICUs or NICU or NICUs or PICU or PICUs or SICU or SICUs or CCU or CCUs).tw.
99 (burn$1 adj3 (unit$1 or centre$1 or center$1)).tw.
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100 ((cardiac or coronary or heart) adj3 (unit$1 or centre$1 or center$1)).tw.
101 (respiratory adj3 (unit$1 or centre$1 or center$1)).tw.
102 ((surgical or surger*) adj3 (unit$1 or centre$1 or center$1)).tw.
103 postsurgical complications/
104 (postoperati* or post-operati* or postsurg* or post-surg*).tw.




109 (psychos* adj3 (toxic* or exogenous* or chemical* or drug or drugs or medication* or substance*)).tw.
110 (acute brain adj (dysfunction* or failure* or syndrome*)).tw.
111 (cloud* adj3 consciousness*).tw.
112 clouded state*.tw.






118 106 and 117
119 95 or 118
120 clinical trials/
121 (randomi#ed or randomly or RCT$1 or placebo*).tw.
122 ((singl* or doubl* or trebl* or tripl*) adj (mask* or blind* or dumm*)).tw.
123 trial.ti.
124 or/120-123
125 119 and 124
126 exp Animals/ not (exp Animals/ and Humans/)
127 125 not 126
128 127 use prmz
129 127 use emczd
130 127 not (128 or 129) [PSYCINFO RECORDS]
131 remove duplicates from 130
132 46 or 94 or 131
133 remove duplicates from 132 [TOTAL UNIQUE HITS]
134 133 use prmz [MEDLINE UNIQUE HITS]
135 133 use emczd [EMBASE UNIQUE HITS]
136 133 not (134 or 135) [PSYCINFO UNIQUE HITS]
Appendix 2. RCT Search Strategy: CCTR, DSR, DARE, CENTRAL, HTA, and NHS SEED
ID Search Hits
#1 (postoperati* or (post next operati*) or postsurg* or (post next surg*)) next (“cognitive dysfunction” or “brain dysfunction”):ti,ab,kw
#2 [mh ˆ“Intensive Care Units”]
#3 [mh “Burn Units”]
#4 [mh “Coronary Care Units”]
#5 [mh “Respiratory Care Units”]
#6 [mh “Intensive Care Units, Pediatric”]
#7 [mh “Critical Care”]
#8 ((intensive or critical or acute) near/4 care):ti,ab,kw
#9 (ICU or ICUs or NICU or NICUs or PICU or PICUs or SICU or SICUs or CCU or CCUs):ti,ab,kw
#10 (burn or burns) near/4 (unit or units or centre or centres or center or centers):ti,ab,kw
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#11 (cardiac or coronary or heart) near/4 (unit or units or centre or centres or center or centers):ti,ab,kw
#12 respiratory near/4 (unit or units or centre or centres or center or centers):ti,ab,kw
#13 (surgical or surger*) near/4 (unit or units or centre or centres or center or centers):ti,ab,kw
#14 [mh “Postoperative Care”]
#15 [mh “Postoperative Complications”]
#16 postoperati* or (post next operati*) or postsurg* or (post next surg*):ti,ab,kw
#17 [mh “Critical Illness”]




#22 [mh ˆ“Psychoses, Substance-Induced”]
#23 psychos* near/4 (toxic* or exogenous* or chemical* or drug or drugs or medication* or substance*):ti,ab,kw
#24 “acute brain” next (dysfunction* or failure* or syndrome*):ti,ab,kw
#25 cloud* near/4 consciousness*:ti,ab,kw
#26 clouded next state*:ti,ab,kw






#32 #19 and #31
#33 #1 or #32
DSR - (did not download - RCT search only)
DARE - (did not download - RCT search only)
CENTRAL -
HTA - (did not download - RCT search only)
NHS EED - (did not download - RCT search only)
Appendix 3. RCT Search Strategy: CINAHL
# Query Limiters/Expanders
S42 S33 AND S40 Limiters - Exclude MEDLINE records
Expanders - Apply related words
Search modes - Boolean/Phrase
S41 S33 AND S40 Expanders - Apply related words
Search modes - Boolean/Phrase
S40 s34 or s35 or s36 or s37 or s38 or s39 Expanders - Apply related words
Search modes - Boolean/Phrase
S39 TI trial Expanders - Apply related words
Search modes - Boolean/Phrase
S38 TI ( (singl* or doubl* or trebl* or tripl*) w1 (mask* or blind*
or dumm*) ) OR AB ( (singl* or doubl* or trebl* or tripl*) w1
Expanders - Apply related words
Search modes - Boolean/Phrase
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(Continued)
(mask* or blind* or dumm*) )
S37 TI ( randomised or randomized or randomly or RCT or RCTs
or placebo* ) OR AB ( randomised or randomized or randomly
or RCT or RCTs or placebo* )
Expanders - Apply related words
Search modes - Boolean/Phrase
S36 TI randomised or randomized or randomly or RCT or RCTs
or placebo*
Expanders - Apply related words
Search modes - Boolean/Phrase
S35 (MH “Clinical Trials+”) Expanders - Apply related words
Search modes - Boolean/Phrase
S34 (MH “Randomized Controlled Trials”) Expanders - Apply related words
Search modes - Boolean/Phrase
S33 S1 OR S32 Expanders - Apply related words
Search modes - Boolean/Phrase
S32 S19 AND S31 Expanders - Apply related words
Search modes - Boolean/Phrase
S31 S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30
Expanders - Apply related words
Search modes - Boolean/Phrase
S30 TI hallucinat* OR AB hallucinat* Expanders - Apply related words
Search modes - Boolean/Phrase
S29 (MH “Hallucinations+”) Expanders - Apply related words
Search modes - Boolean/Phrase
S28 (MH “Confusion+/CI”) Expanders - Apply related words
Search modes - Boolean/Phrase
S27 TI ( (“psycho-organic” w1 syndrome*) or (psychoorganic w1
syndrome*) or (organic w1 psychosyndrome*) or “organic psy-
cho-syndrome” or “organic psycho-syndromes”) n3 acute ) OR
AB ( (“psycho-organic” w1 syndrome*) or (psychoorganic w1
syndrome*) or (organic w1 psychosyndrome*) or “organic psy-
cho-syndrome” or “organic psycho-syndromes”) n3 acute )
Expanders - Apply related words
Search modes - Boolean/Phrase
S26 TI clouded w1 state* OR AB clouded w1 state* Expanders - Apply related words
Search modes - Boolean/Phrase
S25 TI cloud* n3 consciousness* OR AB cloud* n3 consciousness* Expanders - Apply related words
Search modes - Boolean/Phrase
S24 TI ( “acute brain” n1 (dysfunction* or failure* or syndrome*)
) OR AB ( “acute brain” n1 (dysfunction* or failure* or syn-
drome*) )
Expanders - Apply related words
Search modes - Boolean/Phrase
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(Continued)
S23 TI ( psychos* n3 (toxic* or exogenous* or chemical* or drug
or drugs or medication* or substance*) ) OR AB ( psychos*
n3 (toxic* or exogenous* or chemical* or drug or drugs or
medication* or substance*) )
Expanders - Apply related words
Search modes - Boolean/Phrase
S22 (MH “Psychoses, Substance-Induced”) Expanders - Apply related words
Search modes - Boolean/Phrase
S21 TI deliri* OR AB deliri* Expanders - Apply related words
Search modes - Boolean/Phrase
S20 (MH “Delirium”) Expanders - Apply related words
Search modes - Boolean/Phrase
S19 S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR
S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR
S17 OR S18
Expanders - Apply related words
Search modes - Boolean/Phrase
S18 TI ( critical* w1 (ill or illness*) ) OR AB ( critical* w1 (ill or
illness*) )
Expanders - Apply related words
Search modes - Boolean/Phrase
S17 (MH “Critical Illness”) Expanders - Apply related words
Search modes - Boolean/Phrase
S16 TI ( postoperati* or post-operati* or postsurg* or post-surg*
) OR AB ( postoperati* or post-operati* or postsurg* or post-
surg* )
Expanders - Apply related words
Search modes - Boolean/Phrase
S15 (MH “Postoperative Complications+”) Expanders - Apply related words
Search modes - Boolean/Phrase
S14 (MH “Postoperative Care+”) Expanders - Apply related words
Search modes - Boolean/Phrase
S13 TI ( ((surgical or surger*) n3 (unit or units or centre or centres
or center or centers)) ) OR AB ( ((surgical or surger*) n3 (unit
or units or centre or centres or center or centers)) )
Expanders - Apply related words
Search modes - Boolean/Phrase
S12 TI ( respiratory n3 (unit or units or centre or centres or center
or centers) ) OR AB ( respiratory n3 (unit or units or centre
or centres or center or centers) )
Expanders - Apply related words
Search modes - Boolean/Phrase
S11 TI ( (cardiac or coronary or heart) n3 (unit or units or centre or
centres or center or centers)) ) OR AB ( ((cardiac or coronary
or heart) n3 (unit or units or centre or centres or center or
centers)) )
Expanders - Apply related words
Search modes - Boolean/Phrase
S10 TI ( ((burn or burns) n3 (unit or units or centre or centres
or center or centers)) ) OR AB ( ((burn or burns) n3 (unit or
Expanders - Apply related words
Search modes - Boolean/Phrase
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(Continued)
units or centre or centres or center or centers)) )
S9 TI ( (ICU or ICUs or NICU or NICUs or PICU or PICUs or
SICU or SICUs or CCU or CCUs) ) OR AB ( (ICU or ICUs
or NICU or NICUs or PICU or PICUs or SICU or SICUs or
CCU or CCUs) )
Expanders - Apply related words
Search modes - Boolean/Phrase
S8 TI ( ((intensive or critical or acute) n3 care) ) OR AB ( (
(intensive or critical or acute) n3 care) )
Expanders - Apply related words
Search modes - Boolean/Phrase
S7 (MH “Critical Care+”) Expanders - Apply related words
Search modes - Boolean/Phrase
S6 (MH “Respiratory Care Units”) Expanders - Apply related words
Search modes - Boolean/Phrase
S5 (MH “Coronary Care Units”) Expanders - Apply related words
Search modes - Boolean/Phrase
S4 (MH “Burn Units”) Expanders - Apply related words
Search modes - Boolean/Phrase
S3 (MH “Intensive Care Units, Neonatal”) OR (MH “Intensive
Care Units, Pediatric+”)
Expanders - Apply related words
Search modes - Boolean/Phrase
S2 (MH “Intensive Care Units+”) Expanders - Apply related words
Search modes - Boolean/Phrase
S1 TI ( ((postoperati* or post-operati* or postsurg* or post-surg*)
n1 (“cognitive dysfunction” or “brain dysfunction”)) ) OR AB
( ((postoperati* or post-operati* or postsurg* or post-surg*) n1
(“cognitive dysfunction” or “brain dysfunction”)) )
Expanders - Apply related words
Search modes - Boolean/Phrase
Appendix 4. Web of Science
# 41 #39 NOT #40
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 40 (#39) AND DOCUMENT TYPES: (Editorial Material OR Letter OR News Item)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 39 #38 AND #31
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 38 #37 OR #36 OR #35 OR #34 OR #33 OR #32
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
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(Continued)
# 37 TI=trial
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 36 TS=((singl* or doubl* or trebl* or tripl*) NEAR/1 (mask* or blind* or dumm*))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 35 TS=(randomised or randomized or randomly or RCT or RCTs or placebo*)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 34 TS=“clinical trials as topic”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 33 TS=(“randomized controlled trial” or “randomised controlled trial”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 32 TS=“controlled clinical trial”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 31 #30 OR #1
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 30 #29 AND #21
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 29 #28 OR #27 OR #26 OR #25 OR #24 OR #23 OR #22
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 28 TS=hallucinat*
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 27 TS=(clouded near/1 state*)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 26 TS=(cloud* NEAR/3 consciousness*)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 25 TS=(“acute brain” NEAR/1 (dysfunction* or failure* or syndrome*))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 24 TS=(psychos* NEAR/3 (toxic* or exogenous* or chemical* or drug or drugs or medication* or substance*))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 23 TS=deliri*
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 22 TS=delirium
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
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# 21 #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6
OR #5 OR #4 OR #3 OR #2
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 20 TS=(critical* NEAR/1 (ill or illness*))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 19 TS=“Critical Illness”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 18 TS=(postoperati* or post-operati* or postsurg* or post-surg*)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 17 TS=“Postoperative Complications”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 16 TS=“Postoperative Care”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 15 TS=((surgical* or surger*) NEAR/3 (unit or units or centre or centres or center or centers))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 14 TS=(respiratory NEAR/3 (unit or units or centre or centres or center or centers))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 13 TS=((cardiac or coronary or heart) NEAR/3 (unit or units or centre or centres or center or centers))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 12 TS=((burn or burns) NEAR/3 (unit or units or centre or centres or center or centers))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 11 TS=(ICU or ICUs or NICU or NICUs or PICU or PICUs or SICU or SICUs or CCU or CCUs)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 10 TS=((intensive or critical or acute) NEAR/3 care)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 9 TS=“Intensive Care”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 8 TS=“Critical Care”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 7 TS=“Intensive Care Units, Neonatal”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
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# 6 TS=“Intensive Care Units, Pediatric”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 5 TS=“Respiratory Care Units”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 4 TS=“Coronary Care Units”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 3 TS=“Burn Units”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 2 TS=“Intensive Care Units”
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
# 1 TS=((postoperati* or post-operati* or postsurg* or post-surg*) NEAR/1 (“cognitive dysfunction” or “brain dysfunction”))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
In our protocol (Burry 2015), we planned the primary outcome to be duration of delirium, defined as the time from which it wasfirst
identified to when it was first resolved (i.e. screened negative as defined by study authors (e.g. first negative screen, two consecutive
screenings)), measured in days, and our secondary outcome to be the total duration of delirium, measured in days. There was far more
variability in the definition of the outcome used than we had anticipated. Only two trials reported on the duration of delirium’s first
episode, and the remaining trials reported days with delirium, time in delirium, or total duration of delirium; most did not report when
delirium was identified or how trial authors defined resolution of delirium. We therefore chose to report the total duration of delirium
as our primary outcome and to pool the variable definitions. We added the outcome number of days in coma, as this outcome was
reported in four trials, and we believed it important to include it in this review, as it is a newer outcome that is likely to be included in
subsequent studies.
We chose not to report mortality in our ’Summary of findings’ tables, as this was reported at various time points and settings, and
NMA was judged by the research team to be inappropriate to pursue. Also, mortality is more likely the consequence of the same causes
that led patients to become critically ill, rather than the intervention for delirium. In its place, we chose to report the most commonly
reported adverse drug effect - QTc prolongation. We also chose to report “days with coma” in place of “delirium-free and coma-free
days”, given that the RoM analysis for “days with coma” is relatively more reliable and is less impacted by the different time windows
of measurement.
Estimates from NMAs are included in the ’Summary of findings’ tables, in addition to estimates from pairwise meta-analyses. The
mean difference on the log scale from pairwise meta-analyses was exponentiated and interpreted as RoM, which we presented alongside
estimates from the NMAs, to provide estimates both from direct comparisons (i.e. pairwise meta-analyses) and from mixed comparisons
(i.e. NMAs). In the case of no direct evidence available between an intervention and placebo, we presented only the estimate of indirect
comparison from NMA. SUCRA values, mean rankings, and Pr(‘best’) values were provided as additional measures of treatment effect,
which are commonly of interest to readers.
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